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Abstract 
Background 
In a university hospital, disparate and unsatisfactory thromboprophylaxis in surgical 
patients was found. No hospital consensus was in place for the prevention of 
postoperative deep vein thrombosis (DVT). Literature review suggested low 
molecular weight heparin (LMWM) and anti-embolic stockings were the best 
prophylaxis, however the optimal length of stocking was unknown. 
Method 
An audit of thromboprophylaxis in surgical patients and surgical doctors was 
perfonned. 
A randomised controlled trial investigated the efficacy and safety of a new single 
protocol of LMWH and the best length of stocking, for every patient requiring 
surgery under general anaesthesia. Of 426 patients interviewed, 376 were 
randomised into three stocking groups, Medi ThrombexinS ClimaXTMthigh-length, 
ThrombexinS ClimaXTm knee-length and Kendall TEDTMthigh-length. All patients 
received LMWH. DVT incidence was assessed by duplex ultrasonography. 
Complications of thromboprophylaxis were recorded. Compliance and health 
outcome measures were developed to assess patient stocking acceptability. 
Results 
Audit of thromboprophylaxis revealed inadequate surgical thromboprophylaxis. A 
simple 'single protocol' improved doctors' thromboprophylaxis compliance on 
replicate audit. 
The randomised trial assessing the 'single protocol' showed no postoperative DVT 
occurred in the low or moderate-risk patients (n=85). Twenty-one DVT occurred in 
nineteen patients, all were high-risk patients (n=291): two with Thrombexint 
ClimaXTMthigh-length stockings and eleven with Thrombexint ClimaXTm knee- 
length (p<0.05). Six patients wearing TEDTm thigh-length stockings developed 
DVT. Groups were similar for age, gender, thromboembolic risk, surgical type and 
protocol compliance. One significant bleeding complication occurred. 
A validated health outcome measure showed patient satisfaction with knee-length 
stockings was significantly greater than with thigh-length. However, stocking 
compliance for in-patients was equal. Whereas patients' compliance with knee- 
length was significantly greater after hospital discharge. 
Conclusion 
A single protocol employing LMWH and thigh-length stockings abolished DVT 
(diagnosed by duplex) in low and moderate-risk patients and reduced DVT to 2% in 
high-risk patients. The 'Blanket LMWH/thigh-length stocking protocol' was 
effective, safe and the length of stocking proved significant. A new single protocol 
and hospital consensus to prevent postoperative DVT was achieved. 
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1.1 Definition of Deep Venous Thrombosis 
The term thrombosis refers to the formation within the vascular system (in a living 
animal) of an abnormal mass made up of blood constituents. Thrombosis is defined 
as a mass of aggregated platelets immobilised within fibrin, adherent to the vessel 
wall. There is variable content of red cells and entrapped leucocytes and the 
proportions and arrangements of these various components are dependent on local 
and general conditions. Venous thrombi are composed of large amounts of fibrin and 
erythrocytes that form a loose friable mass called the red thrombus, which randomly 
enmeshes platelets and leucocytes. The most proximal portion often contains 
prominent platelet masses and is paler than the distal coagulum of red cells and fibrin 
(De Gruchy 1990). Venous thrombi differ from arterial thrombi by their early 
obstructive nature within the vessel whereas the latter enlarge progressively by 
deposition of new layers of platelets and fibrin to produce the lines of Zahn with 
eventual partial or complete obstruction of the arterial flow. However the most 
serious consequence of venous thrombosis is embolisation to the pulmonary 
circulation, which is not uncommonly fatal. The thrombosis of veins and arteries, and 
the resultant embolic complications, together produce the largest cause of morbidity 
and mortality in the western world. 
Venous thrombosis is classified according to the anatomical distribution of the 
affected vein. The veins of the lower extremity are subdivided, like those of the 
upper extremity, into two sets; superficial and deep. The superficial veins are placed 
beneath the integument between the two layers of superficial fascia. The deep veins 
accompany the arteries and their branches, ftequently in pairs that are referred to as 
venae commitantes. Venous thrombi may occur in the superficial or deep venous 
systems, the former may cause local symptoms as a result of superficial 
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thrombophlebitis. Where as, deep venous thrombosis (DVT) may cause local and 
systemic complications. Deep vein thromboses are classified as 'proximal' when 
they involve the popliteal vein or more proximal deep veins of the lower limb and 
pelvis. Distal DVT are classified as major calf thrombi, when they are more than five 
centimetres in length but confined to the deep veins of the calf, or as minor calf 
thrombi when they are less than five centimetres in length (Fordyce & Ling 1992). 
The importance of this classification is underlined by evidence to suggest that the 
minor calf thrombi of less than five centimetres may resorb spontaneously (Kakkar et 
al. 1969) which is in stark contrast to the potential clinical outcome of proximal 
thrombi that have been shown to produce pulmonary embolism (PE) in as many as 
fifty percent of cases (Moser & Le Moine 198 1). 
Both superficial and deep veins are provided with valves, these are more numerous 
in the deep venous systems. Deep vein thrombosis more commonly occurs within 
the deep veins of the leg rather than the arm. This is probably related to the fact that 
valves are more numerous in the veins of the leg than in those of the upper limb 
(Gray 1918). Authors have reported the importance of blood stagnation behind deep 
venous valve cusps that encourages the formation of DVT (Lewis 1976 & Kalebo et 
al. 1990). Venous thrombosis develops under conditions of slow blood flow and is 
augmented by further retardation and stagnation of flow in the venous system. 
The development of an 'early' surgical DVT is thought to begin during the surgical 
procedure, with any clinical manifestations usually evident during the first 
postoperative week, where as prolonged immobility in the convalescing patient may 
lead to the formation of a 'late' DVT' that may not be directly related to the 
operation itself Successful prophylaxis against the surgical complication of venous 
thromboembolism (VTE), in the first instance needs to prevent the development of 
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the 'early' DVT around the time of surgery and then continue until the patient is fully 
ambulant to prevent the development of a 'late' DVT. 
1.2 Historical review of the venous thrombosis 
The notion of blood transport by two types of vessels (phlebos) was described as 
early as the sixth century BC by Alcmeon of Croton, the first Greek known to 
practice dissection. The separation of vessels into two types was also found in the 
Hippocratic Corpus (5 th century BC), where the term 'artery' refers to the trachea, 
bronchi and vessels originating from the heart, these were described as transporting 
blood to the connecting 'veins'. Early reports of blood clotting were found in the 
writings of the Greek philosophers of the 4 th century B. C. Plato described fibres 
within the blood that caused clotting when blood left the body and cooled, this view 
was held until the 18'hcentury. Aristotle added that the fibres were solid and blood 
removed from the fibres did not clot. Observations made through the act of blood 
letting which was active in the Hippocratic school and dates back to the early 
Egyptian times, was the basis for the Greek humoral hypothesis of the four humours 
which is set out in the treatise on the 'Nature of Man' of the Hippocratic code (400 
BC). The clotting of blood emptied into a container was assumed to be the normal 
behaviour of blood within the body and was reported to slowly separate in to the four 
humours. The upper portion clearing to become a transparent yellow colour (named 
yellow bile), the bottom would form a thick red ahnost black layer (black bile), at the 
surface a thin bright red layer formed (blood) and in disease a greeny white layer 
(phlegm) would separate from the black layer at the bottom. It was the separation of 
clotted blood and formation of the phlegm in disease that formed the basis of 
pathology for over two thousand years. The phlegm layer was renamed innumerable 
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times and also known as the crusta sanguinis, inflammatoria, phlogostica, the buffy 
coat. Even today, the interplay of fibrinogenesis and fibrinolysis, and erythrocyte 
sedimentation rate have important roles in clinical practice. 
King Ptolemy who ruled from 323 to 282 BC established his library and museum in 
the Egyptian capital Alexandria in order to install Greek learning in the new 
Egyptian environment. The library became the wonder of the scholarly world, 
attracting distinguished medical talent, notably Herophilus of Chalcedon (330-260 
BC). Herophilus improved Aristotelian anatomy by distinguishing between arteries 
and veins through the dissection of living humans. Four centuries later the 
anatomical and physiological discoveries of the Alexandrian physicians were utilised 
and improved upon by Galen, born in AD 129 in Pergamon (now Bergama, Turkey). 
He affirmed that the two systems of arteries and veins were anastomosed, however 
there is no evidence in Galen's work that he saw the possibility of blood circulating 
from the former to the latter. Galen supported and elaborated on the humoral 
pathology, he was a great advocate of phlebotomy, described the 'buffy coat' and 
founded 'Galenic' anatomy. For fourteen centuries Galenic concept of anatomy 
prevailed despite continued criticism and correction. The arguments over blood 
letting caused anatomists to pay more attention to venous anatomy. Hieronymus 
Fabricius ab, Aquapendente (c. 1533-1619), a great comparative anatomist described 
the valves of the veins and their possible function by reporting that the valves helped 
the central and upper parts of the body to get blood thus preventing the extremities 
from gathering excessive blood (Porter 1997). His work was a major influence on 
William Harvey who performed demonstrations on the blood circulation. William 
Harvey (1578-1657) of Folkestone, England, praised Galen for his evidence for 
pulmonary blood circulation however he questioned Galen's account of transit of air 
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and waste in opposite directions through the venous artery. Through his dissection, 
Harvey found that blood travelled from the vena cava, through the pulmonary 
circulation via the right ventricle and into the aorta via the left ventricle. As a 
favoured pupil of Hieronymus Fabricius, he deduced from studies of the venous 
valves that blood must flow from the arteries to veins and back to the heart. 
Franciscus Sylvius (1614-1672) introduced clinical bedside teaching and the first 
chemical laboratory in Europe. Sylvius assigned a prominent part of disease to the 
chemical properties of the blood. Inflammation of the blood was dependent on 
stagnation of the blood in the vessels, which he felt could result in the production and 
deposition of pus. The lay term 'inflammation of the blood' most probably dates 
back to the work of Sylvius. 
By the middle of the 17th century, early microscopists were studying the composition 
of the blood. In 165 8, Jan Swammerdam (163 7-1680) was the first to describe 
(during microscopic studies of frogs blood) the red corpuscle floating in serum. 
Richard Lower (163 1-169 1) was famous for his work on transfusion and the uptake 
of 'air' by the blood in the lungs with its resultant change in colour form dark to 
bright red. He also noted the similar colour change on the upper side of a venous 
blood clot exposed to the air compared to the dark underside, which would then 
become florid if turned over. A pioneer anatomist, Marcello Marpighi in 1666 
washed clotted blood to reveal white fibrous strands (Ratnoff & Wintrobe 1980). A 
great clinician and teacher, Herman Boerhaave (1668-1738) began the first formal 
lectures in physiology, the "Institutiones Medicae", that were the origins of the 
"Institutes of Medicine". Boerhaave held that blood coagulated if it ceased to move 
due to the natural tendency of cells within the blood to cohere one with another, with 
some intermixed serum. He believed that disease was due to stagnation and 
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coagulation of blood in the blood vessels, either due to alterations in the vessels 
themselves or the blood. 
Up until this time, a frequent error of the blood coagulationist was to assume that the 
behaviour of the blood in the bleeding bowl was the same as the blood in the bodY. 
The eighteenth century saw the beginnings of the modem ideas on the formation and 
behaviour of the blood. Joseph- Lieutaud (1703-1780) described the condition of 
44anaernia", an exhaustion of the blood vessels associated with blood lost and 
starvation. In 1760 Richard Davies wrote essays in which he described his 
scrupulous experimental techniques to examine the fractions of the blood in its fluid 
and coagulated states and initiated studies on clot retraction. He showed quite 
clearly that red blood cells themselves have no power of coagulation. 
The first 'haematologist' William Hewson (1739-1774) was bom in Hexam, 
England. He is principally remembered for his work on coagulation, where he proved 
that blood serum was the main coagulant of the blood by skimming off the plasma 
from a ligated vein. The clear plasma that he called "coagulable lymph" - later to be 
known as "fibrinogen" - then clotted. He observed that blood in fact slowed its rate 
of clotting if cooled contrary to the teachings of Plato. In the 1770s, Hewson 
localised the source of coagulation fibres to the liquid part of the blood known today 
as plasma. He also showed that the walls of the blood vessel exert a 'remarkable 
influence' on restraining coagulation (Hewson 1846). 
The early nineteenth century led to a definite regression in the study of the functions 
of the blood with much of the 18'ý' century's findings forgotten. Phlebotomy as part 
of therapy slowly but steadily disappeared. Jean Cruveilhier (1791-1874), the first 
professor of pathological anatomy in Paris, revived interest in the blood. 
Inflammation of the veins or phlebitis occupied the centre of his concept of disease. 
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He distinguished adhesive phlebitis or thrombosis, from suppurative phlebitis, areas 
of infarction were called fibrinous deposits or capillary phlebitis, however he failed 
to recognised the possibility of embolism. William Addison (1802-188 1) was the 
first to reveal some of the functions of the leucocytes in inflammation and pus and he 
recognised platelets and their relationship to the fonnation of fibrin. 
Rudolph Virchow (1821-1902), a graduate from Berlin, dominated Gennan 
biomedical research for half a century. Through his studies of blood coagulation and 
the chemical nature of the fibrin clot, he found that fibrin was only found in the 
blood stream after the onset of coagulation and he named its precursor fibrinogen. 
Through animal experiments, autopsies and clinical observations, he elucidated the 
nature of phlebitis. He described that in most cases of vascular inflammation 
associated with blood clots, the clot usually formed first which led to local 
inflammatory and obstructive effects. The emboli commonly found in the 
pulmonary circulation at autopsy did not result from a general disease but originated 
from the venous clot elsewhere in the body and travelled via the venous and right 
cardiac circulatory systems to the lungs, which in turn set off local vascular and 
respiratory reactions that were often fatal. In 1846, he published his first paper on 
embolism, noting the frequent association of infected venous thrombi and lung 
abscesses. In 1856, he described the pathogenesis of venous thrombosis, and 
emphasised the importance of changes to the composition of the blood to increase 
coagulability, changes in the vessel wall, in particular endothelial damage, and 
disturbances to blood flow, especially stasis (Virchow 1858, Porter 1997). 
Only at the end of the nineteenth century, the studies of Bizzozero, Eberth and 
Schimmelbusch , and others 
found that platelets, the last of the blood cells to be 
discovered, provided a significant contribution to thrombus formation (Ratnoff & 
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Wintrobe 1980). Travers of St. Thomas's Hospital in cooperation with Cooper of 
Guy's Hospital, wrote a historical account of the surgery of the veins, noting the 
occasional suppuration of the ligated veins, occasionally accompanied by fatal 
pulmonary embolism. In the 1920s to 30s, pulmonary embolectomy was perfon-ned 
regularly as an emergency procedure. Crawford and Kirschner achieved 
international recognition for this procedure despite only limited successes. John 
Homans (1941) of Boston stressed the importance of division of the deep veins of the 
leg in circumstances of thromboembolism. For repetitive episodes of thrombus 
migration surgeons would occasionally interrupt the vena cava below the renal veins 
by ligature or insertion of a screen filter that prevent further clot migration centrally. 
TJ Fogarty and associates devised a catheter with an inflatable balloon that could 
assist in the removal of thrombus from veins or arteries (Krause et al 1966). 
The discovery in 1916 of heparin by McLean and William H Howell and dicoumarin 
by Campbell and Link in 1939 provided anticoagulant substances that could be used 
in the treatment and prophylaxis of thrombotic and embolic states (Beck 1984). 
Early clinical studies carried out before the routine use of anticoagulant therapy 
demonstrated that in the region of six percent of patients with untreated deep vein 
thrombosis died of pulmonary embolism (Zilliacus 1946). The prophylactic and 
therapeutic use of anticoagulants and venous compression techniques, has largely 
eradicated the need for emergency surgical intervention for the treatment of venous 
and pulmonary thrombi. However, pulmonary embolism is still a major cause of 
death in hospitalised patients in the developed world. The root of the problem stems 
from the development of deep vein thrombosis, which still commonly occurs in our 
hospitals today. 
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1.3 Epidemiology of Venous Thromboembolic Disease 
1.3.1 Size of the problem 
Surgical practice continues to be complicated by venous thromboembolic disease, 
despite continued efforts over the last four decades to reduce its occurrence. In the 
face of the increased use of thromboprophylaxis, rates of WE have not reduced 
significantly since the 1980's. Patients are continuing to suffer from the severe 
complications of DVT and PE; ten percent of hospital deaths have been associated 
with PE (Sandler & Martin 1989). Although a fatal PE may be the first presentation, 
a DVT may propagate to produce a PE and up to seventy percent of patients with 
proven PE have venographic evidence of peripheral deep venous thrombosis (Hull et 
al 1983). Venous thromboembolism is a common complication among hospital in- 
patients and is known to contribute to longer hospital stays, increased morbidity and 
mortality. 
1.3.2 Prevalence and Incidence 
Venous thromboembolism is a major health problem affecting at least one person per 
thousand annually. In people below the age of forty the incidence of VTE episodes 
(DVT and PE) is approximately one in 10,000 people per year, which increases to 
one in 100 per year for those aged 75 years and over (Anderson et al 1991 & 
Martinelli 2001). Epidemiological data shows the annual rate of symptomatic DVT 
to be around 160 per 100,000 in the general population. Deep vein thrombosis ranks 
third as the most common cardiovascular disease behind acute ischaemic coronary 
disease and stroke and affects approximately 8 in every 10,000 individuals per year 
(Anderson et al 199 1). Reports from the United States Vital Statistics and the 
National Hospital Discharge survey from 1970 to 1985 demonstrated an age-adjusted 
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DVT rate of 79 per 100000 and for pulmonary emboli, 51 per 100000 (Gillum 1987). 
The prevalence, defined as the number of cases of a disease existing in a given 
population at a specific period of time (period prevalence) or a particular moment in 
time (point prevalence) and incidence, the number of new specified events of disease 
during a specific period in a specified population are hard to establish with regard to 
VTE. Because, in the general population and hospitalised patients the limited 
published evidence and the clinically silent nature of the disease prevents the 
identification of all of the victims. The prevalence has been reported for 
asymptomatic DVT in adult patients on admission to hospital to be around five and a 
half percent with a rise to 17.8 percent in patients aged over eighty years 
(demonstrating the increased risk with age) (Oger et al 2002). The development of 
VTE in patient populations with specific risk factors has also been demonstrated by 
the high prevalence in patients suffering from malignancy; DVT (5.5%) and PE 
(7.6%) with the recurrence of WE reaching approximately fifty percent (Joung & 
Robinson 2002). The prevalence of DVT in hospice patients with advanced cancer 
was in the region of fifty percent (Johnson et al 1999). In critically ill patients 
admitted to Critical care units, the prevalence of objectively determined DVT ranged 
from 13 to 31 percent (Geerts et al 2002). 
The majority of fatal PE arise from DVT in the lower limb. Pulmonary embolism 
continues to be a major cause of death in hospitalised patients in the United 
Kingdom; nine percent of all patients admitted to hospital died and of these ten 
percent were due to PE - 0.9% of all admissions (Sandler and Martin 1989). In 
surgical patients, the incidence of fatal PE in low-risk patients is approximately 
0.5%, and in high risk-patients; such as elective hip surgery patients (1.5%) and as 
high as 5% in patients undergoing surgery for hip fracture (Gallus 1993). 
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1.4 Pathophysiology of venous thrombosis 
1.4.1 Aetiology and risk factors 
Excessive activation of coagulation or inhibition of the normal anticoagulant 
mechanisms may result in hypercoagulability and thrombosis. The abnormalities of 
the vessel wall, alterations in blood flow and changes in the composition of the blood 
are major factors involved in the development of thrombosis that were recognised in 
the nineteenth century by Virchow and other authors as previously discussed. These 
three main aetiological factors are considered, they are frequently referred to as the 
triad of Virchow. 
Abnormalities of the vessel wall 
In venous thrombosis, in contrast to arterial thrombosis, the vessel wall is usually 
histiologically non-nal however an exception to this generalisation is direct venous 
trauma or venous vascular disease. A reduction in venous tone may be an important 
factor in the increased incidence of deep vein thrombosis in pregnancy or in women 
taking oral contraceptives (Goodrich and Wood 1964). 
Studies have reported the over-distension of the vein wall during surgery which has 
been linked to an increase in venous thrombosis (Coleridge Smith et al 1990, 
Comerota et al 1989, Goldsmith 1972, Thomas et al 1985). 
Abnormalities in bloodflOw 
Venous thrombosis develops in an environment of stagnant or slow venous blood 
flow. The pathophysiological role of stasis in the creation of venous thrombosis is 
theorised to be due to the impaired removal of activated coagulation factors due to 
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inadequate venous blood flow (Strandeness et al 1977). The venous circulation does 
not require an abnormality, pathological or mechanical, to reduce the blood flow to 
prothrombotic levels. Physiological venous stasis can occur in relation to disrupted 
retrograde currents in venous valve pockets of normal veins and in the arcades of the 
soleus muscle of the calf. These effects may be compounded by the effects of ageing 
that may cause venous enlargement and reduced tone in these areas of the venous 
circulation (Nicolaides et al 1970 & 1971). 
Abnormalities of the blood composition 
The ability of the blood from certain patients' to coagulate at an abnormally rapid 
rate has led to the concept of hypercoagulability which implies that prethrombotic 
changes exist in the blood due to its composition that are important in the 
pathogenesis of thrombosis (Hirsh 1977, Kitchens 1985, Thomas 1988). Platelets are 
incorporated into all forms of thrombus, however they appear to play a more 
important role in the formation of arterial rather than venous thrombi. Antiplatelet 
agents have not been shown to offer any major clinical use in the prevention of deep 
vein thrombosis (Fourth ACCP consensus 1995, Hirsh & Hoak 1996); the effective 
methods of thromboembolic prophylaxis will be discussed later. 
The hypercoagulability of the blood is found mainly in relation to acquired or 
inherited disorders that predispose to deep vein thrombosis, these conditions are 
surnmarised in table I a. Acquired elevation of coagulation factors, such as 
fibrinogen and factors V and VIII have been reported in patients with thrombosis, 
prothrombotic disorders, pregnancy and women receiving oral contraceptives, and as 
a result of an acute-phase reaction to inflammation or tissue damage. However, 
increased activation of coagulation in animal studies is a major factor in 
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experimenta venous thrombosis rather than increased levels of coagulation factors 
(Deykin & Wessler 1964, Wessler et al 1967). Venous stasis in addition to 
activation of coagulation consistently lead to the formation of thrombosis, which 
appears to be a more potent stimuli than damage to the vein wall (Thomas et al 1985, 
Wessler et al 1967). 
Tissue factor (TF) is thought to be a primary initiator in the development of in vivo 
thrombosis (Nemerson 1988), in the absence of TF, endothelial cells maintain 
thromboresistance whereas immunological injury to the endothelium may lead to 
expression of tissue factor (Vermylen et al 1986). Patients with carcinoma are 
known to be more susceptible to venous (and arterial) thrombosis, adenocarcinomas 
can express TF (Callender & Rapaport 1993) and other tumours substances, such as 
cancer procoagulant A, that activate factor X (Gordon &Cross 198 1). 
Pregnancy and oestrogen medication produce a hypercoagulable state (Weiner et al 
1984) that can increase the risk of venous thromboembolism (Daly et al 1996, 
Grodstein et al 1996). Pregnancy has been described as a physiological chronic form 
of disseminated intravascular coagulation (DIC) (Woodfield et al 1972). Oestrogens 
therapy is known to induce activation of coagulation with reduction of inhibitors of 
coagulation such as antithrombin III and protein S, and has been reported to induce 
an acquired protein C resistance (Quehenberger et al 1996; Rosing et al 1997; 
Vanderbroucke et al 1994). 
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Classification & Mechanism of Inheri Estimated Prevalence 
Disorders Thrombosis -tance (%)* 
Deficiency or qualitative abnormalities of activated coagulationfactors Activated protein C APC fails to AD 20-60 
resistance (Factor V inactivate factor Va 
Leiden) due to highly 
conserved point 
mutation 
Protein C deficiency Failure to generate AD 5-6 
APC; failure to 
inactivate factors Va 
and V111a 
Protein S deFiciency Failure of APC to AD 5-6 
inactivate factors Va 
and V111a 
Thrombomodulin Failure to generate AD 5 
deficiency APC 
ATIII deficiency Failure to inhibit AD 1-2 
thrombin, factor Xa, 
and other activated 
factors 
Heparin cofactor 11 Failure to inhibit AD <1 
deficiency thrombin 
Abnormality of coagulation zymogens 
Prothrombin mutation Elevated prothrombin AD 
level 5-10 
Impaired clot lysis 
Dysfibrinogenaemia Abnormal fibrin AD 1-2 
resists fibrinolysis 
Plasminogen Failure to generate AD 1-2 
deficiency plasmin (AR) 
t-PA deficiency Failure to activate AD ? 
plasminogen 
Excess PAM activity Neutralisation of t- AD ? 
PA 
Metabolic deficiency 
Homocysteinaemia Endothelial cell AR I in 335,000 live births 
cytoxity and (homozygous) 
perturbation of 25% of patients with 
vascular haemostatic recurrent arterial or 
mechanisms venous thrombosis 
10% of patients with first 
episode of arterial or 
venous thrombosis 
Table la: The inherited venous thrombotic disorders. (Adapted and modified from 
Florell & Rodgers 1997). Abbreviations: AD, autosomal dominant; AR, autosomal 
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recessive; , activated protein C; ATIII, antithrombin 111; t-PA, tissue 
plasminogen activator. * refers to a percentage that each disorder may constitute in 
the total population with inherited thrombosis. 
Hereditary tendency to thrombosis, now known as thrombophilia, was first described 
by Egeberg in 1965, when he discovered a deficiency of antithrombin Ill. In the 
1980s, both protein C deficiency and protein S deficiency were associated with VTE, 
and over the last decade numerous other inherited abnormalities in the clotting 
system that predispose to venous thrombosis have been discovered, including the 
highly investigated mutation in the clotting factor V, known as factor V Leiden. 
The inherited disorders of coagulation that may lead to venous thromboembolism are 
numerous and complex (table I a). Many patients who suffer a thrombotic event are 
found to have a combination of inherited and iatrogenic aetiological factors, such as 
the oral contraceptive pill. The incidence of thrombosis due to inherited conditions 
alone is small, therefore patients should only be considered for evaluation of these 
inherited disorders if they are less than 45 years with recurrent thrombosis or in the 
primary episode with a family history (Rodgers & Chandler 1992). This is based on 
the fact that the majority are autosomal dominant and therefore most patients would 
have a positive family history. 
1.4.2 Prognosis 
The large majority, greater than ninety percent of venous thromboses occur in the 
deep veins of the legs, with the remainder usually involving the veins of the pelvis 
and approximately one percent in the upper limb. Most venous thrombi begin in the 
calf veins, usually in the sinuses above the venous valves. In this location, venous 
thrombi have several potential fates. In the short term the following may take place: 
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* Lysis - Venous thrombi generally remain small and are eventually lysed, 
posing no further threat to health. 
e Organisation -Many thrombi undergo organisation similar to thrombi of 
arterial origin. Small organised venous thrombi may be incorporated into the 
wall of the vessel, whereas larger thrombi can obstruct venous outflow. 
9 Propagation - Venous thrombi may form a nidus for further thrombosis and 
more proximal propagation of thrombus into the larger iliofemoral veins. 
Proximal extension of calf vein DVT occurs in approximately 20-50% of 
cases (Huisman et al 1989, Kakkar et al 1969). 
* Embolisation -Large venous thrombi or proximal iliofernoral thrombi 
represent a significant threat to the pulmonary circulation via embolisation 
and may be fatal. Pulmonary emboli have been detected in as many as 50% of 
the cases with proximal DVT (Kakkar et al 1969) and 10- 13% of patients 
with postoperative asymptomatic deep calf vein thrombosis (Giannoukas et al 
1995). 
In the long term, obstructive venous thrombi may undergo canalisation, with partial 
restoration of venous drainage, commonly with incompetent valves in the affected 
segment of vein. The long-term sequelae represent a major burden to the modem 
health services with the frequent complications of post-phlebitic syndrome and 
venous ulceration. The prevalence of symptomatic post-thrombotic syndrome (PTS) 
in patients who have suffered previous DVT appears to vary between 29 and 79% 
(Lindner et al 1986, Johnson et a] 1999, Prandoni et al 1996,1998). The symptoms 
and signs of PTS, which include pain, swelling, skin discolouration and 
hyperpigmentation, development or progression of varicose veins, and ulceration 
have been reported to be mild, moderate and severe in 55%, 4% and 4% of patients 
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respective y (Biguzzi et al 1998). Other reports have documented a higher 
symptomatic rate of 78% in patients with previous DVT (Bergqvist et al 1997). The 
prevalence of venous insufficiency in patients with PTS has been shown to be as 
high as 88.9% (McColl et al 2000, Lindhagen et al 1986). Moderate PTS has been 
reported more often (44%) in patients with recurrent DVT (McColl et al 2000). 
Recurrent thrombosis in patients that are adequately treated for DVT occur in up to 
thirty percent at 8 years and PTS may develop in up to twenty eight percent at five 
years (Prandoni et al 1996). The treatment of PTS is difficult due to its chronic 
nature and gradual worsening of venous insufficiency leading to the eventual 
development of venous ulceration in 2-10% of patients. Surgery is usually reserved 
for the extreme cases of PTS due to the sensitivity of the deep veins to surgical 
manipulation causing further thrombosis. The mainstay of treatment is the use of 
compression hosiery for life, which is aimed at palliation rather than cure. 
1.5 Current attitudes to the prevention of deep vein thrombosis in 
surgical patients 
1.5.1 Current recommendations for thromboembolic prophylaxis 
Numerous recommendations for effective venous thromboprophylaxis have been 
published over the last fifty years. Over forty years ago the evidence was emerging 
for the routine use of graduated compression stockings (GCS) in surgical patients 
and more than fifteen years ago a review of over seventy randomised trials 
investigating the preoperative use of subcutaneous heparin recommended its use in 
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Patient factors Disease or Surgical factors 
Age Trauma, surgery, especially of hip, pelvis, lower 
limb. 
Obesity Malignancy, especially pelvic, abdominal, 
metastatic. 
Immobility Heart failure or recent myocardial infarction 
(bed rest over 4 days) 
Pregnancy Lower limb paralysis 
Puerperium Infection 
High dose oestrogen therapy Inflammatory bowel disease 
Previous WE Nephrotic syndrome 
Thrombophilia, deficiency of Paraproteinaemia 
antithrombin 111, protein C or Polycythaemia 
S, Antiphospholipid antibody Paroxysmal nocturnal haernoglobinuria 
or lupus anticoagulant Behcet's disease 
Homocysteinaemia 
Table lb - Risk factors for venous thromboembolism in hospitalised 
patients (modified from THRIFT consensus group 1992. ) 
general, urology and orthopedic surgery due a significant reduction in the rate of 
DVT, PE, fatal PE and overall surgical mortality (Collins et al 1988). The results of 
this review confirmed the findings of the first large international multicentre trial 
assessing the use of perioperative subcutaneous heparin in the prevention of WE 
(IMT 1975,1997). In 1992 the Thromboembolic Risk Factors (THRIFT) consensus 
group advocated that all surgical and medical patients should receive specific 
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preoperative thromboprophylaxis in accordance with their risk of developing VTE. 
This idea was modified from some of the first authors to separate the 
thromboprophylactic requirements of patients into categories in relation to their 
thromboembolic risk (Salzman & Hirsh 1982). 
The risk of WE in hospitalised patients is not only dependent on the patients' 
current illness, planned treatment or operation, but also on pre-existing patient 
variables that predispose to VTE. Epidemiological studies have demonstrated that 
age is an important risk factor with forty years designated as an threshold to separate 
risk groups, however other factors are also important that can place patients at high 
risk even if they are younger than forty (table I b). The THRIFT group recommended 
that all patients admitted to hospital should be assessed for thromboembolic risk and 
then the intensity of the prophylaxis they receive should be tailored accordingly so 
that low-risk patients should be encouraged to mobilise as early as possible, 
moderate and high-risk should receive additional specific prophylaxis together with 
early mobilisation, such as GCS, intermittent pneumatic compression (IPQ and 
subcutaneous heparin injections. 
Risk category Risk of WE 
Calf DVT Proximal DVT Fatal PE 
High-risk 40-80% 10-30% 1-5% 
Moderate-risk 10-40% 2-10% 0.1-0.7% 
Low-risk <10% <1% <0.01% 
Table 1c - Risk categories in surgical patients. (Modified from the 
European Consensus Statement 1993 and Salzman & Hirsh 1982) 
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The recommendations of the THRIFT group were reinforced by the European 
consensus statement (Haas 1993), the risk to each of the groups were more clearly 
defined (table I c) with their recommended prophylaxis requirements. High-risk 
patients should receive a combination of pharmacological and mechanical methods 
of prophylaxis, namely low molecular weight heparin (LM") or low dose 
unfractionated heparin (LDUH) subcutaneous injections and GCS (and/or IPQ 
respectively. Moderate risk patients should receive one or a combination of the 
above 'high-risk' prophylaxis. Low-risk patients may be given prophylaxis, such as 
GCS on the basis of a risk-benefit ratio, however there was insufficient data at this 
time (1993) for guidance in this risk group. The author emphasized the need for 
comparisons of LMWH to LDUH, and pre- and post-operative commencement of 
pharmacological and mechanical modalities. 
There are numerous large and small consensus groups that produce guidelines for 
prescribing effective prophylaxis against VTE in hospitalised patients. The majority 
rely on the theoretical basis of WE risk categories for patients who require increased 
prophylaxis according to their increased risk. The majority of surgical patients that 
stay in hospital for treatment do so because of the severity of their illness, as a 
product of their comorbidity this results in most patients falling into the high and 
moderate risk groups with very few low thromboembolic risk in-patients. The 
common theme of 'risk proportional thromboprophylaxis' means that the majority of 
surgical in-patients are therefore recommended subcutaneous heparin and GCS (or 
IPQ for the high or moderate risk patients (Table I d). In other words, heparin and 
stockings for any patients with one or more risk factors or an age over thirty-nine 
years undergoing more than minor surgery. The recommendations for low-risk 
patients are not proven as RCTs for this group have not been performed, however 
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these patients undergoing minor surgery are commonly treated in hospital day- 
surgery facilities, or if hospitalised for a more major procedure they are usually 
anecdotally recommended early mobilisation with or without GCS. 
Risk Clinical Features Recommended 
DVT Piýophylaxis 
Subcutaneous 
Heparin and GCS, or 
IPC 
Categorv 
----------- -- -- --- 01 ..... .- --------- -- High Major surgery, >60 
years 
and >40 with risk 
factors. 
Major OrthoPaedic leg 
surgery 
Moderate Major surgery; >40 yrs 
Minor surgery; >60 yrs 
and >40 with risk 
factors 
Low Major surgery; <40 yrs 
Minor Surgery; <60 yrs, 
No risk factors 
Subcutaneous 
Heparin and/or GCS, or 
IPC 
Early Mobilisation or 
GCS 
Table ld - Recommended thromboembolic prophylaxis 
for surgical 
patients. Modified from the Intemational Consensus Statement 
(Nicolaides et al 2001) 
Abbreviations: DVT; deep vein thrombosis, GCS; graduated compression stockings, 
IPC; intermittent pneumatic compression. Additional riskjactors include: 
malignancy, previous DVT or pulmonary embolus, varicose veins, oestrogen 
medication, thrombophilia, ongoing sepsis, morbid obesity and general 
immobility. 
Operations: Minor Surgery; less than 30 minutes, Major Surgery; more than 30 
minutes operating time. 
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The most recent and comprehensive guidelines for the prevention of VTE in surgical 
patients is from the International Consensus Statement (Nicolaides et al 2001 & 
2002). The recommended prophylactic requirements for general surgical and 
orthopaedic patients are summarised in table I d. 
At the time this study was performed (2001-2003), the current edition of the 
International consensus (Nicolaides et al 2002) provided more evidence for the use 
of GCS, IPC and LMWH in specific surgical groups of patients, these will be 
discussed in more detail in chapter two. However, in general the international 
consensus guidelines rely on the relationship between the risk of WE and an 
increase in the intensity of recommended prophylaxis. 
1.5.2 Reported application of thromboembolic prophylaxis 
The use of thromboprophylaxis by surgeons has reportedly increased over the last 
two decades, however rates of WE episodes have not decreased significantly since 
the 1980s. At this time, surveys of the prophylactic methods used by surgeons have 
shown that in the United Kingdom and North America, only about 25% of general 
surgeons and 5% of orthopaedic surgeons reported using perioperative administration 
of subcutaneous heparin routinely (Morris 1980, Simon 1974, Conti & Daschbach 
1982). Since this time, numerous investigators have provided a substantial amount of 
evidence to show that prophylaxis against venous thromboembolism is effective by 
reducing the incidence of DVT and PE by as much as two-thirds. Despite the 
apparent benefits of prophylactic measures Anderson and colleagues showed that 
only one-third of patients received prophylactic therapy (Anderson et al 1991). 
Evidence has laid the foundations for the numerous comprehensive guidelines and 
frameworks for prophylactic practice that have been published in recent years (see 
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1.5.1 Current recommendations for thromboembolic prophylaxis). However, there is 
still controversy over the correct prophylactic methods for surgical patients from 
different surgical specialties (Jones 199 1). This uncertainty is may partly explain the 
frequent occurrence of inadequate clinical application of thromboembolic 
prophylaxis in many centres in the UK and globally (George et al 1998, Jones 1991, 
Stephens et al 1995, Audet et al 1998, Fletcher et al 1992, Conti & Daschbach 1982, 
Bratsler et al 1998). These reports have demonstrated a lack of prophylaxis 
administered to surgical patients despite an abundance of excellent prophylactic 
techniques and international guidelines. The failure of the prophylaxis reaching the 
patients was shown to be related to the inability of clinicians to understand guidelines 
with the resultant poor application of prophylactic methods (Ahmad et al 2002). 
1.6 Aims of study and hypotheses 
With the aid of literature analysis and investigative results, the overall objective of 
this study was to establish a new evidence-based policy in order to improve the 
prevention of post-operative DVT in a large multidisciplinary teaching hospital. The 
original objectives set out in the thesis application were as follows, 
1. Assess whether knee-length stockings are as effective as thigh-length at 
preventing postoperative DVT through incidence of DVT and stocking 
satisfaction and compliance 
2. Assess the WE prophylactic practices in Charing Cross Hospital 
3. Compare the venous flow characteristic of knee and thigh-length stockings to 
determine whether these may account for different efficacies of the stockings 
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However, during the preparation for the clinical trial required for the comparison of 
the knee and thigh-length stockings it soon became apparent that the state of surgical 
DVT prophylaxis in our hospital was in disarray. This led to a formal audit 
assessment of the status of thromboembolic prophylaxis in our surgical departments 
and research of the literature to develop a possible solution. Failure by the surgical 
departments in our hospital to use or implement the current European or International 
guidelines for the prevention of DVT lead us to believe that a simplified protocol 
was necessary to improve the application of DVT prophylaxis. Hence, the first two 
original objectives set out in the thesis application became a larger study than 
originally anticipated due to the major failures in DVT prophylaxis in our institution. 
The main study objectives were therefore changed accordingly: 
1. Assess the state of thromboembolic prophylaxis in surgical patients in our 
multidisciplinary teaching hospital. 
2. Report to each surgical department the status of thromboembolic prophylaxis 
in surgical patients with an overview of the current evidence in order to 
achieve a hospital consensus. 
3. Assess the impact of a new single blanket protocol on hospital prophylaxis 
compliance. 
4. Development of the new single protocol for DVT prophylaxis through a 
randomised clinical trial to compare knee to thigh-length stockings and the 
blanket application of LM" for all surgical in-patients undergoing surgery. 
5. The development of a specific HRQL and compliance questionnaire to assess 
satisfaction Of Patients wearing GCS. 
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6. Introduction of the new single protocol to all surgical departments to achieve 
a hospital consensus for patients admitted to a large teaching hospital for 
surgery. 
The following plan of investigations for the study were undertaken: 
1. Literature review and summation-analysis 
An overview of the literature assessing pharmacological and mechanical 
prophylaxis. A summation analysis of the current literature comparing the 
efficacy of knee to thigh-length graduated compression stockings for the 
prevention of post-operative DVT. 
2. Audit of current practice 
An audit of the current status of venous thromboprophylaxis in a large 
teaching hospital. An education and awareness program to improve practice 
where needed prior to repeat audit. 
3. Questionnaires 
The development of a questionnaire to formally assess the status of DVT 
preventive practice by surgical finns in Charing Cross Hospital. 
4. Investigations 
a) A randomised controlled trial (RCT) to compare the efficacy of knee to 
thigh length GCS for the prevention of post-operative DVT 
Assess the safety of LM" used across the board as part of a single 
blanket protocol for all surgical in-patients undergoing surgery. 
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c) The development and use of a specific 14RQL questionnaire and 
compliance assessments to assess satisfaction and compliance 
respectively of patients wearing GCS. 
The ultimate study goal was to develop a new single 'blanket' protocol to prevent 
post-operative DVT, in a university hospital, suitable for all surgical patients 
undergoing surgical procedures. In our hospital this included low, moderate and 
high-risk patients 8 from breast and oncology, ear, nose and throat (ENT), 
gastrointestinal, neurosurgery, orthopedic, urology and vascular surgical 
specialities. If proven to be safe and effective for all surgical specialities, a single 
protocol - as a product of its simplicity - would theoretically improve hospital 
prophylaxis compliance. 
1.6.1 Study hypotheses and end-points 
The primary study hypothesis was, 
'Provided all patients receive LMWH, 
thigh-length anti-embolic stockings are equivalent to knee-length of the same 
design in the prevention OfPOst-OPerative deep vein thrombosis' 
The primary end-point of the study was the incidence of post-operative deep vein 
thrombosis diagnosed by duplex scanning. 
The secondary study hypothesis was, 
'A protocol of low molecular weight heparin and anti-embolic stockings 
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is safe and effective to implement as blanket prophylaxis to prevent post-operative 
deep vein thrombosis in all surgical patients and procedures 
requiring general anaesthesid. ' 
The secondary end-point was the incidence of complications associated with the use 
of low molecular weight heparin and anti-embolic stockings. 
The tertiary study hypothesis was, 
'The satisfaction and compliance ofpatients wearing knee-length anti-embolic 
stockings is greater than with thigh-length stockings. ' 
The tertiary end-points were the specific FfRQL measurement for patient stocking 
satisfaction and the patient stocking compliance. 
1.7 Statistical analysis 
Statistical analysis was perfonned using STATA 6.0 statistical package (Stata 
Corporation, College Station, USA). Logistic regression analysis was used to 
estimate crude odds ratios (ORs) between Medi thigh-length and Medi knee-length 
and between Kendall thigh-length and Medi knee-length stocking groups. These 
crude ORs were also adjusted for the use of preoperative LMWH. 
1.8 Computer equipment, software and database 
A Dell@ Optiplex TM Gxi computer was used (Pentium III 80OMHz) with 128Mb of 
ram for the majority of the study work, all patient data was kept in offline storage 
databases. A database of all patients entered into the study was completed using 
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Microsofte 2000 Professional (Microsoft Corporation, Seatle, USA) AcceSSTM 
database. The Access database was used as the primary database from which 
information could be taken for analysis in other databases for statistical analysis and 
graphs, namely Microsofto ExcelTm, SPSSO'(SPSS Inc, USA) and STATA 6.0 
statistical package (Stata Corporation, College Station, USA). Reference Manager 
(Research Information Systems) was used to store and compile references. 
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A review of the literature: 
The prevention of deep vein thrombosis in 
surgical patients 
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2.1 Introduction 
A vast amount of literature and studies involving the prevention of venous 
thrombosis have been published over the last fifty years. The aim of this chapter is 
to provide the reader with a succinct overview on the prophylaxis of DVT in surgical 
practice and an update on the latest evidence for recommendations and advances in 
this area. In recent years, meta-analysis has been applied as a means of bringing 
together the large collection of data on WE prophylaxis. However meta-analysis has 
its potential pitfalls through it nature of combining information from smaller studies 
to produce an overall result, hence these articles should be interpreted with caution, 
especially with regard to the inclusion criteria. Traditional reviews of the literature 
offer insights into possible trends within the disease pattern, however they rarely 
offer new evidence as the data from studies is usually kept in the original form and 
not surnmated. The foundation of evidence-based practice is the prospective 
randomised controlled trial, of which many have been performed over the last five 
decades on the prevention of VTE. 
2.2 Why prevent deep vein thrombosis? 
Deep vein thrombosis causes considerable harm to the patient, acutely it can 
propagate and embolise to form a fatal pulmonary embolus and in the long term may 
progress in at least thirty percent of cases to the chronic and incurable condition of 
post-thrombotic syndrome which can lead to venous ulceration (Kakkar et al. 
1969, 
Giannoukas et al 1995 & Prandoni et al 1996). The alternative to primary prevention 
is secondary prevention that involves screening, diagnosis and treatment of 
DVT. 
Deep vein thrombosis is not only a dangerous disease, but also elusive and 
difficult 
to treat, less than half of all DVT are symptomatic, and these symptoms, when 
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present are non-specific. The long-terin anticoagulation treatment of DVT is not 
always absolute, as some patients continue to suffer from the acute - recurrent DVT 
and pulmonary emboli - and the chronic sequelae of VTE and in addition it is not 
uncommon for patients to suffer severely from the side effects of long-terrn 
anticoagulation. Among the patients that are adequately treated for DVT, recurrent 
thrombosis may occur in up to thirty percent at 8 years and PTS may develop in up to 
twenty-eight percent at five years (Prandoni et al 1996) 
In general the burden to patients and professional staff, the inability of treatment to 
reliably resolve the effects of DVT and the huge costs of screening and treatment 
(Bergqvist 1988) has led to primary prevention of DVT (and therefore WE in 
general) being the only viable mode of action followed by secondary prevention for 
the relative few that escape the prophylactic net. 
2.3 Types of prophylaxis: mechanisms of action, efficacies and 
complications 
The prophylaxis of DVT can be achieved by using a variety of different means; these 
can be divided in to mechanical or pharmacological methods. Each method targets 
one or more of the areas of Virchow's aetiological triad, the mechanical methods in 
general prevent the stasis of venous blood and damaging effects of venous over- 
distension. Whereas the pharmacological agents combat the increased coagulability 
of the blood. The different types of established prophylaxis are summarised in table 
2a. 
50 
--- - ------- 
Mechanical Prophylaxis Pharmacological Prophylaxis 
Graduated compression stockings 
Intermittent pneumatic 
Subcutaneous low dose heparin 
(unfractionated or low molecular 
weight) 
Warfarin 
compression 
Early mobilisation and leg Dextran 
elevation 
Aspirin 
Table 2a - The different types of thromboembolic prophylaxis 
2.3.1 The mechanical methods of prophylaxis 
The mechanical methods of prophylaxis include graduated compression stockings 
and intermittent pneumatic compression devices, which are thought to prevent DVT 
through increasing the emptying of blood from venous valve pockets, increase the 
velocity of distal to proximal venous blood flow and reduced over-distension of the 
veins during surgery. Mechanical methods have a number of advantages over 
pharmacological modalities: 
9 They do no alter the clotting mechanisms within the blood and therefore the 
bleeding tendency, 
o Simple to use, 
0 Cheap and cost-effective, 
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* Can be combined with pharmacological methods to increase the efficacy of 
prophylaxis, 
* Can be considered for use in low risk patients due to their low complication 
rate and minimal cost. 
However, there are a number of disadvantages: 
* They have not been shown to reduce the risk of PE unlike anticoagulant 
prophylaxis (Nicolaides et al 2002). 
* Effectiveness is reliant on compliance which may be decreased in patients 
who find them uncomfortable 
9 Mechanical methods are contraindicated in patients with peripheral vascular 
disease due to risk of producing limb ischaemia 
Prophylaxis Mean incidence of DVT (%) by 125, 
fibrinogen scanning [95% CII 
None 
Low dose unfractionated heparin 
Graduated compression stockings 
Intermittent pneumatic compression 
Dextran 
Aspirin 
25.1 [23.9,26.5] 
8.7 [7.8-9.7] 
9.3 [6.4-13.3] 
9.9 [6.9-13.9] 
16.6 [13.1-18.4] 
20.4 [16.5-25.0] 
Table 2b - Summary of DVT prophylaxis efficacies. Modified table 
from meta-analysis in general surgical patients (Clagett & Reisch 1988) 
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The specific characteristics and properties of graduated compression stockings are 
reviewed in chapter three of this thesis, with particular attention paid to the efficacies 
of the thigh and knee-length designs. The efficacy of GCS in the prevention of 
postoperative DVT in general surgical patients was calculated by meta-analysis 
performed by Clagett and Reisch (1988), the results are shown in table 2b. 
Intermittent pneumatic compression has been recognised as a useful inhibitor of 
postoperative DVT formation, on a par with GCS stockings and recommended for 
prophylactic use as an alternative to GCS (Nicolaides et al 2001). However, IPC has 
been shown to have limited prophylactic benefit in patients undergoing surgery for 
malignancy (Clagett et al 1988). Graduated compression stockings have the benefit 
of improved practicality as IPC requires an electrical supply and thereby limits 
mobility on the ward and is more expensive. However, IPC can be used 
simultaneously over GCS, especially on the operating table. 
2.3.2 The pharmacological methods of prophylaxis 
In the forty-five years since the pioneering randomised clinical trial investigating the 
efficacy of anticoagulation in the management of venous thromboembolism (Barritt 
& Jordan 1960), there has been substantial progress in the management of WE with 
major advances in anticoagulation therapy used for the primary prevention of VTE. 
Venous thrombosis usually occurs at the vessel wall with stasis or hypercoagulability 
as predisposing factors. Venous thrombosis, unlike the 'platelet-dependent' arterial 
thrombosis, relies more on the formation of thrombin and fibrin. Therefore 
anticoagulant medications that reduce the formation of thrombin and hence reduce 
the initiation and the extension of fibrin-rich venous thrombi are of major importance 
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in the prevention of deep vein thrombosis and pulmonary embolism. The mainstream 
pharmacological methods of prophylaxis are summarised in table 2b. 
2.3.2.1 Subcutaneous heparin 
In 1916, W. H. Howell discovered heparin and its ability to prevent the clotting of 
blood. Heparin is a naturally occurring glycosaminoglycan normally present in 
human tissues, the properties of heparin are summarised below in table 2c. Heparin 
was first isolated from ox liver by J. McLean who also identified its anticoagulant 
capabilities (McLean 1916). Unfractionated heparin is obtained commercially from 
either bovine lung or porcine intestinal mucosa, and consists of a heterogeneous 
mixture of polysaccharides with a range of molecular weights from 4,000 to 30,000, 
with a mean molecular weight of approximately 12,000. 
Most commercial heparins have specific activities usually around 150 U/mg, 
however the calcium salts of heparin are thought to have decreased local bleeding 
with subcutaneous injections and greater bioavailability than sodium heparin (Hirsh 
et al. 1970). The heparin structure consists of alternating residues of uronic acid and 
glucosamine that are variably sulphated, this sulfation of residues is a major 
determinant of heparin's anticoagulant activity. By itself, heparin is not an 
anticoagulant but a catalyst with a high binding affinity for anti-thrombin III (ATIII). 
ATIII regulates coagulation by inactivating coagulation proteases, such as thrombin 
and Xa, whose activity is enhanced by the binding of heparin. Low molecular 
weight heparins primarily inhibit factor Xa and have a lesser effect on the inhibition 
of thrombin. In addition to its anticoagulant properties, heparin has other biological 
effects, such as; hydrolysis of triglycerides from chylomicrons, activation of 
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platelets, suppress cell-mediated immunity, and affect the metabolism of a1dosterone 
and thyroxine. 
The Properties of Heparin 
Chemistry 
Route of administration 
Site of action 
Mechanism of action 
Dosage for prophylaxis 
Dosage for treatment of 
thromboembolism 
Monitoring 
Negatively-charged glycosaminoglycan 
Intravenous, subcutaneous 
Blood, vascular endothelium 
Catalyses antithrombin III inactivation of 
serine proteases (thrombin, factor Xa) 
5000 U subcutaneous 8-12 hr 
5000-10000 U initial intravenous bolus, 
30,000 U/24 hr continuous infusion until 
oral anticoagulation established 
Activated partial thromboplastin time 
(aPTT), 
Heparin levels for patients receiving very 
high doses or for patients in which aPTT 
is unreliable, for example lupus 
anticoagulant. 
Table 2c The Properties of Heparin 
Pharmacokinetics. The highly charged nature of heparin prevents its passage through 
cell membranes and thus prevents the oral use of heparin. Heparin is active when 
given parenterally, either intravenously or subcutaneously. The half-life of heparin 
increases with increasing dosage and decreases with increased clearance. Heparin is 
cleared by the reticuloendothelial system, metabolised by the liver, and the metabolic 
products are excreted in the urine. Clearance is also increased secondary to the 
extent of thromboembolism. Finally, the activity of heparin is also affected by its 
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binding to plasma proteins and the endothelium. Therefore the anticoagulation 
achieved by heparin has a number of dependent variables so that the therapeutic use 
has to be closely monitored to maintain a range that is effective but without over- 
anticoagulation to reduce risk of bleeding. Low dose subcutaneous unfractionated 
heparin for prophylaxis of WE usually does not require monitoring with the 
standard twelve or eight hourly subcutaneous injection regimes. The standard 
unfractionated heparin has a number disadvantages when compared to the more 
recently developed LMWH, which has led to the increasing use of the latter in 
clinical practice (discussed later). 
Low dose unfractionated heparin (LDUH) - usually prescribed 5 000 units 8-12 
hourly - has been the most common form of anticoagulant prophylaxis used over the 
last four decades. Its use has been advocated for the moderate and high-risk patients. 
In general, it is a safe and effective fonn of prophylaxis proven to reduce not only the 
rate of DVT but also fatal PE and overall patient mortality (Collins et al 1988, Flyers 
et al 1989, Salzman & Hirsh 1977). Despite the promising results from large RCTs 
investigating the prophylactic benefits, LDUH prevents only about two-thirds of 
DVT and two-thirds of fatal PE (Collins et al 1988 & International multicentre trial 
1975). 
The prevention of postoperative DVT with pharmacological methods is unfortunately 
achieved with infrequent but occasionally serious side effects from the treatment, 
however with careful administration of heparin the risks can be kept to a minimum. 
Bruising at the injection site can be minimised by using a concentrated solution 
(25000 units/ml), a small bore needle and good injection technique. With LDUH 
there have reports of increased risk of intra- and postoperative bleeding 
complications of around two percent (Collins et al 1988, Clagett et al 1988 & IMT 
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1975,1997), however an equal number of reports have detected no difference in 
bleeding complications from placebo, and even less with the more contemporary 
LMWH. In the majority of studies, of which many are from orthopedic and 
neurosurgery specialities who particularly fear operative bleeding complications, 
LDUH was shown to not increase the incidence of operative bleeding when 
compared to placebo (Dunn & Goa 1996, Freedman et al 2000, Howard & Aaron 
1998, Palmer et al 1997, Koch et al 1997). Operative bleeding complications have a 
number of causes and distinguishing those due to heparin coagulopathy maybe 
difficult and for this reason many randomised clinical trials have investigated this 
phenomena. Randomised controlled trials, some with double-blinding have shown 
rates of bleeding complications for LMWH, LDUH and placebo in orthopaedic 
surgery that ranged between 1.5-6%, 6-9% and 2.4-8% respectively (Levine et al 
1991 & 1996, Menzin et al 1994, Turpie et al 1986, Leclerc et al 1996). Likewise, in 
neurosurgery bleeding complications occurred at 2-3%, 0-1.8% and 0-3% 
respectively (Raab et al 2001, Macdonald 1999, Agenlli 1988, Nurmondamed 1996), 
and results from gastrointestinal surgery studies were very similar (Ockelford et al 
1989, Gallus et al 1993). Contraindications to subcutaneous heparin include bleeding 
disorders such as thrombocytopenia, haernophilia, hepatic or renal failure; potential 
or ongoing bleeding, such as from peptic ulceration or varices; history of 
hypersensitivity to heparin or heparin induced thrombocytopenia. Heparin induced 
thrombocytopenia occurs in approximately 0.3% of patients given prophylactic 
porcine heparin, the Committee on the safety of medicines advises that heparm 
activity and platelet levels should be monitored after five days of prophylaxis and 
stopped if thrombocytopenia is detected. Other unfavourable reactions include skin 
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necrosis, raised serum concentrates of serum transaminases, osteoporosis with long- 
term heparin especially in pregnancy (Hirsch 1991) 
Low molecular weight heparin, like unfractionated heparin exerts its anticogulant 
function by potentiating the action of antithrombin against its target proteases 
(thrombin and factor Xa) and by mobilising the tissue factor pathway inhibitor 
(TFPI) from the vascular endothelium into the circulation. In contrast to 
unfractionated heparin, LMWH has little effect on factor 11 but has a similar effect on 
factor X. The ability of LMWH to inhibit factor ten is the cornerstone of its 
anticoagulant properties. TFPI is a potent inhibitor of the extrinsic coagulation 
cascade, which exerts its function by neutralising the catalytic activity of factor Xa 
and by feedback inhibition of the factor VIIa-TF complex in the presence of factor 
Xa. The observed superior efficacy of LMWH over unfractionated heparin in clinical 
trials assessing prophylaxis and treatment of VTE may be explained by the decreased 
circulating antithrombin and TFPI (free- and bound) found with unfractionated 
heparin but not with subcutaneous LMWM treatment (Hansen & Sandset 1998). 
The monitoring of the anticoagulant activity of LMWH is through measurement of 
antifactor Xa levels, however this not necessary with the low dose required for WE 
prophylaxis. During the last two decades several LM"s have been developed by 
chemical or enzymic degradation of unfractionated heparin. The LMWHs currently 
available for use in clinical practice are produced by different techniques and 
therefore have varied pharmacological properties, which may have important clinical 
implications such as associated bleeding complications. Examples of LMWH that 
have been investigated in clinical trials include, enoxaparin, certoparin, dalteparin, 
nadroparin, parnaparin, tinzaparin and clivarine. In the UK, only Enoxaparin (20-40 
mg/d), tinzaparin (3500 units/d) and daltaparin are currently licensed for use in WE 
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prophylaxis in the UK. Enoxaparin and tinzaparin are LMWH with an average 
molecular weight of about 4500 daltons (Kakkar et al 1993). They have better 
bioavailability by the subcutaneous route and a longer half-life in the circulation than 
unfractionated heparin, allowing a once daily administration for prophylaxis and 
treatment. The anti-Xa/anti-Ila ratio ranges from 1.5 to 1.8 for tinzaparin and around 
3.2 for enoxaparin, these ratios theoretically would be important in predicting the 
antithrombotic efficacies and bleeding risk of the LM" (Bara et al 1999). 
Low molecular weight heparin has been heavily investigated over the last decade to 
establish its efficacy and safety when compared to LDUH and placebo. A large of 
number of trials and meta-analyses have demonstrated that LM" is undoubtedly 
no worse and in many instances better at preventing thromboembolic complications 
than LDUH. A meta-analysis by Mismetti and colleagues (2001) comprehensively up 
dated the surgical profession on the efficacies and complications of LM" 
compared to placebo and LDUH. Previous meta-analysis have demonstrated a 
reduction of asymptomatic DVT with LMVM and LDUH that was associated with a 
reduction in the risk of PE or death (Leizorovicz et al 1992 & Jorgensen et al 1993). 
Mismetti and colleagues found 82 studies from 1984 to 1999 evaluating LMWH in 
general surgery, urology, gynaecology, and cancer surgery, of which 21 were 
excluded for poor techniques of randomization, methodology, or use of heparinoids. 
In comparison to placebo, LMWH was found to significantly reduce the risk of DVT 
by 72 percent (relative risk (RR) 0.28(95% CI 0.14,0.54) p<0.00 1), clinical PE by 75 
percent (RR 0.25 (0.08,0.79); p=0.0 18) and clinical VTE by 71 percent (RR 0.29 
(0.11,0.73); p=0.009). Haemoffhage was found to be more frequent in patients with 
preoperative LMWH than placebo, the incidence of major haernorrhage was 2.8 
percent and wound haematoma was 10.3 percent. Individual LMWH groups were 
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not analysed due to small numbers of studies. In comparison to LDUH, LMWH 
reduced the risk of DVT, clinical PE by a non-significant margin, 10% and 12% 
percent respectively. However, LMWH was significantly better at reducing clinical 
WE (p = 0.049). As far as haemorrhagic complications were concerned, with 
LM" there was a reduced risk of major haemorrhage and wound haematoma, but 
not significantly less than LDUH. When the dosage of LMWH was introduced into 
the analysis, low-dose LM" (3400 anti-Xa units or less) achieved an equal 
efficacy to LDUH, but with significantly less risk of haemorrhage (RR 0.76 
(0.63,0.92); p=0.005). Conversely, high-dose LMWH (more than 3400 anti-Xa 
units) appeared to be more effective than LDUH, especially with clinical PE, 
however this was counterbalanced with by a significant increased risk of 
haernorrhagic complications. Other more recent meta-analyses have reinforced the 
argument for LM" over LDUH and placebo in the prevention of VTE with 
minimal bleeding complications (Counsell & Sandercock 2002, Will-Jorgensen et al 
2002 & Handoll et al 2002). 
In addition to improved efficacy, LMWI has other advantages in terms of patient 
acceptability, practicality and cost. Patient acceptability is improved with only one 
daily subcutaneous injection compared to a possible three injections with LDUH. 
The single daily administration is more practical for health professionals and at the 
time writing LMWH daily cost (e. g. enoxaparin 20mg - 90 pence) was less than the 
daily cost for LDUH (from 98 pence/day). The fact that LMVvH requires only a once 
daily dose, pen-nits the injection to be given on the evening before surgery, which 
allows the peak plasma anti-Xa activity that occurs one to four hours after the 
injection to pass during the night, therefore reducing further any risk of pero- 
operative bleeding. Many anaesthetists also prefer LMWH prophylaxis to be given 
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up to twelve hours before placement of spinal and epidural anaesthesia (Bergqvist & 
Wiklund 2000). Therefore LMWH should be administered on the 'evening' before 
surgery to allow these patients to safely receive regional anaesthesia and LMWH 
prophylaxis. LWME has other potential side effects apart from the 'bleeding', which 
include allergy; inducing skin necrosis and heparin induced thrombocytopenia. In 
contrast to unfractionated heparin, in cases reviewed from the literature, the LMWH 
induced minimal thrombocytopenia or thromboembolic complications and skin 
necrosis usually only occurred after previous heparin exposure. Whereas in cases 
with unfractionated heparin that induced skin necrosis, the patients were rarely 
pretreated with heparin and showed greater tendency towards thrombocytopenia and 
thromboembolism. This would suggest that LM" is less immunogenic than 
unfractionated heparin and requires repeated exposure to initiate skin necrosis 
(Fureder et al 1998). 
2.3.2.2 The recent orthopaedic literature comparing 
unfractionated to low molecular weight heparin for 
thromboprophylaxis 
The main area of controversy with the use of LMWH has been in orthopedic 
surgery, some of these surgeons argue that the potential risk prosthetic joint infection 
secondary to haematomae caused by the bleeding tendency of LM" far outweigh 
the benefits of preventing 'asymptomatic DVT and the occasional PE'. A summary 
of the literature assessing the incidence of bleeding complications after orthopaedic 
surgery with heparin thrombo-embolic prophylaxis is included. 
An search of electronic databases, Medline and Pubmed, for orthopedic meta- 
analyses or randomised controlled trials (RCT) published over the last 10 years 
has 
produced the following studies assessing heparin for the prophylaxis of deep vein 
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thrombosis and pulmonary embolism in patients undergoing orthopaedic surgical 
procedures. Their conclusions about efflicacy of LMVM and LDUH and bleeding 
complications are summarised below. 
Freedmanetal. A meta-analysis of thromboembolicprophylaxisfollowing elective 
total hip arthroplasty. JBJS July 2000; 82-A: 929-38. 
(1) In this study LDUH was the least effective and least safe pharmaceutical 
prophylaxis, LMWH was second to warfarin for efficacy and safety. 
(2) Significant bleeding risks were associated with both LDUH 
(minor and major bleeding complications) and LMWH (minor 
only). Major bleeding complications included gastrointestinal, 
spinal/epidural anaesthesia related or wound haematomas requiring 
surgical decompression. 
HowardA W, Aaron SD. Low molecular weight heparin decreases proximal and 
distal deep vein thrombosisfollowing total knee arthroplasty. A meta-analysis of 
randomised trials. Thromb Haemost 1998 May; 79: 902-6 
(1) LMWH is more efficacious than LDUH or warfarin for DVT prevention. 
(2) No excess of bleeding was recorded in the LMWH group. 
Palmer et al. Efficacy and safety of LAIWH, unftactionated heparin and warfarinfor 
thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of 
randomised clinical trials. Haemostasis]997; 27: 75-84. 
62 
(1) In orthopaedic surgery LM" is significantly superior to both LDUH 
and 
warfarin in the prevention of DVT 
(2) LMWH results in significantly less bleeding complications when 
compared to LDUH and warfarin. 
Koch et al. LMWH and unftactionated heparin in thrombosis prophylaxis after 
major surgical intervention: update ofprevious meta-analyses. BJS 1997; 84: 750- 
59. 
(1) LM)WH was superior to LDUH with respect to efficacy and safety in 
orthopaedic surgery (safety analysis reported wound haernatomas and other 
bleeding complications). 
(2) Low dose LM" was equally efficacious to LDUH and 
provided increased safety over LDUH. 
(3) High dose LMVVH did not provide an increase in efficacy of prophylaxis. 
Imperiale TF and Speroff TA meta-analysis of methods to prevent venous 
thromboembolism following total hip replacement. JAAM 1994; 271: 1780-85. 
(1) All treatments except aspirin reduced the risk of DVT 
(2) Only LMWH and stockings reduced the risk of pulmonary 
embolism. 
(3) Percentage of patients with clinically important bleeding was 
1.8% and 2.6% with LMWH and unfractionated heparin 
respectively. 
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Anderson et aL Efficacy and cost ofLMWH compared with standard heparinfor the 
prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 
1993; 119: 1105-12. 
(1) LM)WH is more effective in DVT prevention than LDUH 
(2) No significant differences in minor and major bleeding 
complications were found between the two groups. 
(3) The use of LMWH results in an overall saving in cost. 
In summary, the issue of bleeding complications is controversial because some 
studies have shown fewer wound haernatomas and bleeding complications with 
LMWH while other studies have shown the opposite. Summations of the available 
data by meta-analyses show a trend towards LMWH having an increased efficacy 
with fewer postoperative bleeding complications. A large European trial (Leyvraz et 
al 199 1) showed that LMWH with adjusted dose for weight showed no increase in 
bleeding complications. A recent review of WE prophylaxis found that the 
discrepancy between trials reporting different rates of bleeding complications with 
LMWH was related to the doses used (Agnelli & Sonaglia 2000). It has been shown 
that doses of LMWH greater than 3400 anti-Xa IU/day were associated with higher 
rates of bleeding than experienced with LDUH. In contrast, LMWH used in doses 
lower than 3400 anti-Xa IU/day produced similar levels of VTE prevention with less 
bleeding. 
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2.3.2.3 Oral anticoagulants 
In the 1920's, it was found that cattle fed on spoiled sweet clover developed a severe 
bleeding tendency. The active agent was later identified as bishydroxycoumarin 
(dicoumarol) (Campbell & Link 1941) and from this, synthetic derivatives - 
including warfarin - were developed. The therapeutic efficacy of vitamin K 
antagonists ed to their widespread use in the 1970s, however drug associated 
bleeding disorders became troublesome. The subsequent acceptance of the 
International Normalised Ratio (INR) has improved the clinical application of 
warfarin. Commercially available warfarin is a racernic mixture of levorotatory and 
dextrorotatory forms, which has a half-life of approximately 36 hours. Warfarin 
inhibits the synthesis of y-carboxylated vitamin K dependent proteins (prothrombin, 
factors VII, IX, X) and this leads to the anticoagulant effect in the circulation. 
Complications of warfarin include haemorrhagic complications; there is a direct 
relationship with bleeding and the intensity of anticoagulation. And non- 
haemorrhagic complications, such as alopecia, abdominal discomfort, liver 
dysfunction and skin necrosis, these are rare. Warfarin induced skin necrosis an 
uncommon but devastating complication that usually occurs in the first week of 
treatment. Thrombosis of skin vessels results in skin necrosis that frequently 
requires plastic surgery or even amputation. 
Warfarin is effective in the prevention of DVT after orthopaedic surgery (Francis et 
al 1983, Morris & Mitchell 1976, Powers et al 1989) and gynaecological surgery 
(Tabemer et al 1978 & Poller et al 1987). It has been shown to be effective, whether 
started preoperatively or post-operatively (Hirsch 1990 & 1991, Gallus 1990). Due 
to the potential bleeding risk with the recommended general use of an international 
normalised ratio (fNR) of 2-2.5 and 2-3 for orthopaedic hip operations, some authors 
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have advocated using a preoperative low-dose of warfarin or commencing 
prophylaxis after surgery (Francis et al 1983, Poller 1987 & Hirsch 1991). Warfarin 
is usually reserved for high-risk patients due to the required daily laboratory INR 
assessments and increased risk of bleeding (Hirsch 1990 & 1991, Gallus 1990). 
Warfarinisation if contraindicated in patients with bleeding disorders or bleeding 
pathology (as for heparin) and in pregnancy due to risk of fetal abnormalities. 
Caution should be taken with spinal or regional anaesthesia due to the risk of 
haemoffhagic complications (Wille-Jorgensen P et al 1991 & Wildsmith & McClure 
199 1). Warfarin has been shown to be effective for orthopedic surgery but is not 
practical for other specialities that involve abdominal surgery because post-operative 
ileus would prevent its administration. 
Oral forms of LMWH are currently under investigation, which would avoid the cost 
and patient discomfort of the subcutaneous route of administration. The relative 
large size and negative charge of the molecule has lead to the unreliable absorption 
of LMWH via the gastrointestinal tract. A compound has been developed 
(Emisphere Technologies, Tarry-town, New York, USA) to act as a 'carrier' for 
LM" to be administered orally; sodium N-[10-(2-hydroxybenzoyl)amine 
decanoate, (SNAD). LMWH and SNAD are bound by a noncovalent interaction that 
allows the compound to pass through the gastrointestinal mucosa. Once in the 
bloodstream the complex dissociates to leave the free LMWH molecule. Animal 
experimental studies have demonstrated a significant anti-Xa activity with decreased 
thrombosis after oral LMWH treatment (Salartash et al 2000). In future years oral 
LM" may become the treatment of choice for the prevention of VTE in the large 
proportion of hospitalised patients who can receive oral medication, the remainder 
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who are only tolerant of parental medications, would therefore receive subcutaneous 
form of LMWH. 
2.3.2.4 Dextran infusion 
Dextran 70 has been shown to exert antithrombotic effects on the lysability of fibrin, 
platelets and the endothelium (Bergentz 1978). However it has limited ability to 
prevent DVT, more so in orthopaedic patients, and it seems to have achieved better 
results in preventing PE, possibly due to its fibrin lysing ability (Clagett & Reisch 
1988, Hirsch 1990, Gallus 1990, Wille-Jorgensen 1991). Dextran has been shown to 
reduce fatal PE in data surnmated from 29 randornised studies, the controls (n=298 1) 
had an incidence of 1.5% compared to the patients treated with dextran (n=2964) the 
fatal PE rate was 0.34% (Relative risk 0.22; 95% confidence interval (CI) 0.11-0.44), 
however the effect on preventing DVT was small (RR 0.76; 95% Cl 0.64-0.91). 
Dextran has the risk of bleeding complication, as for heparin, requires intravenous 
infusion with risk of fluid overload in the susceptible, and noteworthy allergic 
reactions, which include anaphylaxis (TIMFT consensus 1992). 
2.3.2.5 Antiplatelet agents (Aspirin) 
Aspirin exerts its antithrombotic effect by irreversibly inhibiting (by acetylation) 
platelet cyclooxygenase, preventing synthesis of thromboxane A2, and impairing 
platelet secretion and aggregation. Non-steroidal anti-inflammatory drugs (NSAID) 
such as aspirin have the well-documented complication of damaging the 
gastrointestinal (GI) mucosa, commonly resulting in gastric ulceration causing 
perforation or GI haemorrhage. Other side effects include abdominal discomfort, 
systemic bleeding and blood loss. Aspirin (acetylsalicyclic acid) and 
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hydroxychloroquine have been shown to offer only minimal protection from VTE 
(Clagett & Reisch 1988, Gallus 1990). The antithrombotic effects of aspirin occur at 
low doses around 75mg, however these antithrombotic effects are mainly on the 
arterial side of the circulation. 
2.3.2.6 Others 
Hirudin, and its synthetic analogues are direct thrombin inhibitors that do not require 
antithrombin III for their activity consequently making them more efficient at 
inhibiting clot-bound thrombin (Weitz et al 1990). The advantages of hirudin include 
good bioavailablity after subcutaneous injections, weak immunogenicity and ease of 
monitoring with activated partial thromboplastin time (aPTT) or thrombin time. 
Disadvantages include the lack of reversing agent and expense. Recombinant 
hirudin has been shown to be a possible alternative to subcutaneous heparin in two 
level one orthopaedic hip surgery studies (Eriksson et al 1994 and 1997). 
Other novel anticoagulants include Tick anticoagulant peptide isolated from the Soft 
Tick, antistasin isolated from the Mexican leech, pro-uronase, and tissue 
plasminogen activators such as those isolated from the Vampire bat (Desmodus 
rotundus). These substances have limited human studies to provide evidence for their 
efficacy and safety. 
Cavalfilters are used to prevent imminent PE and not DVT and together with their 
invasive nature, they are not indicated as part of routine VTE prophylaxis. 
Drugs that stimulate fibrinolysis, such as anabolic steroid have only limited efficacy 
for VTE prophylaxis (THRIFT consensus 1992). 
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2.4 The recent recommendations for the use of prophylaxis in 
clinical practice 
As previously discussed in chapter one, over the last four decades the continued 
development of evidence-based guidelines for surgeons to practice effective 
prophylaxis of VTE has lead to the protocols found in the THRIFT, European and 
International Consensus Statements. These guidelines advocated that all surgical and 
medical patients should receive specific thromboprophylaxis in accordance with their 
risk of developing VTE. This idea was modified from some of the first authors to 
separate the thromboprophylactic requirements of patients into categories in relation 
to thromboembolic risk (Salzman and Hirsh 1982). The risk of WE in hospitalised 
patients is not only dependent on the patients' illness, planned treatment or operation, 
but also on pre-existing patient variables that predispose to VTE. The patient factors 
that increase the risk of VTE include; age, obesity, immobility, increases in 
oestrogen levels, varicose veins, previous history of VTE, systemic infection, 
acquired and hereditary thrombophilias. Epidemiological studies have demonstrated 
that age is an important risk factor with forty years designated as a threshold to 
separate risk groups, however the other factors mentioned can unite to place patients 
at high risk even if they are younger than forty years of age. 
The THRIFT group recommended that all patients admitted to hospital should be 
assessed for thromboembolic risk and then the intensity of the prophylaxis prescribed 
should be tailored accordingly. This resulted in the recommended prophylaxis for 
low-risk patients was early mobilisation, the moderate and high-risk patients were 
recommended combinations of prophylaxis such as GCS, IPC and subcutaneous 
heparin, together with early mobilisation. 
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The European consensus statement (Haas 1993) separated the risk of each group 
more clearly and allocated their recommendations for the prophylactic requirements 
of each group (table 2d). 
.......... ------- Risk Risk of VTE Recommended 
catei! orv Prophylaxis 
Calf DVT Proximal Fatal PE 
DVT 
High 40-80% 10-30% 1-5% LMWH or LDUH 
with GCS or IPC 
Moderate 10-40% 2-10% 0.1-0.7% LMWH or LDUH 
and/or GCS or IPC 
Low <10% <1% <0.01% Mobilisation or 
GCS 
Table 2d - Risk categories and recommended prophylaxis in surgical patients 
(Modified from the European Consensus Statement. Haas 1993). Abbreviations: 
DVT, deep vein thrombosis; VTE, venous thromboembolic disease; PE, pulmonary 
embolism; LMWH, low molecular weight heparin; LDUH, low dose unfractionated 
heparin; GCS, graduated compression stockings; IPC, intermittent pneumatic 
compression. 
A number consensus groups have recommended very similar guidelines for the 
prescription of effective prophylaxis against WE in surgical patients. The majority 
base their protocols on the theory of thromboembolic risk categories for which an 
increasing intensity of prophylaxis is recommended for a patient deemed to be at 
increased risk. This common premise results in the majority of patients staying in 
hospital for surgical treatment are usually of high or moderate risk of developing 
DVT or PE (any patients with one or more risk factors or over the age of forty years 
70 
having more than minor surgery) and therefore receive subcutaneous heparin and/or 
GCS or IPC. 
However, there are a number of potential flaws in the risk category system for 
prescribing WE prophylaxis: 
* Firstly, each different consensus uses slightly different risk factors for their 
risk categories which may lead to the inconsistent and disparate use of 
prophylaxis by doctors in hospital practice, 
e Secondly, the evidence for the correct prophylaxis for one of the three risk 
groups is not available, i. e. the low risk patients. 
e Thirdly, the risk categorisation depends on the characteristics of the 
individual patient and the type of surgery planned. If some of these factors 
used to 'predict' the correct prophylaxis inadvertently change intra- or post- 
operatively, then the patient will receive sub-optimal prophylaxis; such as the 
planned duration of surgery, the malignant status of a presumed benign 
lesion, and the patients' postoperative mobility and infective status. 
Despite these potential problems, the most recent and comprehensive guideline for 
the prevention of WE in surgical patients is from the International Consensus 
Statement (Nicolaides et al 2002). The guidelines issued in this statement are 
surnmarised below (Table 2e). For the majority of patients from all of the 
specialities shown in the table, the evidence suggests that the most frequently 
effective modalities of prophylaxis are LMWH, for which the evidence is continually 
accumulating to make LMWH the drug of choice in VTE prevention, and GCS or 
IPC. Combinations of LMWH with GCS have been shown to be more effective than 
single prophylaxis, however more evidence is required. In comparison to IPC, GCS 
are cheaper, more acceptable to patients, easier to use, and more practical patients 
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Risk Recommended Thromboembolic Prophylaxis 
Category (Level of evidence I-III) 
High 
Moderate 
General 
Surgery 
LMWH or 
LDUH (I) 
Orthopaedic 
Surgery 
Neurosurgery Gynaecology 
TKR - LMWH Combinations of LMWH or 
(I), GCS & IPC LMWH and LDUH (I), 
GCS (III) or IPC 
THR - LMWH for and IPC (I), 
(I), Adjusted neurosurgery GCS (III), 
dose warfarin patients in 
(I), IPC (I), general Combination 
recombinant prophylaxis 
Hirudin (I), 
and GCS (III) 
GCS or 
IPC (I) 
Combinations 
of above (II) 
LMWH of 
LDUH (I), 
LMWH or 
LDUH (I) 
GCS or IPC (I) 
Trauma - 
(insufficient 
evidence) 
As above by 
extrapolation 
(insufficient 
evidence) and IPC (I) or 
GCS (III) 
Low 
Early Early GCS (III), 
ambulation ambulation Ambulation 
Hydration Hydration (M) I 
GCS GCS Hydration (III) 
(Insufficient (Insufficient 
evidence) evidence) 
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Table 2e - Summary of the 'International Consensus Statement' 
recommendations for thromboembolic prophylaxis in surgical patients 
(Nicolaides et al 2002) Abbreviations: Levels of evidence, (1) - from sound clinical 
trials, (11) - from studies with some inconsistencies, (111) - Extrapolated evidence or 
small or poorly designed trials; LMWK low molecular weight heparin; LDUH, low 
dose unfractionated heparin; GCS, graduated compression stockings; IPC, 
intermittent calf or foot compression; TKR, total knee replacement; THR, total hip 
replacement. 
and staff. Thus GCS in the majority of instances are the preferred choice of 
mechanical prophylaxis, however IPC used with GCS adds supplementary 
protection. 
2.5 Cost effectiveness of prophylaxis 
In every part of the health service, whether state-run or self-funded, health 
economics are an important part of health care practice. Without the efficient and 
effective use of available resources the quality of care would soon deteriorate. 
In medium and high-risk surgical patients the costs of screening, diagnosis and 
treatment of VTE are so high that the current recommendations of primary 
prevention utilise the resources most efficiently and therefore cost effectively (Haas 
1993). VTE prophylaxis becomes less cost effective as age progresses due to the 
decreasing life expectancy. There is no data available as yet for low-risk patients and 
unfortunately this situation may not change as due to the low incidence of WE in 
this group the very large RCT's required to attain the necessary data. Despite the 
lack of data, the prophylaxis of low-risk patents should not be ignored as there is 
firm evidence demonstrating that this group develop VTE complications even if 
infrequently. 
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The cost effectiveness of DVT prophylaxis has been reported (Bergqvist 1997 & 
1988, Anderson & O'Brien 1997, Menzin 1994), and because the cost of LMWH has 
reduced - to less than LDUH - since its conception it is now more cost effective. 
Though LMWH is 5 to 10 times more expensive than unfractionated heparin for the 
treatment of established DVT, it is now the cheaper heparin for prophylaxis at 90 
pence per day (single daily injection of enoxaparin) compared to 98 pence per day 
for the twice daily regime of LDUH, thus making LMWH more economically 
acceptable than unfractionated heparin. The prices - at the time of study (2001-2003) 
- for Hammersmith Hospitals NHS Trust (Charing Cross Hospital) are summarised 
below: 
)ý- LMVM 
m Clexane (enoxaparin) 90p per day (one injection) 
a Fragmin (dalteparin sodium) 83.5p per day (one injection) 
m Tinzaparin 3500u 85p per day (one injection) 
)ý- LDUH 
m 98p per day (12 hourly: two injections per day at 49p per injection of 
mini-heparin) 
m fl. 47p per day (8 hourly: three injections per day at 49p per injection of 
mini-heparin) 
2.6 Commencement and duration of prophylaxis 
The best time for the commencement and the duration of thromboembolic 
prophylaxis is unknown. Many authors have investigated both sides of the dispute 
over commencing prophylaxis before or after surgery and for continuing prophylaxis 
for different periods of time post-operatively. There is some evidence in the existing 
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literature, but only very little from RCTs investigating this particular area of VTE 
prophylaxis. There are two main questions that need to be answered: 
L Should DVT prophylaxis be started before or after surgery? 
ii. For how long does DVT prophylaxis need to be continued in the 
postoperative period? 
The European consensus (1993) states clearly that 'prophylaxis should be initiated 
before operation in all groups. The current recommendation is to continue 
prophylaxis for 7-10 days. Although the evidence is weak, consideration should be 
given to exten ing prophylaxis when the hospital stay is prolonged or the risk 
continues. 
Other authors have made similar recommendations that the prophylaxis of DVT 
should continue at least until discharge, and only in some selected high-risk cases 
after they have left hospital; therefore not for a predetermined time after surgery 
which may not be best for the individual needs of the patient (THRIFT consensus 
group 1992 & Scurr et al 1988). Three RCTs in orthopaedic surgery have 
investigated the optimal duration of prophylaxis after elective hip replacement 
surgery, which showed a marked reduction of venographically detected DVT - from 
19-26% to 7-12% - in patients treated with one month of LM" anticoagulant 
prophylaxis (Bergqvist et al 1996, Planes et al 1996, Dahl et al 1997). Conversely in 
a review of 29 general surgical trials involving over eight thousand patients, 
subcutaneous heparin was given to the majority of patients for only seven days. The 
authors of this recent comprehensive review on the methods of DVT prophylaxis 
recommended that 'prolonged prophylaxis with either LM" or adjusted-dose 
warfarin (INR 2-3) can be adopted in patients with additional risk 
factors such as leg 
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paralysis, malignancy, or previous episode(s) of venous thromboembolism' (Agnelli 
& Sonaglia 2000) 
2.1 Conclusions 
A number of conclusions can be drawn from the literature, 
0 Primary prevention is better for the patient and more effective than secondary 
prevention as the mainstay of WE management. 
m In general, graduated compression stockings are the preferred mechanical 
prophylactic modality in terms of efficacy, safety, cost, practicality and 
patient acceptability. 
m Overall, low molecular weight heparin is the better pharmacological 
prophylaxis for the prevention of postoperative DVT again in terms efficacy, 
safety, cost, practicality and patient acceptability. 
m Consensus groups recommend combination prophylaxis for high and 
moderate risk patients. The low risk recommendations are without evidence, 
however complication-free prophylaxis would be beneficial if not cost- 
effective. 
0 Risk categorisation of patients for thromboprophylaxis suffers a number of 
failings that can potentially result in inadequate prophylaxis. 
m As surgery initiates the WE process, it is probably more beneficial to start 
prophylaxis prior to surgery if safety can be guaranteed, however this is 
theoretical and yet unproven. The optimal duration of postoperative 
prophylaxis is unknown. 
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A number of areas for future research in the prevention of postoperative DVT were 
highlighted by the literature. If one considers the variety of patient characteristics and 
surgical procedures, together with the continuing advances in prophylactic methods, 
the whole subject of VTE prevention is vast. However, the key questions in surgical 
VTE prophylaxis that have arisen time and time again from many authors will 
require investigation via prospective randomised clinical trials in the future. These 
include: 
0 The efficacy of above-knee compared to below knee compression 
stockings (see chapter three) 
0 The efficacy of pre-operative compared to post-operative subcutaneous 
heparin prophylaxis 
0 The optimal duration of prophylaxis after surgery 
E The best methods of improving the rate of application of 
protocols/guidelines for WE prophylaxis in our hospitals 
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Chapter Three 
A review of the literature: 
The prevention of deep vein thrombosis with graduated 
compression stockings 
List of contents 
3.1 Background 
3.2 Mechanism of action 
3.3 Efficacy of graduated compression stockings in the 
prevention of post-operative deep vein thrombosis 
3.4 Complications of graduated compression stockings 
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graduated compression stockings in the prevention of post- 
operative deep vein thrombosis 
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3.1 Background 
The use of external lower limb compression devices were first reported in the 17th 
century by Pierre Dionis, the surgeon-in-ordinary to the Queen of France and to the 
Empress Maria Theresa of Austria. The application of GCS to the lower extremity 
for the prevention of venous thromboembolism was formerly investigated as early 
the 1950's (Wilkins et al 1952; Wilkins & Stanton 1953). Since then, the use of 
GCS has been varied and inconsistent, largely due to the dispute over their exact 
mechanism of action and their effectiveness in the myriad of patients undergoing a 
wide range of surgical procedures in our hospitals. There is evidence to suggest that 
GCS increase the velocity of distal to proximal venous flow in the leg (Meyerowitz 
& Nelson 1964; Makin et al. 1969) and reduce the distension of the deep veins of the 
calf during surgery (Coleridge Smith et al 1991). However, other studies have 
shown conflicting evidence against the beneficial effects of GCS in terms of 
alterations in venous flow and prevention of venous thrombosis. What is certain is 
the practicality, ease of use, low cost and safety of GCS that have ensured that GCS 
with the help of encouraging results from continued research are at the forefront of 
DVT prophylaxis in surgical patients. 
Graduated compression stockings are available in a number of designs, which 
include varying lengths and compression profiles. Sigel and coworkers (1975) found 
the optimal degree of graduated compression to be a pressure of 18 mmHg at the 
ankle and 8 mmHg over the upper thigh in order to produce the best gradient to 
encourage distal to proximal venous blood flow. Interestingly, the optimal 
length of 
stocking has still not been decided despite the use of GCS for over thirty years 
in 
hospitals worldwide. Stockings are available in a number of 'lengths' that in general 
equate to either above-knee or below-knee designs. The 
below-knee stockings are 
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applied to the leg from the distal foot over the ankle to just proximal to the knee joint 
and are commonly referred to as 'knee-length' GCS. Whereas, the above-knee 
stockings, referred to as 'thigh-length' GCS are applied from the distal foot, over the 
ankle and knee joint up to the proximal thigh. Varying mechanisms enable the 
above-knee stockings to stay in place, the most commonly used design in hospital 
practice are those with a 'band' around the upper thigh. Other forms of above-knee 
stockings have waist 'bands' or 'belts' that keep the stockings in place, however 
these are less common as they cause some interference with the wounds from 
inguinal, hip, pelvic and lower abdominal surgery without any added benefit of 
increased area of compression to the leg. Essentially, the above-knee stockings 
apply pressure to the calf and thigh whereas the knee-length stockings compress only 
the calf 
3.2 Mechanism of action 
In the early 1940's, Hunter and his colleagues reported on three hundred and fifty 
one autopsies and concluded from their findings that sudden immobilisation in bed of 
previously ambulant elderly patients was a major contributor to the development of 
DVT by altering the function of the venous circulation (Hunter et al. 194 1). In the 
same decade, studies went on to investigate preventive measures for DVT by 
deten-nining the effects of external compression on the flow of venous blood in the 
deep veins of the leg. Initially, the increase in venous flow with compression was 
demonstrated by observing the time taken for blue dye injected into the foot to be 
cleared from the common femoral vein, external compression was shown to increase 
venous blood flow velocity in the leg by as much as 45% (Stanton et al 1949). 
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Subsequent clinical studies using radioactive isotopes added further information by 
confirming the reduced transit time from foot to femoral vein in the presence of 
lower extremity compression. In 1960, using radiolabelled human albumin 
Meyerowitz and Crook showed that an external calf compression of 10 mmHg could 
increase blood flow by as much as 60% when compared to the unstockinged 
contralateral leg. Meyerowtz and Nelson demonstrated similar results in a repeat of 
this study. (Meyerowitz et al 1964). On theoretical grounds the application of elastic 
compression to the legs soon became the main mechanical method of DVT 
prevention. However the effect of greater external compression to the leg was 
investigated in animal and human studies by Spiro et al (1970) and Sabri et al (197 1). 
These studies demonstrated that excessive pressure was detrimental to venous blood 
flow and external compression for DVT prevention should be less than 20 mm Hg. 
Early designs of stockings were flawed and hence offered little benefit and in some 
instances were detrimental. Due to the 'inverted cone' shape of the leg, a stocking of 
uniform compression along its length actually applies greater external pressure 
proximally because of the wider circumference of the thigh compared to the calf. 
These 'tubular' or 'tubigrip' stockings failed to prevent DVT as they produced a 
reverse pressure gradient which inhibited the flow of venous blood out of the leg and 
actually increased the risk of venous stasis (Makin et al 1969 & Rosengarten et al 
1970). Sigel and his colleagues (1973) subsequently demonstrated that although 
external elastic compression decreased venous capacitance of the lower limb, the 
resultant alteration in the venous blood flow is dependent on an inverse pressure 
gradient. Correctly applied graduated compression, with a greater pressure distally 
that gradually reduced proximally along the length of the leg increased the velocity 
of venous flow in the direction of the decreasing pressure gradient (Sigel et al 1975). 
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These findings have subsequently been supported by Lawrence and Kakkar (1980), 
the venous clearance of radioisotopic substances injected into the foot of recumbent 
subjects was substantially enhanced to between 2-5 cm/s by graduated compression. 
The mode of application of graduated compression was found to be of critical 
importance, the use of elastic bandages was unreliable with regard to the pressure 
applied, even with the greatest care of application. Bandages were found to easily 
produce a tourniquet effect and an inverse pressure gradient that delayed rather than 
enhanced the venous emptying (Lewis 1976). On the basis of these studies an above- 
knee (thigh-length) GCS was developed which was seamless with a circumferential 
knit and one-way stretch, the stocking is shaped to the foot and calf, with a gusset at 
the top to fit over the femoral triangle and prevent gartering. The stocking was 
manufactured in nine sizes, classified in length as short, regular and long and in 
circumference as small, medium and large which enabled the stocking to suitably fit 
ninety five percent of the population. A below-knee stocking was later available that 
fitted the remaining five percent of the population that were unable to get an 
adequate fit with the above-knee variety. Holford (1976), Scurr et al (1987) and 
Turner et al (1984) showed by randomised controlled prospective studies that this 
thigh-length GCS reduced the occurrence of the postoperative DVT after major 
surgical and gynaecological operations. The earlier studies by Rosengarten et al 
(1970) and Browse et al (1974) failed to show any prophylactic benefit from elastic 
compression stockings that were of the two-way stretch material, not contoured to fit 
the leg and had no gusset. Subsequent studies have shown that the stocking must 
provide a graduated compression, no garter at the top and the fit is of critical 
importance (Lewis et al 1976). More recently, an increased rate of postoperative 
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DVT has been demonstrated in the presence of poor fitting stockings that do not 
achieve the required distal to proximal pressure gradient (Best et al 2000). 
Graduated compression stockings are thought to prevent the development of DVT 
via their acceleration of venous emptying from the superficial to deep and from distal 
to proximal veins in the leg. This increased venous velocity was found to persist for 
thirty minutes after the stockings were removed in bedresting patients (Sigel et al 
1973). Additionally, GCS produced faster clearance of venographic contrast from 
behind venous valve cusps, which are known to be an important site of venous stasis 
and subsequent DVT development (Lewis 1976 & Kalebo et al 1990). 
It has been speculated that damage to the vessel wall, one of the elements of 
Virchow's aetiological triad of venous thrombosis, is also prevented by GCS. 
Passive dilatation of the veins to such an extent that the media no longer provides 
support for the enclothelium, resulting in endothelial tears was thought to be an 
integral part of DVT development (Stewart et al 1980). During surgery, the presence 
of venous stasis and activated clotting factors, with endothelial tears that allow the 
migration of white cells underneath the venous endothelium leads to the exposure of 
the underlying thrombogenic subendothelial collagen. In the study by Comerota et al 
(1985) this relationship was demonstrated between venous distension (in the upper 
limb) during surgery and the occurrence of post-operative DVT (in the lower limb). 
Coleridge-Smith et al (1990) confirmed the development of venous distension in the 
lower limb during surgery. Further investigation into this phenomena has shown that 
GCS (Kendall TED Stockings, Tyco Healthcare) produced a significant reduction in 
the median gastrocnemius vein diameter immediately after stocking application at 
the start of surgery and progressively during the surgical procedure. The total 
reduction in vein diameter was forty-eight percent in the group wearing 
GCS, 
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whereas the control group experienced significant venous distension by nineteen 
percent (Coleridge Smith et al 1990). This study demonstrated that GCS protected 
against the venodilation effects of surgery that were suggested by Comerota et al 
(1989) as a cause of prothrombotic endothelial injury. 
3.3 Efficacy of graduated compression stockings in the prevention 
of post-operative deep vein thrombosis 
Until the last decade, the effectiveness of GCS in the prevention of postoperative 
DVT has been in some doubt despite the use of compression stockings in surgery 
since the 1950's. A large number of clinical studies have been conducted in order to 
assess the efficacy of GCS, however many of these failed in their objectives due to 
the lack of randomisation, suitable control groups and poor diagnostic techniques. A 
meta-analysis performed by Wells et al (1994) employed strict inclusion and 
exclusion criteria for the studies investigating GCS to be included for the final 
analysis. Their search of the literature between 1966 and 1992 found 122 studies, of 
these only thirty-one were properly randomised. A further twelve studies were 
ineligible due to the lack of suitable control groups, and seven used inaccurate or 
inadequately evaluated diagnostic methods to detect postoperative DVT. Overall, 
from the original 122 studies published prior to June 1992, only twelve articles were 
judged eligible for analysis. The results of this meta-analysis provided strong 
evidence that GCS produce a significant risk reduction in the development of post- 
operative DVT in Patients undergoing abdominal, gynaecological and neurosurgery. 
The risk reduction was sixty eight percent (p value less than 0.000 1). Their results 
were inconclusive for orthopaedic surgery and for the overall prevention of 
pulmonary embolism. In all of the studies analysed it was reported that thigh-length 
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GCS were used in all patients. The literature available at this time was unable to 
provide evidence for the efficacy of below-knee GCS compared to thigh-length GCS. 
The available good quality studies comparing knee to thigh-length GCS were small 
and hence did not exclude a possible true difference between stocking lengths 
(Williams & Palfrey 1988 & Porteus et al 1989). The data on GCS in general was 
insufficient for Wells et al to draw conclusions about the efficacy of GCS as a 
prophylactic method when used singularly or in combination with another 
prophylactic modality such as heparin, intermittent pneumatic compression or 
dextran 70 (Wells et al 1994). 
A comprehensive review by Jefferey and Nicolaides (1990) of the 'stocking' 
literature over a similar period; between 1974 and 1987 found the rate of 
postoperative DVT in general surgical and orthopaedic patients using GCS ranged 
from zero to twenty three percent compared to a DVT rate of between thirteen and 
fifty-four percent in patients without prophylaxis. 
Graduated compression stockings used in conjunction with LDUH in three studies 
showed a DVT rate of between two and four percent compared to patients using 
LDUH alone with a DVT rate of between twelve and twenty seven percent. The 
results from one study using intermittent calf compression (Scurr et al. 1987) and 
another using dextran 70 (Bergqvist & Linblad. 1984) displayed a similar trend of 
improved efficacy with 'combination prophylaxis'. The realisation by Virchow 
( 18 5 8) that multiple factors are involved in the pathogenesis of venous thrombosis 
led to the advancement of present day theories for DVT prophylaxis in surgical 
patients. The fact that combined prophylaxis may show 
improved efficacy of DVT 
prevention over solo modalities may be related to the targeting of 
different parts of 
Virchow's triad, so that if one method fails the other is still acting on another part of 
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the 'triad' to reduce DVT. More recent literature has since reinforced the evidence 
for these trends shown in the earlier studies. The Cochrane library was set up in order 
to provide an accurate source of information to guide clinicians in the pursuit of 
6evidence-based' practice. A recent Cochrane review on the use of elastic 
compression for the prevention of DVT in hospitalised patients (Amarigini & Lees 
2000) identified sixteen RCT eligible for assessment. All but one of these trials were 
surgical; they included general, orthopaedic, neurosurgery or gynaecological surgery. 
The one medical trial (Kierkgaard & Norgren 1993) investigated patients who had 
suffered acute myocardial infarction. The patients from this study all received 
aspirin and some from one other trial by Barnes et al (1975), however these studies 
were included because current evidence indicated that aspirin has little effect on the 
venous side of the circulation (Amarigiri & Lees 2000). The reviewers sought to 
ascertain from a meta-analysis; the effectiveness of GCS in preventing DVT when 
used alone or in combination, the prophylactic requirements of low-risk patients and 
the complications associated with the use of GCS. The use of GCS alone in post- 
surgical patients was found to significantly lower the risk of DVT, the incidence in 
the control group (of 581 patients) was twenty seven percent compared to thirteen 
percent in the treatment group of 624 patients: odds ratio 0.34 (95% Cl 0.25,0.46). 
The use of GCS on a background of another prophylactic modality, demonstrated a 
DVT incidence of two percent in 501 patients compared to fifteen percent in 505 
control patients who received only the background prophylaxis and no GCS: odds 
ratio 0.25 (95% Cl 0.15,0.37). This 'observed' evidence, as compared to evidence 
gleaned directly from RCTs suggests that GCS combined with another method of 
DVT prophylaxis are more effective than when use alone. None of the patients in 
these trials were of low thromboembolic risk and therefore no conclusions could be 
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taken for the prophylactic requirements of this group. The GCS were predominantly 
of the thigh-length design, which highlights the need to formerly compare the 
efficacy of above-knee to below-knee GCS. None of the trials mentioned the 
complications associated with the use of GCS. To date, the most extensive 
evaluation of the literature covering the prevention of VTE is available from The 
International Consensus Statement (ICS), which was established during the 
International Union of Angiology World Congress in London, April 1995. 
Subsequent regular consensus meetings involving leading authors from the USA, UK 
and the rest of the world ensure the most recent major advances and supporting 
evidence are included in each edition published. The latest edition (at the time of 
writing), published in 2002, recommends certain clinical practices in accordance to 
the levels or grades of evidence available; levels I to III or grades A to C (Nicolaides 
et al 2002). The use of GCS for preventing DVT in general surgical and urology 
patients is recommended by level I evidence (table 3a). The numbers of subjects in 
the studies are too small to assess the effects of GCS on pulmonary embolism. The 
recommendation for the use of GCS in other areas of surgery is extrapolated from the 
evidence from general surgery and the limited numbers of studies within their own 
speciality, therefore the evidence currently available for neurosurgery, orthopaedics 
and gynaecological surgery is level Ill. 
There is more recent evidence from RCT that combining GCS with another 
prophylactic modality is more effective than when each agent is used separately 
(Nicolaides AN 1994). These include studies that employed GCS and LDUH (see 
tables 3b & 3c), GCS and LMWH (Kalodiki et al 1996, Lassen et al 1991, Leyvraz et 
al 1991 & Nurmoharned et al 1992), GCS and Dextran (Bergqvist & Lindblad 
1984), GCS and IPC (Scurr et al 1987). 
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Author Control GCS 
Groups Groups 
Number of DVT Number of DVT 
patients patients 
Allan et al. 103 37(36) 97 15(15) 
1983 
Borow & 89 32(36) 91 14(15) 
Goldson, 1981 
Holford 1976 48 23(48) 47 11(23) 
Scurr et al 70 26(37) 70 8(11) 
1977 
Tsapogas et al 44 6(14) 54 2(4) 
1971 
Tumer et al 92 4(4) 104 0(0) 
1984 
Total 446 128(29) 463 50(11) 
Table 3a - The effect of GCS on DVT after general and gynaecological surgery. 
Modifiedfrom the International consensus statement (Nicolaides et al 2002) 
The evidence is good for LDUH and LM" combined with GCS, however the 
numbers of studies for other combinations are too small to offer valid 
recommendations. Therefore the ICS in general recommends the combined use of 
88 
GCS with LMWH (with other prophylactic modalities in some specific instances) for 
the prevention of DVT in high and moderate risk patients in general surgery, 
urology, neurosurgery, orthopaedics and gynaecological surgery. 
Author GCS Heparin & GCS 
Borow & 
Goldson 1983 
Moser & 
Froidevaux 
1976 
Nicolaides et al 
1972 
Rasmussen et al 
1988 
Number of DVT 
patients 
Number of DVT 
Patients 
106 15(14) 63 2(3) 
20 5(25) 20 2(10) 
122 29(24) 122 
74 22(30) 89 23(26) 
Total 322 71(22%) 294 28(9.5%) 
Table 3b - Effect on DVT of GCS alone versus 
GCS with 
subcutaneous heparin in general and orthopaedics surgery. 
Modified 
from the International consensus statement (Nicolaides et al 2002) 
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Author Heparin Heparin & GCS 
Number of DVT 
patients 
Number of DVT 
patients 
Borow & Goldson 86 23(26) 63 2(3) 
1983 
Moser & Froidevaux 15 0 20 2(10) 
1976 
Rasmussen et al 85 25(29) 89 23(26) 
1988 
Tomgren 1980 98 12(12) 98 4(4) 
Wille-Jorgensen et al 86 11(13) 90 2(2) 
1985 
Wille-Jorgenesen et 81 12(15) 79 2(3) 
al 1991 
Total 451 83(18) 439 35(8) 
Table 3c - Effect on DVT of subcutaneous heparin alone and in 
combination with GCS. Modifiedftom the International consensus 
statement (Nicolaides et al 2002) 
The evidence for recommendations in low risk patients is insufficient (Nicolaides et 
al 2002) and due to the low incidence of DVT in this group, extremely large RCTs 
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would be required to attain level-one verification. Nevertheless, these 'low-fisk' 
patients do suffer from postoperative DVT and very occasionally die from PE, hence 
an almost 'complication-free' prophylactic modality, such as GCS may be advisable 
for this group. 
3.4 Complications of Graduated Compression Stockings 
Mechanical means of DVT prevention have been preferred in certain surgical 
specialities where bleeding complications secondary to pharmacological prophylactic 
treatments may result in potentially catastrophic postoperative intra-cranial 
haernorrhage or prosthetic joint haernatomas. Graduated compression stockings have 
been reported to cause very few complications, rarely they cause minor abrasions or 
blisters and for this reason are regarded as generally 'safe'. However in some very 
rare instances, severe complications of limb ischaemia have been reported (Heath et 
al 1987) with thigh-length stockings without a gusset, however in this report other 
causes of limb ischaemia could not be completely ruled out. Since this time, many 
stocking manufacturers have modified their stocking design and introduced a gusset 
into the thigh band. No similar severe complications have been reported in gusseted 
stockings. 
3.5 Cost-effectiveness of graduated compression stockings 
A number of studies have investigated the cost-effectiveness of prophylaxis for 
venous thromboembolism (Salzman et al 1980, Oster et al 1987 & 1987, Bergqvist et 
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al 1988, Hull et al 1982). Prevention of DVT is recommended as cost-effective 
(Nicolaides et al 2002) due to the very high cost of the alternative; screening, 
diagnosis and treatment of DVT. Prophylaxis has the obvious advantage of 
potentially preventing the majority of acute and possibly fatal complications of VTE 
and the long-term problems experienced by patients who develop post-thrombotic 
syndrome. The economic evidence for low risk patients is again insufficient and 
may never be available due to the large studies required to investigate the low 
incidence of DVT in these patients. Knee-length stockings are in general two-thirds 
of the price of the thigh-length variety and therefore would be more economical if 
found to be equally effective at preventing postoperative DVT (Agu et al 1999). 
3.6 A review of the evidence for thigh-length or knee-length 
graduated compression stockings in the prevention of deep 
vein thrombosis 
The majority of recent meta-analyses and reviews of DVT prophylaxis have 
highlighted the need for information regarding the comparative efficacies of thigh 
and knee-length stockings. Investigations into the optimal length of compression 
devices have revealed that knee-length stockings may be equal to the thigh length 
GCS in terms of efficacy. Lawrence and Kakar (1980) provided further evidence for 
graduated compression with a multi-compartment pneumatic sleeve and 
demonstrated that venous velocity changes with compression to the lower leg, below 
the knee alone, was not significantly different from full-length compression. 
Sparrow et al suggested from their scintigraphic investigation of leg blood volumes 
with elastic compression stockings that thigh compression may 
be detrimental to 
92 
performance of stockings. In some patients thigh length compression can produce a 
reverse ofvenous flow. Wilkins et al (1950) suggested that after large clinical trials 
with full-length compression hosiery for DVT prophylaxis that knee length stockings 
would be acceptable to patients. Porteous et al (1989) demonstrated that patients 
more readily accepted knee length stockings. 
The most recent International Consensus Statement (Nicolaides et al 2002) lists the 
difference between thigh and knee-length stockings as one of the 'Key Questions to 
be Answered'. Authors who have reviewed the current literature state that there is 
insufficient data from RCT to recommend one over the other in the prevention of 
postoperative DVT (Agu. et al. 1999). In light of reports about the knee-length 
version of compression stockings achieving greater acceptability and patient 
compliance at a lower cost (Agu et al 1999), a proven equivalent efficacy would 
most likely lead to a widespread change in stocking prescription for surgical patients. 
The data from published studies assessing the efficacies of thigh compared to knee- 
length GCS in the prevention of postoperative DVT was reviewed and summated. 
3.6.1 Methods 
Studies were obtained from an electronic search of Medline and Pubmed and 
secondary hand searches of article reference lists. The search was performed using 
key words; 'graduated compression stockings', 'anti embolic stockings', 'thigh 
length', 'knee length', 'above-knee', 'below-knee', 'efficacy', and 'deep vein 
thrombosis' for studies in all languages. The inclusion and exclusion criteria for 
studies to undergo summation analysis was as follows: 
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Inclusionle-xclusion, studies were required to have the following: 
* Records of the incidence of DVT in patients under study 
0 Prospective randomise, trial in surgical patients 
9 Sound methodology 
* Clear interpretation of the results for knee and thigh length groups 
The following data from each study was recorded (if stated): 
* Number of patients treated with GCS and included in study analysis 
* Thromboembolic risk of subjects 
o Method of randomisation 
o Brand and compression profile of stockings 
* Type of surgery performed 
Method of DVT diagnosis 
* Incidence and percentage of postoperative DVT for each stocking length 
0 Areas of possible controversy 
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3.6.2 Results 
A total of eleven studies were found from the search of the literature, of which eight 
studies were excluded (Table 3d). 
Author Journal, Year 13- Reason for exclusion 
Tsapogas et al Arch Surg, 1971 
Williams et al JBJS [Br] 1994 
McNally et al JBJS [Br], 1995 
No investigation of DVT incidence 
No investigation of DVT incidence 
Berridge et al Phlebology, 1999 
Benko et al Phlebology, 1999 
Best et al JBJS [BrI 2000 
Benko et al Clin Orth Rel Res, 2001 
No investigation of DVT incidence 
No investigation of DVT incidence 
No comparison to thigh 
GCS 
No investigation of DVT incidence 
Harneed et al S Aft J Surg, 2002 No investigation of DVT incidence 
. ................ .-............. 
Table 3d - Articles excluded from analysis 
Two studies assessed only knee-length stockings for DVT incidence and six of the 
studies did not compare the two stocking lengths for DVT incidence but for other 
properties such as venous blood flow and velocity, acceptability and wrinkling. 
The 
data from the remaining three studies (Table 3e) was summated in order to produce 
an overall efficacy for thigh and knee-length GCS (Table 3f). 
No comparison to thigh GCS 
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Author Patents with Risk Method of DVT incidence 
Thigh & and DVT (percent) 
Knee Surgery Diagnosis 
--------- ___ 
Length GCS type Thigh Knee 
Williams 44 & 44 High Isotopic 6(13.6) 8(18.2) 
& Fibrinogen 
Palfrey Abdo Uptake 
1988 
Porteus 56 & 58 High Isotopic 3(5.4) 1(1.7) 
et al Fibrinogen 
1989 Abdo Uptake 
Venography 
Hui et al 44 & 40 High Venography THR THR 
1996 
Ortho Ipsi (22) Ipsi (50) 
Cont (9) Cont (7) 
TKR TKR 
lpsi (65) lpsi (68) 
Cont 
(12) 
Table 3e - Articles included for analysis 
Cont 
(10) 
The patient numbers in each of the studies were small, however the summation of the 
data produced at total of 288 legs in the thigh-length group and 284 in the knee- 
length group. All of the information required to convert the numbers of patients into 
numbers of legs for each study was clear without discrepancies. However the study 
by Hui et al stated that they could only provide valid data from the ipsilateral legs 
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Study Thigh Length Knee Length 
Legs DVT Legs DVT 
Williams 1988 88 9 88 12 
Porteus 1989 112 3 116 1 
Hui 1996 48 lpsilateral 5 36 lpsilateral 9 
(THR) 
(Contralateral (Contralateral 
2) 1) 
Hui 1996 40 Ipsilateral 13 44 Ipsilateral 15 
(TKR) 
(Contralateral (Contralateral 
2) 2) 
--------------------- ---- ------------------------------- ............ -------------------------------------- ........... ................................................ . ......................... ............... . ....................................................................... . ... . ..... . ............. ....... 
Total Number 288 34 284 40 
of 
Legs & DVT 
DVT Percent 12 14 
Table 3f - Summation of data for thigh and knee length stockings 
because some of the patients were unable to have venograms on the contralateral legs 
(n=12). All of the studies were randomised; either by envelope (Williams & Palfrey 
1988) or by number (Porteus et al 1989 & Hui et al 1996). None of the studies were 
able to show a significant difference between the two stocking lengths, 
however the 
numbers of subjects in each trial were small so a difference cannot 
be ruled out. In 
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addition, there were some discrepancies (shown below) in the data that makes their 
results questionable. 
i. Non of the trials demonstrated a statistically significant difference in overall 
DVT for either stocking length, 
ii. Williams et al used different brands of thigh and knee-length stockings, 
iii. Hui et al used a Robert-Jones bandage under the stockings after TKR which 
would probably change the compression profile exerted on the leg, and only 
found statistical significance for the knee-length stocking in the prevention of 
proximal and major calf thromboses in patients having total knee 
replacements. 
3.7 Summary 
Within the literature there are a small number of published studies comparing the 
properties of thigh to knee-length stockings that provide some evidence to explain 
the behaviour of each stocking type. Benko et al (1999) showed good evidence for 
the ability of thigh length stockings to increase venous velocity to a greater extent 
than the knee-length design. Colour Doppler measurements of peak velocity in the 
femoral vein of patients (n= 15) with thigh-length GCS was significantly greater 
(p<0.002 paired t-test) than in the control group (n=15). The thigh group also 
showed a significantly (p<0.05) reduced popliteal vein diameter, which is thought to 
limit vein wall damage and thus the development of popliteal DVT. Another study 
by the same author, (Benko et al 200 1) demonstrated in a study with 200 adults that 
thigh and knee length stockings all significantly increased venous capacitance and 
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venous outflow when compared to control subjects (p<0.001 Wilcoxon). Although 
there was no significant difference between mean changes in venous capacitance and 
outflow, the knee length stockings increased venous outflow less than the thigh 
length stockings. Similar changes in venous haernodynamics where publicized in a 
small study by Berridge et al (1999), where only the thigh length stockings produced 
an increased deep venous velocity. Conflicting evidence has been reported that show 
no benefit of thigh-length over knee-length GCS in terms of venous haemodynamics 
and indeed suggest an advantages of the knee-length for patient acceptability and 
compliance. Work performed by Lawrence and Kakkar (1980) suggested that thigh- 
length stockings effect no greater increase in femoral vein blood flow than knee- 
length. A knee-length stocking of 18 mmHg compression at the ankle gradually 
reducing to 14 mmHg in the upper calf, was equally effective at augmenting deep 
venous velocity as a full length stocking of 18 mmHg ankle compression and 8 
mmHg upper thigh compression. This evidence together with Kakker's report in the 
Lancet (1969) that most deep vein thromboses following major abdominal surgery 
originate in the calf veins led to the theory that the knee length GCS were not inferior 
to thigh-length in the prevention of DVT. McNally et al (1995) reported in a study 
of two hundred patients that the increases in venous blood flow, assessed by 
plethysmography, achieved by thigh and knee-length stockings were not dissimilar, 
and that the knee-length design were more acceptable to patients, caused less 
uncomfortable wrinkling and improved stocking compliance. In other studies, 
knee- 
length stockings have been found by the use of simple tests to be more acceptable to 
patients and nursing staff and to roll down and wrinkle less (Porteus et al 
1989, 
Benko et al 2001). Indeed the trivial sounding problem of rolling down and 
wrinkling experienced more commonly with above 
knee stockings can produce 
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severely detrimental effects by causing a reversal of the pressure gradient and 
tournique effects. An increased external pressure of 28 mmHg in the popliteal fossa 
has been shown to develop with thigh-length stockings and the knee flexed, which 
predisposed to a reverse pressure gradient in seventy percent of the subjects wearing 
thigh-length GCS (Wildin et al 1998). Not only has the reverse pressure gradient 
effect been demonstrated to cause excessive pressure, increase venous congestion 
and contribute to the development of DVT (Best et al 2000), but limb ischaemia has 
been reported in two cases secondary due to a tournique formed by a 'rolled-down' 
gussetless thigh-length stocking (Heath et al 1987). The thigh stocking when 
compared to the knee-length stocking, has been found to be more difficult to achieve 
an adequate fit which then leads to more rolling down and wrinkling with resultant 
changes in the external compression gradient upon which the function of stockings is 
reliant (Williams et al 1994). The patient acceptability has an important role, it is 
reported to be greater for the knee length stockings and a GCS is only effective in 
preventing DVT as long as it is wom by the patient and correctly applied. 
The results from the trials assessing the different lengths of GCS for the prevention 
of DVT have demonstrated no difference in the prevention of DVT in each study and 
the summation of the data from all three trials has produced the same result. 
However, a steadfast conclusion cannot be taken from three small trials and further 
work in this important area is required. The comparative efficacies of thigh and knee 
length stockings is important to clarify in order to improve patient care with regard to 
the prevention of DVT. It is clear from this summation of the available data that a 
reliable and valid answer to this question could only be achieved through a 
large 
prospective RCT, this major undertaking became a large part of the 
investigations in 
this study. 
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Chapter Four 
An audit of 
surgical thromboembolic prophylaxis in a teaching hospital 
and the response of medical staff to an education and awareness 
program promoting a single 'blanket' protocol 
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4.1 Background 
4.1.1 The evolution of medical audit 
The King of Babylon, who had drawn up a set of rules for doctors, known as the 
Code of Hammurabi, first introduced the assessment of the effectiveness of health 
care nearly four thousand years ago. The ancient Greeks regulated their health care 
through medical ethics and codes, with onus on the doctor to deliver a standard of 
care. The Hippocratic oath sets the requirement for health care through good 
knowledge about the treatment efficacies and results. The modem literature on 
medical audit first started to evolve in the 1950s on the west coast of America 
(Lembcke 1967). It is only over the last two decades that audit has become regarded 
as an important component in surgical practice in the United Kingdom. A major 
stimulus was the Confidential Enquiry into Peri-Operative Deaths, which 
demonstrated the amount of variation in practice and outcomes for similar 
populations of patients in the National Health Service (Buck et al 1987). Medical 
audit has now becomes an integral part of maintaining the standards of care within 
the health service, since its formal introduction in the White Paper Workingfor 
Patients (Department of health 1989) and by the Standing Medical Advisory 
Committee in 1990. 
Medical audit is an ongoing process of evaluation and development of health care 
processes. Early on, audit results are often mistaken for apportioning blame, and 
doctors were initially hesitant with the use of audit. Audit data must therefore be 
collected with a view to improving the service in that particular area, hence reluctant 
doctors will see the benefits. Audit should be a series of planned short studies in the 
target area of interest, the results of which should move the practice forward as 
required in a health service with ever increasing demands and expectations. 
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4.1.2 Essential properties of medical audit 
Medical audit has five essential properties: 
* Peer Review - the standards of medical care are set by the professionals who 
utilise clinical results, research and feedback from the patients. 
* Standards and Quality - The specification of required standards and quality 
of care at a local level allows inadequate performance to be identified. 
Utilisation of national professional standards and evidence-based medicine is 
a necessity. 
* Patient Based and Multi-dimensional - the focus of any health care 
intervention is the patient and therefore audit should encompass patient's 
treatments and outcomes in a holistic manner. 
e Systematic Approach -a clear and systematic approach is required to perform 
good quality audit studies. The patient selection should be from a defined 
population. 
e Commitment to Change Practice - audit is designed to improve the service of 
care and achieve an optimum level of care at a local level. A commitment to 
change practice in accordance with audit findings is essential to its success. 
It is important to recognise the differences in the principles of medical audit and 
medical research. Medical audit defines the requisite local standards of clinical 
practice and hypothesises that these standards of health care should be in place. 
Thus, there is no experimental component in medical audit, just a process to ensure 
that the patients receive a quality of care set by predetermined standards. Medical 
research however investigated a new or experimental treatment or seeks to establish 
a cause for a condition. The results are unknown and therefore research requires 
close supervision, ethical approval and informed consent. In clinical practice the 
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results of audit may be unpredictable and therefore audit may still contribute to the 
medical literature. 
4.1.3 Audit cycle 
Shaw first described the audit cycle in 1980, which has frequently been used to 
illustrate the processes of audit (Figure 4a). The audit cycle summarises the 
information requirements for completing a successful audit. 
STAGE I 
Setting 
Standards 
STAGE2 
Recording 
Practice 
STAGE 3 
Effecting 
Change 
Figure 4a - The audit cycle 
Setting standards - predefined criteria to allow accurate data collection 
0 Recording practice - Collection of specified data and data analysis to enable 
comparison to the set standards and highlight the deficiencies 
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Effecting change - professionals and management combine efforts to improve the 
care to the required level and then re-audit to record any change in practice. If the 
standards are still not met then further change followed by re-audit is required until 
the requisite standards are met. This process may take months to years for 
department alterations in practice because of resistance to change and increased 
funding required to support these changes. Audit should be re-run on regular basis 
(audit cycle) to ensure the maintenance of standards. 
4.1.4 Audit and quality of care 
Audit involves the assessment of the quality of care assuming quality can be assessed 
reliably and accurately. Despite setting standards of quality to be achieved through 
audit, defining the actual quality of the care may be difficult with the multi-faceted 
nature of healthcare. Maxwell (1984) defined a recognised set of quality criteria: 
* Access to service 
* Relevance to need 
o Effectiveness 
o Equity 
Social acceptability 
e Efficiency 
Economy 
Each criteria must be viewed from the standpoint of the professional and 
the patients, 
especially as the patient is the focus of quality 
in the care process. The patients' 
views on the quality of care may not be informed, 
however their views are still 
important. 
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4.1.5 Focus of audit 
Audit can easily become complex and convoluted due to the multiple requirements 
described above. Hence in order to minimise this, audit must be focused 
appropriately. Various approaches are available to achieve this: 
* Problem selection - Problems that are amenable to change as perceived by 
peers and patients 
* Prioritisation - processes that are higher priority can be defined by one of 
Shaw's criteria (1989): 
o High risk 
o High volume 
o High cost 
o Wide variation in clinical practice 
o Local clinical anxiety 
Optimising benefits - Audit focuses on areas in which maximal benefit can 
be achieved. Improvements to practice should be in line with evidence 
based principals and national framework guidelines. 
The duration of audit should also be targeted in order to achieve an accurate and 
compact data assessment. True outcomes of any treatment encompass early and late 
complications and benefits, hence the duration of audit assessment needs to be 
tailored accordingly. There is no defined time span for audit activities and the 
duration is dependent on the chosen area of practice. 
Finally, the feasibility of audit was highlighted by Fowkes (1982), the properties of 
the audit should be as follows: 
* Common practice to produce adequate numbers 
* Significant effect on outcome/resources 
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* Defined area of practice 
9 Standards can be defined 
* Amenable to change 
4.1.6 The audit protocol 
The audit protocol forms the definition of the information requirements that should 
be agreed before the commencement of the audit. The protocol delivers the 
information necessary to instigate change in the practice and therefore has to be laid 
out in a clear and succinct fashion to avoid analysis problems of the results. Clinical 
protocols set the benchmark for the agreed practice at a local level and often lead to 
clinical audit. The audit may then influence the clinical practice and protocols 
depending on the audit results. Audit may be retrospective, prospective or 
concurrent. The latter allows changes to the clinical practice before the end of the 
audit process. Concurrent audit has the advantages of being preventive by 
preventing bad practices or limiting suboptimal outcomes by introducing clinical 
practice alterations as the current audit is performed. However, the use of data 
concurrently has the disadvantage of having only a limited part of the data set when 
compared to the end results of a prospective audit. The audit protocol is used to 
record patients details and outcomes and therefore must confidential. Audit has now 
developed so that it is a normal part of clinical practice and therefore patient 
infori-nation is kept confidential similarly to patients' clinical notes. 
4.1.7 Summary 
This introduction to audit has highlighted the necessary requirements for a successful 
audit. Over the last three decades, the importance of prophylaxis against post- 
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operative DVT has been recognised, however its use and compliance is variable and 
in many hospitals very poor. In light of the vast wealth of literature and guidelines 
available to clinicians it is confusing to find that surgical patients are still not 
receiving adequate prophylaxis to prevent DVT. This may be due to complexity of 
recommendations in the literature and the lack of consensus between clinicians. A 
commentary by John Bergan (1997) discussed the reasons for 'physicians to 
underplay the value of prophylaxis', these included: 
1. An individual clinician's experience suggests a low level of occurrence of 
fatal PE and therefore they forget the need for DVT prophylaxis 
2. Failure of education - continuing medical education programs dramatically 
increase the awareness of DVT and prophylaxis (John Bergan 1997, 
Anderson et al 1994) 
The use of DVT prophylaxis has been audited in the surgical patients of this 
multidisciplinary teaching hospital in order to gauge the overall status of 
prophylaxis. It was clear that the majority of our surgical patients came under an 
'umbrella' of DVT risk - the majority were high risk and very few were of low risk 
for developing postoperative WE - that could therefore be treated with a 'single 
prophylaxis protocol' of graduated compression stockings and subcutaneous heparin 
in accordance to International and European consensus guidelines for the prophylaxis 
of DVT in high and moderate risk surgical patients. An assessment was then 
performed that highlighted the inadequacies of the current DVT prophylaxis, 
measured the effect of an education program and proposed a 'single prophylaxis 
protocol' to achieve a consensus between the doctors of different surgical specialities 
and healthcare staff in our hospital. 
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4.2 Methods 
The audit process was carried out in three phases: 
I- Audit of existing practice 
2. Education of hospital medical staff 
3. Re-audit of surgical patients after the completion of an education and 
awareness programme and introduction of the new single prophylaxis 
protocol. 
Phase One - All of the surgical patients at Charing Cross Hospital, already 
occupying a ward bed or admitted to a hospital bed over a period of forty-eight 
hours, were assessed for the audit on venous thromboprophylaxis. The inclusion 
criteria for the audit study, were that the patients were: 
m Under the care of a surgical consultant 
m Admitted to a surgical ward. 
Patients were excluded from risk analysis and therefore the audit if- 
m They had not undergone an operation during that admission, as the current 
recommendation from the International Consensus (Nicolaides et al 2002) 
requires the details of the operation to be included in the risk categorisation. 
m Patients that had just arrived in the hospital ward at the time of the audit and 
the nursing staff and/or doctors had not had sufficient time to implement their 
DVT prophylaxis. 
Patients were recorded as having optimal prophylaxis if they had received 
subcutaneous heparin in combination with GCS. However, optimal prophylaxis for 
patients with contraindications to heparin or GCS was recorded if the patient had 
received the maximal appropriate prophylaxis for that particular patient. Relevant 
contraindications to certain methods of prophylaxis were as follows: 
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a Any history of peripheral vascular disease (PVD) or diagnosis of PVD in the 
hospital notes and the presence of dressings or external fixators on lower 
limbs. 
a Allergy to subcutaneous heparin, 
Concurrent use of other forms of anticoagulation such as warfarin or 
intravenous heparin 
m Surgery in the previous 12 hours for orthopaedic and neurosurgery 
specialities (as these specialities refused peri-operative heparin within twelve 
hours). 
All patients were interviewed and assessed for their DVT risk and prophylaxis of 
VTE. The data for each patient was recorded by using a pre-defined audit proforma 
sheet (Appendix). The proforma documented the patient's age, sex, speciality, 
consultant, surgical procedure, risk factors for VTE disease in accordance to the 
International Consensus statement 2001 (table 4a). All data was stored on a secure 
computer site. All audit was performed without prior waming to medical staff to 
avoid last minute changes to prophylactic practice. 
Phase Two - An education program was given to surgical house officers, senior 
house officers, registrars and surgical nurses via thirty-minute verbal presentations 
and the use of handouts and posters for the ward notice boards. The surgical 
consultants were informed by the use of postal letters. Information regarding the 
findings of the WE prophylaxis in the surgical patients at Charing Cross hospital, a 
summation of the literature covering WE disease and how a single protocol for the 
prevention of DVT in surgical patients could be applied in our hospital was given. 
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Risk Clinical Features DVT Risk Risk of Recommended 
Category without Fatal PE DVT Prophylaxis 
Prophylaxis 
High Major surgery, >60 Calf 40- 1-5% Subcutaneous 
years 80% Heparin and GCS, 
and >40 with risk Thigh 10- or IPC 
factors. 30% 
Major Orthopedic 
leg surgery 
Moderate Major surgery; >40 Calf 10- 0.1-0.7% Subcutaneous 
yrs 40% Heparin and/or 
Minor surgery; >60 Thigh 2- GCS, or IPC 
yrs and >40 with 10% 
risk factors 
Low Major surgery; <40 Calf <10% <0.0 I% Early Mobilisation 
yrs Thigh < 1% or GCS 
Minor Surgery; <60 
yrs 
No risk factors 
Table 4a - Thromboembolic risk categories and recommended prophylaxis for 
surgical patients. Information and recommendations from the International 
Consensus Statement on the Prevention of Venous Thromboembolism (Nicolaides et 
al 200 1). Additional riskjactors include: malignancy, previous DVT or pulmonary 
embolus, varicose veins, oestrogen medication, thrombophilia, ongoing sepsis, 
morbid obesity and general immobility. Abbreviations: DVT; deep vein thrombosis, 
GCS; graduated compression stockings, IPC; intermittent pneumatic compression. 
Surgery: Minor Surgery; less than 45 minutes, Major Surgery; more than 45 minutes 
operating time. 
The new single protocol advocating a 'blanket' approach to DVT prophylaxis - that 
negates the need for risk categorisation - using subcutaneous heparin and anti- 
embolic stockings for all surgical patients. The 'single protocol' was implemented 
with the permission from consultants from the Gastrointestinal, Urology, Vascular, 
Breast and Oncology surgical specialities. All of the junior surgical doctors and 
nursing staff were made aware of the introduction of the new protocol for the 
prevention of postoperative DVT. Approximately three months later, without 
warning medical staff, the audit was repeated for DVT prophylaxis and the accuracy 
of implementation for all surgical patients on surgical wards who had received, or 
were due to receive surgery on that admission. 
4.3 Results 
Phase One Results -A total of 178 patients under the care of surgical consultants 
were identified for inclusion into the audit. The demographics of the patients are 
displayed in table 4b, the mean age of the patients demonstrated a generally elderly 
population that remained in hospital for an average of 23 days, with an 
approximately equal gender ratio. 
One hundred and six of these patients had undergone one or more surgical 
procedures during the current hospital admission so the risk of WE and the correct 
application of prophylaxis as recommended by the International Consensus statement 
could be assessed in these patients. These patients had very similar demographics to 
overall group (table 4b), with an mean age of sixty-one years, equal sex ratio and 
average hospital stay of 32 days. These patients had received surgery from a wide 
range of surgical specialities; Ear nose and throat (ENT), Breast and Oncology, 
Gastrointestinal (GIT), Neurosurgery, Orthopedics, Plastics, Urology, and Vascular 
surgery (table 4c). 
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Number of patients 
Mean age of patients 
Sex ratio 
Average hospital stay 
Table 4b - Patient demographics 
178 
62 years (range 19-94) 
56% Male 
23 days (range 1-365) 
Thromboembolic risk categories (according to the International Consensus) of these 
106 patients showed that the majority of the patients were of high risk for developing 
postoperative DVT and PE (75 patients, 71% high risk), twenty percent were of 
moderate risk (21/106), and only a smal I proportion were (10/ 106,9%) of low risk. 
These risk proportions are displayed in graphical form (Figure 4b). 
The numbers of patients who had received adequate physical prophylaxis against 
DVT, either adequately fitted GCS or intermittent pneumatic compression (IPC), ) 
were found to be low with only 35 patients wearing correctly fitted GCS and one 
patient with IPC out of a total of 82 patients who had no contraindication to lower 
limb external compression. These findings equate to only 43 percent of patients 
were correctly fitted and appropriately prescribed GCS and overall a total of only 44 
percent of patients received mechanical prophylaxis (GCS and IPQ (table 4d and 
figure 4c). The patients that received subcutaneous heparin injections totalled fifty- 
two out of a total of 96 patients who were eligible to receive subcutaneous heparin. 
(Ten patients were contraindicated subcutaneous heparin; one due to allergy and nine 
patients were already undergoing anticoagulant therapy with either warfarin or 
intravenous heparin for non--prophylactic reasons. ) This equates to only 54 percent 
of the patients who appropriately received subcutaneous heparin and 58 percent of 
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Patients received some form of pharmacological prophylaxis (subcutaneous heparin 
or full anticoagulation) out of the total 106 patients. 
Surgical Specialities Number of Patients 
ENT 
Breast 
GIT 9 
Neurosurgery 12 
Orthopaedics 31 
Plastics 14 
Urology 7 
Vascular 25 
Total 106 
Table 4c - Surgical specialities of patients 
In addition, amongst the patients who received subcutaneous heparin, the use of 
unfractionated low dose heparin (LDUH) and fractionated low molecular weight 
heparin (LM") was inconsistent with less than half (48%) of the surgical patients 
undergoing surgery received the preferential LM" and 52% received LDUH. The 
International consensus recommends that high and moderate risk patients should 
receive subcutaneous heparin in combination with GCS or IPC for the optimal 
prophylaxis of postoperative DVT (the evidence for recommendations in the low risk 
patients is not yet available). In this cohort of patients, 91 percent of the patients 
were high or moderate risk (n=96) and should consequently have received 
mechanical and pharmacological prophylaxis in combination, some of the patients 
were protected by full anticoagulant therapy (n=9) for reasons other than for 
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prophylaxis. The total number of patients who received optimal prophylaxis in line 
with the current international recommendations (Nicolaides et at 2002) amounted to 
forty-seven percent (Table 4d). 
The optimal prophylaxis given to each risk category of patients was worst for the 
moderate and high-risk patients with only 38% and 44% of these patients 
respectively receiving the correct prevention therapy. The results for individual 
specialities and wards may indicate areas of weakness with regard to DVT 
prophylaxis in our institution, however the numbers are small for individual 
specialities and therefore must be interpreted with caution (Figure 4d). 
Figure 4b- The Risk Categories 
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Figure 4c - DVT Prophylaxis Given to Patients 
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Figure 4d - DVT Prophylaxis by Each Surgical Speciality 
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Type of Prophylaxis Number of 
Patients (n=106) 
Mechanical Prophylaxis 
Number of patients fitted with GCS 39 
Number of patients fitted with stockings of incorrect size 
Number of patients fitted with IPC I 
Number of patients with a contraindication to GCS or IPC 24 
Number of Patients correctly fitted with GCS 39 
Percentage correctly fitted with mechanical prophylaxis 44% 
Pharmacological Prophylaxis 
Number of patients administered subcutaneous heparin 52 
Number of patients with allergy to heparin I 
Number of patients with other medical prophylaxis 9 
Percentage of patients correctly administered s. c heparin 54% 
Number of patients correctly administered pharmacological 61 
prophylaxis (intravenous heparin and warfarin inclusive) 
Percentage correctly administered pharmacological prophylaxis 58% 
Optimal Prophylaxis 
Total number of patients with optimal DVT prophylaxis 50 
(combination prophylaxis or full anticoagulant therapy) 
Total percentage of patients with optimal DVT prophylaxis 47% 
Table 4d - Prophylaxis given to surgical patients 
The Breast and GIT surgical specialities were the only specialities that achieved 
optimal prophylaxis in fifty percent or more of their patients, the remaining 
specialities achieved very unsatisfactory levels of prophylaxis. 
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The data for each of the surgical wards revealed a marked variation in the efficiency 
of applying DVT prophylaxis, however in some of the wards, the number of patients 
who had undergone a surgical procedure during the hospital stay was small (Figure 
4e). The wards with the worst performances were 7 West and 10 South, these consist 
mainly of orthopaedic and neurosurgery patients respectively, where the poor 
compliance with prophylactic recommendations may stem from the fear of using 
subcutaneous heparin with some of their operations. 
Figure 4e - DVT Prophylaxis by Each Surgical Ward 
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Phase Two Results - The results of the first phase of the audit that demonstrated the 
substandard DVT prophylaxis in our hospital, were received with surprise; many of 
the staff had assumed that the general status of prophylaxis was good. The education 
sessions to junior doctors and nursing staff were received with enthusiasm. The 
consultants were concerned about the inadequate DVT prophylaxis used in their 
patients and many showed interest towards developing a hospital consensus for the 
protection of patients from the complications of postoperative VTE. However, there 
was still debate on the use of subcutaneous heparin in certain patients, namely those 
undergoing orthopaedic prosthetic surgery, spinal surgery and neurosurgical cranial 
procedures - despite the high risk of these patients for developing VTE. The length 
and type of stocking was also raised as an uncertainty that was important to clarify. 
At this early stage of the proceeding the consultants from the breast and oncology, 
GIT, urology and vascular specialities agreed to the use of a new single blanket 
protocol of subcutaneous LMVM and GCS for all of their patients undergoing or 
who may undergo surgery. The consultants from the other specialities; ENT, 
neurosurgery, orthopaedics and plastic surgery recognised the need for change, but 
required more evidence from the awaited RCT that would assess the use of blanket 
LMWH and different lengths of GCS in surgical patients (see chapter 6). 
After the education program, the second phase audit showed the application of 
prophylaxis - in the patients who had undergone surgery, from the specialities that 
agreed to a single blanket protocol (breast and oncology, GIT, urology and vascular), 
significantly improved (p<0.05). The demographic data and 'risk' of patients from 
phases one and two audits are summarised below in table 4e and figure 4f The 
patient populations were very similar with regard to numbers of patients, age, gender 
ratio, length of hospital stay and risk of VTE disease (according to the International 
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Consensus Statement). The use of mechanical (p=O. 1), pharmacological (p=0.03) and 
overall optimal prophylaxis (p=0.003) improved considerably in accordance with the 
international consensus statement, over a three-month period (table 4f and figure 4g). 
Audit Phase One Audit Phase Two 
'Before Education' 
45 patients 
Mean age 65 years 
Males 65% 
'After Education and Single 
Protocol' 
34 patients 
Mean age 63 years 
Males 59% 
Mean hospital stay 49 dMs Mean stay 22 days 
Table 4e - Patient demographics 
Figure U- DVT Risk Categories of Patients 
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Phase One'Before Education' Phase Two 'After Education' 
Types of Prophylaxis Phase One Phase Two 
'Before 'After 
Education' Education' 
Mechanical prophylaxis: 
Mechanical prophylaxis fitted appropriately 54% (n=28) 81% (n=16) 
lp=o. II 
Pharmacological prophylaxis: 
Subcutaneous heparin administered 67% (n=37) 92% (n=26) 
appropriately [p=0.03] 
Full Warfarin or Intravenous heparin 16% 24% 
administered 
Combined Prophylaxis: 
Subcutaneous heparin with stockings 24% 32% 
Subcutaneous heparin (No stockings due to 
contraindication to compression) 16% 32% 
Optimal Full 'D VT'Prophylaxis: 
Total number with stockings and s. c heparin 56% (n=45) 88% (n=34) 
or full anticoagulation for other clinical [p=0.003] 
reasons 
Table 4f -Improvements in surgical (breast and oncology, GIT, 
urology and vascular) DVT prophylaxis after education and 
introduction of single blanket prophylaxis protocol 
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Figure 4g - Improvements in DVT Prophylaxis after 
Education and Introduction of Single Protocol 
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These changes were due to increased compliance by doctors and nurses, with respect 
to prescribing and application of GCS and subcutaneous LMWH in all patients 
undergoing surgery. The introduction of a simple single protocol negates the need for 
complex VTE risk assessment. The breakdown of the changes in prophylactic 
practice before and after the education and introduction of a single blanket protocol 
is shown in table 4f and figure 4g. 
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Phase One 'Before Phase Two 'After 
4.4 Conclusions 
A simplified 'blanket' approach to DVT prophylaxis led to a significantly improved 
use of DVT prophylactic measures. A single protocol using GCS and subcutaneous 
heparin, preferably LMWH, was acceptable for all surgical in-patients having an 
operation in our hospital for a number of reasons: 
1. The majority of the surgical patients undergoing surgery at Charing Cross 
Hospital were of high and moderate risk for developing complications of 
VTE. 
2. The International consensus (Nicolaides et al 2002) and many other 
published guidelines such as the European consensus and THRIFT 
guidelines advocate the use of subcutaneous heparin and GCS for high and 
moderate risk patients. 
3. The evidence to recommend venous thromboembolic prophylaxis in low risk 
patients is not reported in the literature. 
4. Current guidelines in the literature recommend the separation of patients into 
risk categories - high, moderate and low risk - followed by the prescription 
of increasing amounts of prophylaxis according to the patients' risk. This 
method has a number of weaknesses: 
a. Doctors are unable to reliably separate patients into the correct risk 
categories (see chapter 5; 'A Teaching Hospital Audit: Errors of DVT 
Prophylaxis at the Bedside') 
b. The separation of patients into risk categories relies on the 
summation of preoperative risk factors, which may change during or 
after the surgery with a resultant upgrading of the patients' risk. 
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Therefore, low risk patients may easily become moderate or high risk 
after surgery if the patient undergoes prolonged surgery (greater than 
45 minutes) or becomes immobile, infected, thrombophilic, or if 
malignancy is unexpectedly found on histological examination of the 
surgical specimen. 
5. The complications of low dose subcutaneous heparin and compression 
stockings are rare and usually minimal. Additionally the low risk of 
complications can be minimised by the use of a clear hospital protocol that 
highlights the absolute and relative contraindications to heparin and 
stockings. 
6. The cost of low dose subcutaneous heparin and compression stockings is low 
and has been shown to be cost effective in the moderate and high-risk 
patients for the prevention of DVT. (The economic data for DVT prevention 
in low risk patients has not been reported. ) 
This study demonstrates how the use of audit with structured education and reaching 
a consensus on an area of clinical practice can improve the quality of patient care. 
This has been demonstrated in the realm of DVT prophylaxis in previous studies 
(Jones 1991). The importance of a simple solution to a clinical problem is 
highlighted by this audit, other authors have demonstrated that protocol compliance 
is improved if the protocol is not complicated (George et al 1998). The consensus 
achieved at Charing Cross Hospital promoting the use of a single blanket application 
of low dose subcutaneous heparin and compression stockings for all surgical in- 
patients undergoing any surgical procedure (with specific exclusions) is simple and 
easy to use in every day clinical practice. This resulted in the majority of patients 
receiving prophylaxis and those patients who were unable to receive either 
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subcutaneous heparin or GCS still received their optimal prophylaxis. A single 
protocol allows a simple blanket application of prophylaxis to all patients, however 
continued audit and education is a necessity for the sustained effectiveness of any 
new protocol. 
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Chapter Five 
The disparity in the practice of DVT prophylaxis and 
the difficulties in achieving a general consensus for the prevention 
of deep vein thrombosis in surgical patients 
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5.1 Introduction 
Since its conception, the practice of prophylaxis against deep vein thrombosis in 
surgical patients has been notorious for its controversy and debate. Many consultants 
and junior doctors try to adhere to the guidelines published in the literature that 
undergo continual change due to advancing science, while others use anecdotal 
evidence taken from past experience. Past experience may highlight the immediate 
complications of anticoagulant prophylactic therapy and grossly underestimate the 
rate of WE episodes, many of which present after the ever-shortening hospital stays. 
During the course of this study, work has been directed towards to improving the 
overall standard of the WE prophylaxis in surgical patients in Charing Cross 
hospital. The weaknesses, failures and ways to improve venous thromboprophylaxis 
in our acute multidisciplinary university hospital were investigated. A number of 
surveys, audits, questionnaires, departmental presentations, teaching sessions and a 
randomised clinical trial were performed in order to provide evidence to enable the 
advancement of prophylactic practice in this hospital. The information gathered 
during the course of this work has been presented at international surgical meetings 
and was received with much interest; hopefully this work may then be used to help 
other hospitals address the same problems with thromboprophylaxis. In a 'nutshell', 
the main deficiency locally (and similarly described elsewhere in the literature) is a 
lack of a consensus between surgeons on the correct prophylaxis modalities and 
regimen to use. After more than forty years of scientific progress in this field, many 
hospitals and medical institutions still lack a consensus on how to manage the 
prophylaxis of DVT in their patient population. 
A number of observations in this hospital were made that exemplify the disparity in 
prophylactic practice. The diverse opinions of surgical consultants in charge of 
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surgical firms led to uncertainty in the prescribing and application of prophylaxis by 
junior doctors and nursing staff. The results from the audit of thromboprophylaxis 
(chapter 4) demonstrated the poor application of prophylactic measures in surgical 
patients, with many patients not receiving any pharmacological prophylaxis at all. 
This was because consultants preferred not use subcutaneous heparin in certain 
operations, for example, total knee and hip replacements, spinal and intracranial 
surgery, despite published evidence indicating that these are the very patients that 
required prophylaxis due to their high risk of VTE. In addition, the use of LDUH 
and LMWH was inconsistent, with approximately only one quarter of the surgical 
patients undergoing surgery receiving the preferential LM" (chapter 4). 
The use of GCS was also disparate with many different brands and lengths of 
stocking found on different surgical wards, the choice of which was largely governed 
by cost, not evidence (table 5.1). To date only one make of stocking has level-one 
evidence to prove its efficacy in the prevention of postoperative DVT, namely 
Kendall thigh-length TED graduated compression stockings. Authors have 
demonstrated the importance of an optimal external graduated compression achieved 
by the stocking to reduce venous stasis (Sigel 1973 & 1975, Lawrence and Kakkar 
1980). Thomas et al (2000) has since shown that many of the other stockings on the 
market do not achieve the optimal external compression profiles. 
The audit performed in chapter four highlighted the inadequacies and the need for 
change, however there was still considerable resistance to running a RCT with 
subcutaneous LMWH used across the board (chapter 6), let alone reaching an 
agreement on a hospital consensus for all surgical patients involving the use of 
LMWH and GCS (as recommended by the International consensus statement for 
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high and moderate risk patients who made up the majority of our in-patient 
population). 
Surgical Type of GCS (length) Compression Profile 
Ward (ankle/calf/thigh) mm Hg* 
..... - ------- - -------- ......... 4 South Kendall TED (thigh length) 13/11/3 
7 South Kendall TED (thigh and 13/11/3 
knee length) 
7 West Kendall TED (thigh and 13/11/3 
knee length) 
Preventex (thigh and knee 14/13/3 
length) 
7 North Kendall TED (thigh and 13/11/3 
knee length) 
8 South Preventex (thigh and knee 14/13/3 
length) 
Parama (thigh and knee 17/15/7 
length) 
8 North Kendall TED (thigh and 13/11/3 
knee length) 
10 South Kendall TED (thigh length) 13/11/3 
11 West Kendall TED (thigh and 13/11/3 
knee length) 
ITU Kendall TED (thigh length) 13/11/3 
Table 5a - Different types of stocking used 
by surgical wards at 
Charing Cross Hospital. Legend Intensive care unit (ITU), (* Average 
scores takenftom Thomas et al 2000) 
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Despite readily available prophylactic guidelines from electronic literature sources 
and the prophylactic modalities are readily available if prescribed, however the 
prophylaxis was not reaching the patients. An audit questionnaire of the surgical 
doctors at Charing Cross hospital was performed to investigate the nature of the 
differing views on prophylactic practice and the consequence of the lack of a hospital 
consensus on prescribing prophylaxis. 
5.2 A teaching hospital questionnaire audit: disparity and errors 
in the practice of DVT prophylaxis 
5.2.1 Background 
In our multidisciplinary university hospital a disparate and unsatisfactory use of 
thromboprophylactic measures in surgical patients undergoing surgical procedures 
was found (chapter 4). An investigation via a questionnaire audit of the 
thromboprophylaxis prescription procedures and the use of evidence-based 
guidelines by surgical doctors of all grades was carried out. 
5.2.2 Methods 
A questionnaire was developed to assess the thromboprophylaxis practice of surgical 
doctors. The questionnaire items were developed through interviews with ten doctors 
from all grades. Twenty-four questions made up the questionnaire (Appendix) that 
assessed the individual and departmental practices and the use of 
thromboprophylaxis guidelines. The questionnaire was given to surgical doctors at 
Charing Cross Hospital over the period of one week, doctors completed the 
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questionnaire under supervision without reference to any sources of information that 
could have influenced their answers. Results were collated anonymously. 
5.2.3 Results 
A total of fifty-six surgical doctors were asked to answer the questionnaire, 98% 
percent completed the questionnaire; one consultant refused. Of those who 
completed the questionnaire, thirteen were house-officers, twenty were senior house- 
officers, fifteen were registrars and seven were consultants (figure 5a). The doctors 
belonged to a wide variety of surgical specialities (figure 5b). The answers given in 
the questionnaire by all of the doctors, showed the majority followed their 
consultant's or their own personal opinion when prescribing thromboprophylaxis, 
only 7% used guidelines published in the literature (figure 5c). 
Figure 5a - The different grades of the surgical 
doctors who answered the questionnaire 
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Figure 5b - The variety of surgical specialities 
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The mostjunior members of surgical teams were reported by 87% to most frequently 
prescribe the surgical thromboprophyl axis (figure 5d). The questionnaire revealed 
that literature guidelines were not used by any of the firms' mostjunior doctors (n = 
21) who answered the questionnaire (figure 5e). Interestingly some doctors stated 
that they referred to the hospital guidelines for assistance with prophylactic practice, 
however at this time no hospital guidelines actually existed. Doctors were asked to 
place the single and combined prophylactic methods in order of efficacy, the first 
being the most efficacious. The majority of doctors believed that subcutaneous 
heparin in combination with antiembolic stockings was the best 'combination 
prophylaxis' and more efficacious that using heparin alone (table 5b). Despite this, 
only 42% of the doctors routinely prescribed subcutaneous heparin with GCS (figure 
5f). Forty seven percent of all doctors who answered the questionnaire stated that 
they routinely prescribed subcutaneous heparin alone. 
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Figure 5c - The Sources of Information Used by 
Doctors to Guide Prophylaxis Prescription 
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Figure 5e - The sources of information used by each 
grade of doctor to guide prophylaxis prescriptin... r. 
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Table 5b - Beliefs of surgical doctors about the best prophylactic 
modalities. 
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Figure 5f - The Prophylaxis Routinely Prescribed by 
the Surgical Doctors 
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Most doctors believed that low molecular weight heparin was better than LDUH but 
their choice was governed by firm policy (figure 5g). The surgical doctors were 
asked which type of subcutaneous heparin was better, LMWH or LDUH and which 
GCS type was better, thigh or knee-length. 
When using subcutaneous heparin alone or in combination with another prophylactic 
modality, twenty four percent of doctors routinely prescribed unfractionated 
subcutaneous heparin and 34% used the fractionated LMWH. More than half of the 
doctors also believed that thigh-length GCS were better than the knee-length design. 
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Figure 5g - Beliefs of surgical doctors about the best 
heparin and stocking types for prophylaxis. 
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The separation of patients into high, moderate or low risk categories is a necessity 
required by current International and European guidelines for the successful 
prescription of prophylaxis for surgical patients. This was poorly perfonned by the 
doctors who answered the questionnaire, only 45% of doctors correctly identified the 
thromboembolic risk of three case scenarios. Interestingly, in the event of inaccurate 
risk assessment; GCS with heparin was prescribed regardless in 66% of cases. 
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The current guidelines are complex due to multiple risk factors that must be 
considered before prophylaxis can be correctly prescribed. According to the results 
from this questionnaire, the complexity of guidelines has led to confusion and 
uncertainty in the prescription practices of many doctors. Ninety-one percent of 
doctors experienced confusion on regular occasions over the correct prescribing of 
DVT prophylaxis and 51 percent felt uncertain when actual DVT prophylaxis 
prescriptions were given. When in doubt about the correct prescription; 73% of 
doctors referred to colleagues or seniors doctors for advice on prophylaxis, only 
twenty-four percent referred to the literature guidelines (figure 5h). 
Figure 5h - Actions of surgical doctors when in 
doubt about the correct prophylaxis to prescribe for 
a patient. 
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Most doctors (96%) were in favour of simplifying DVT prophylaxis and agreed that 
a single 'blanket' protocol of subcutaneous heparin and stockings for all surgical 
patients with a small number of designated exclusions would be beneficial. Most 
doctors also agreed that a prophylaxis protocol with subcutaneous heparin and GCS 
should be commenced preoperatively rather than postoperatively, these included 
some consultants from orthopedic and neurosurgery who often commence their 
pharmacological prophylaxis after surgery for fear of increasing bleeding 
complications (figure 5i). 
Figure 5i - The Preferred Time of Commencement of 
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5.2.4 Conclusions 
This audit questionnaire has revealed a marked disparity in the prophylactic practices 
of the surgical doctors at Charing Cross Hospital. Within the different surgical 
specialities, there appears to be no particular structure or framework to explain these 
variations in practice. A number of salient conclusions were drawn from this survey: 
0 Throughout the specialities there is disparity of prescription practice. 
m Very few of the surgical doctors use guidelines published in the literature 
a The least experienced doctors in surgical teams most frequently prescribe the 
majority of the thromboembolic prophylaxis for their firm's patients. 
m None of these junior doctors audited used literature guidelines 
m Subcutaneous heparin and GCS were the most frequently prescribed 
prophylaxis regime 
m LMWH and thigh length stockings were the preferred varieties 
0 Surgical doctors were poor at separating patients into risk categories as 
required for the use of published guidelines in the literature 
0 The majority of doctors were in favour of a blanket protocol with 
preoperative LM" and GCS for all surgical patients with exclusion of 
patients with specific medical contraindications. 
The results of this study were combined with those from the previous audit (chapter 
4) to give an overall appraisal of the thromboprophylaxis in Charing Cross Hospital. 
This information was used to provide evidence to each surgical department. It was 
explained that there was a desperate need for an improvement in our prophylactic 
practice. 
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5.3 Instigating change in a large teaching hospital 
The advent of clinical governance has led to a change in the professional 
environment in which all doctors carry out their clinical duties; the standards of 
patient care are foremost on the list of clinical outcome criteria. The quality of care 
is improved firstly, by the use of national frameworks and local protocols that have 
been developed through the use of evidence-based principals, and secondary through 
the regular appraisal of the service quality by audit and instigating improvements to 
the areas of deficiency. However, even with clinical governance, there are still areas 
of practice throughout the National health service (NHS) that are resistant to change 
and regular audit. Such as venous thromboprophylaxis, which has proved 
unremittingly difficult to keep up to date and compliant in many hospitals throughout 
the NHS. 
5.3.1 Communications to departments 
The collective results from audit (chapter 4) and this questionnaire survey were 
analysed to produce information in order to help understand and deal with the 
difficulties in achieving good thromboprophylactic practice through the development 
of a hospital consensus for the prevention of postoperative DVT in surgical patients. 
Presentations were prepared and presented at specially arranged meetings to each 
surgical department. At this stage only nominal interest for improving the overall 
status of DVT prophylaxis was shown among surgical consultants. There existed a 
certain inertia to any suggestions for changing practice, in fact this began with the 
extreme difficulty experienced when trying to gather together all the senior and 
junior doctors of any one surgical speciality for a presentation. In general, the 
surgical consultants were happy with there own DVT prophylaxis within their 
firms 
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and were unaware - prior to the presentations - of the overall picture of disparity that 
was made up of unstructured 'firm-led' DVT prophylaxis regimes. The junior 
doctors were in favour of improving the system of prophylaxis as long as it was 
recognised by their individual consultants. A few consultants, from a variety of 
specialities, showed enthusiasm for updating their practice; provided the evidence 
was clear and of good quality, these consultants (see acknowledgements) were 
instrumental in helping to organise meetings and instigate change. 
The presentations made use of PowerPoint (MicrosoftS Office 2000) to convey the 
information to the audience. Each presentation lasted for approximately forty 
minutes, followed by twenty minutes of discussion and questions from the 'floor'. 
Presentations were delivered to each department on more than one occasion to allow 
further questions and 'departmental issues' to be addressed. The presentations 
contained the following infonnation: 
0 Background information 
o Epidemiology of WE disease 
o The need for DVT prophylaxis; acute complications of DVT and PE 
and the long ten-n effects of post-thrombotic syndrome 
0 The state of surgical DVT prophylaxis in our hospital, 
Audit and questionnaire results 
m An update on the published literature, 
National and International consensus guidelines 
Specific prophylactic recommendations for surgical specialities; 
comparisons of the published evidence for LMWH versus 
LDUH, and 
GCS versus other mechanical prophylaxis 
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0 Developing a hospital consensus for prevention of DVT in surgical patients at 
Charing Cross Hospital, 
Recommendations for LMWH and GCS 
o Unanswered questions 
m Is LMWH safe and effective to use across the board? 
m Which length of GCS, thigh or knee-length, is the best in 
terms of efficacy and patient acceptability and compliance? 
o The potential benefits of introducing a new single protocol 
o Proposing a RCT investigating the use of a single blanket application 
of LMWH with GCS across the board and which is the best length of 
GCS in patients from all surgical specialities. 
5.3.2 Feedback from departments 
Presentations made to all surgical departments; breast and oncology, ENT, GIT, 
neurosurgical, plastics, urology and vascular, were received with enthusiasm. The 
poor state of the thromboprophylaxis in most surgical departments was found to be a 
surprise to many consultants who had assumed that the prophylaxis in their patients 
was adequate. The information provided from the current literature reassured many 
of the surgeons that subcutaneous heparin and GCS were the best combination of 
prophylaxis to use in general. All consultants without objection accepted the need to 
set up a RCT to resolve the important issue of which is the optimal length of 
stocking. However the use of LMWH for patients in the RCT was somewhat more 
controversial. Some consultants believed, despite evidence to the contrary from the 
current literature, that LMWH offered no prophylactic advantage over unfractionated 
heparins with the added detriment of increased bleeding complications. It was 
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mainly the orthopaedic and neurosurgeons who feared the potentially devastating 
outcome of bleeding complications in prosthetic joint and intracranial surgery 
respectively. The ENT, urology and vascular surgeons agreed to change from 
unfractionated to LMWH for the purposes of the proposed RCT. The breast and GIT 
surgeons had by this stage already incorporated LMMM into the prophylaxis of their 
patients. A final agreement was reached; firstly with the orthopaedic and 
neurosurgical teams that LMWH could be used in their patients recruited into the 
trial on the proviso that the LM" was commenced twelve hours postoperatively. 
And secondly by the majority of consultants that the introduction of a new single 
protocol of LM)NM and GCS for all in-patients undergoing surgery would be 
considered depending on the results from the RCT. 
5.3.3 The use of LMWH and graduated compression stockings 
(Pacross the board' for patients undergoing surgery 
The introduction of LMWH over a decade ago, for the prophylaxis of DVT in 
hospitalised patients has been met with some resistance. This was related to queries 
over its efficacy and bleeding complications when used in surgical patients and the 
initial expense of LM" compared to unfractionated heparins. Since this time, 
numerous randomised clinical trials have been performed to evaluate the 
performance of LMWH in comparison to unfractionated heparin and its cost has 
gradually reduced to such an extent that it is now cheaper per day than its 
unfractionated counterpart. Low molecular weight heparin is the heparin of choice 
for the prophylaxis of the majority of surgical patients for a number of reasons: 
1. Efficacy 
2. Reduced complications 
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Patients acceptability 
Cost 
5. Other benefits, such as reduced hypersensitivity and anti-neoplastic effects 
Graduated compression stockings have been commonplace in the prevention of DVT 
in surgical patients for over forty years. However, it is still not known which length 
of stocking, thigh or knee-length is more effective. This is a relevant and important 
uncertainty to resolve because of the high frequency of their application in surgical 
(and medical) practice. On the surgical wards in the majority of NHS hospitals one 
would expect to see a large proportion of the patients wearing GCS. The 
International and European consensus recommend their use in combination with 
subcutaneous heparin (mainly LMWH), for a large proportion of patients (those of 
high or moderate risk) from many different surgical specialities. However, even with 
numerous guidelines DVT prophylaxis in surgical patients in our hospital and many 
others is still inadequate (Anderson et a] 1991, Bratsler et al 1998, Conti & 
Daschbach 1982, Ahmad et al 2002). Assessment of the literature and the failures of 
DVT prophylaxis in this institution has led me to strongly believe that in order to 
ensure that every patient undergoing surgery appropriately receives prophylaxis 
against DVT a simplified single protocol of LMWE and GCS for all surgical patients 
is the answer to this widespread problem. 
The argument for a single 'blanket' protocol of LMWH and GCS is as follows: 
1. LMVM and GCS have been shown to be the best combination prophylaxis in 
terms of efficacy, practically and patients acceptability. 
2. Low dose LMWH and GCS are safe and rarely cause complications 
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I The majority of patients staying in hospital to undergo surgery are of high or 
moderate risk for WE and are recommended LMWH and GCS by the 
International and European consensus. 
4. Some low risk patients in hospital have the potential to increase their risk to 
moderate or even high risk through surgical complications or unexpected 
histological diagnosis of malignancy. 
5. Many of the surgical doctors administering prophylaxis do not use guidelines 
6. A single blanket protocol does not require the separation of patients into risk 
categories prior to administering prophylaxis, which is an advantage as many 
of the surgical doctors administering prophylaxis cannot risk assess the 
patients correctly. 
7. LM" can be given on the evening before surgery and the patients can still 
receive epidural and spinal anaesthesia on the morning of surgery without 
missing any of the required heparin prophylaxis. 
8. LMVM is a single daily injection that is more acceptable to patients than 
twice or thrice daily injections. 
9. LM" is cheaper than unfractionated heparin for a daily prescription. 
10. A simplified single protocol has been shown to improve the rate and 
compliance of DVT prophylaxis prescription (chapter 4). 
The arguments against a DVT single blanket protocol for surgical patients are 
relatively few. These include factors such as the complications and cost of giving 
low risk patients LMWH and GCS. This query can be answered by the 
fact that low 
risk patient are known to suffer DVT and PE, the evidence 
for low risk patients with 
regard to the required prophylaxis and its cost effectiveness 
is not available in the 
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literature, and low risk patients can easily increase their risk status unexpectedly 
through prolonged or complicated surgery. 
5.4 Discussion 
The need for a new and fresh approach to the prevention of WE in our surgical 
patients is clear. This approach must incorporate the evidence and work completed 
in the many studies and guidelines currently available in the literature. The 
international consensus recommends the use of subcutaneous heparin, in most cases 
LMWH, and GCS for high and moderate risk patients (Nicolaides et al 2002). This 
new single protocol of LMWH and stockings for all surgical patients undergoing 
surgery (in hospital) incorporates these recommendations from the International 
consensus and applies them to the population of surgical patients in a large teaching 
hospital in a simplified manner that has been shown to improve prophylaxis 
compliance (chapter 4). A large RCT was set up to assess the proposed new single 
protocol for efficacy, safety and to investigate which is the optimal length of GCS. 
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Chapter Six 
A randomised control-led trial 
to develop a new blanket protocol of low molecular weight 
heparin and the best - thigh or knee length - stocking 
for the prevention of postoperative DVT 
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6.1 Introduction 
Surgical practice continues to be complicated by venous thromboembolic disease, 
despite continued efforts over the last four decades to reduce its occurrence. Patients 
are continuing to suffer from the severe complications of DVT and PE; ten percent of 
hospital deaths have been associated with PE (Sandier & Martin 1989). Although a 
fatal PE may be the first presentation, a DVT may propagate to produce a PE and up 
to seventy percent of patients with proven PE have venographic evidence of 
peripheral venous thrombosis (Hull et al 1983). In general, the most appropriate 
methods for the prevention of DVT in the surgical patient are subcutaneous heparin 
and graduated compression stockings (GCS) (Nicolaides et al 200 1, Wille-Jorgensen 
et al 2002, Amarigiri & Lees 2000). Other pharmacological and physical 
prophylactic modalities however, are either less effective, less safe or impractical. 
6.1.1 The need for a randomised controlled trial 
In Charing Cross hospital, a large university hospital, there was considerable 
variation in the use of prophylactic methods with regard to types and regimen of 
heparin, GCS and their implementation, was found. None of the surgical specialities 
had a specific departmental protocol for the prevention of post-operative 
thromboembolism. Subcutaneous heparin prophylaxis was disparate, LDUH and 
different brands and doses of LM" were prescribed inconsistently. The status of 
thromboprophylaxis was audited in Charing Cross hospital to establish the areas of 
practice that required improvement (chapter 4). In one hundred and six patients who 
had undergone surgery in our hospital, subcutaneous heparin prophylaxis was 
omitted in forty-six percent. The use of AES was omitted or deficient in fifty-four 
percent of patients. Many of the patients given stockings, received a variety of 
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stocking lengths, 'unproven' brands and with inadequate fitting in many cases. The 
majority of patients in hospital for surgical treatment were found to be of high 
thromboembolic risk (ICS. Nicolaides et al 2001). The combined use of 
subcutaneous heparin and stockings was evident in only twenty-four percent of 
patients (Howard et al 2002). Our findings are similar to other reports from the 
literature describing poor compliance of DVT prevention. In order to correct the poor 
compliance of thromboprophylaxis in our hospital the junior doctors and nurses were 
educated about the merits of a simple protocol of 'heparin and stockings for all' 
surgical patients, the re-audit showed a significant improvement of adequate 
thromboprophylaxis to 88% of patients (P=0.003) (Howard et al 2002). 
Information was fed back to the surgical specialities from our audit and the merits of 
a single protocol were discussed. After presentations to departments, the majority of 
surgeons felt that there was no doubt that LMWH was effective, more acceptable to 
patients due to the single daily injection, and cheaper than LDUH. However, 
surgeons and nurses were not certain of the safety of LM" and what length and 
design of anti-embolic stocking should be applied. 
6.1.2 Aims of the study 
The goal was to develop a single and safe 'blanket' protocol to prevent post- 
operative DVT, in a university hospital, suitable for all surgical procedures for low, 
moderate and high-risk patients (ICS. Nicolaides et al 2001) from a wide range of 
specialities including breast and oncology, ear, nose and throat (ENT), 
gastrointestinal (GIT), neurosurgery, orthopaedic, urology and vascular. Recent 
Cochrane reviews gave encouragement for the combined use of subcutaneous 
heparin and GCS (Wille-Jorgensen et al 2002, Arnarigiri & Lees 2000). A single 
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protocol that recommended a 'blanket' application of LMWH and GCS was 
investigated for safety and efficacy of DVT prophylaxis when prescribed to every 
patient admitted to hospital (excluding day-surgery patients) for any surgical 
procedure that requires a general anaesthetic. . The best length of GCS was 
investigated for efficacy on a background of LMWH and stocking satisfaction with a 
health related quality of life (HRQL) and a compliance assessment (chapter seven). 
6.1.3 Hypothesis and study end-points 
The study hypothesis; 'provided LMWH is given to all patients, thigh length anti- 
embolic stockings are equal to knee-length of the same design in the prevention of 
post-operative deep vein thrombosis', was based on the limited evidence comparing 
thigh to knee-length stockings. The primary end-point of the study was the incidence 
of post-operative deep vein thrombosis by duplex scanning. The secondary end- 
point was the incidence of bleeding complications associated with LM". 
6.1.4 Ethics approval 
The study involved the recruitment of patients undergoing surgery at Charing Cross 
Hospital and therefore ethical approval was gained from the local Riverside Research 
Ethics Committee (Chelsea Westminster Hospital, London). A copy of the approval 
is appended in this manuscript (appendix). The ethical committee reference number 
is RREC 2447. 
6.1.5 Sources of funding 
Funding for this research came from a number of sources, these included the 
payment of my salary for Clinical Tutor in Surgery by Imperial College and the 
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Hammersmith Hospitals NHS Trust, additional costs from the Charing Cross 
vascular surgical department research fund, and we are very grateful for the free 
donation of GCS and partial funding of colour duplex scanning costs by Medi UK 
Ltd. 
6.1.6 Venous colour duplex scanning 
The ability to visualise directly the superficial and deep venous systems by non- 
invasive means with colour duplex scanning has revolutionised the approach to the 
investigation of venous disease. In the early 1980's, '13' mode compression 
ultrasonography of the veins in the lower limb was introduced for the diagnosis of 
DVT. Since this time, venous ultrasound scanning has been the subject of numerous 
studies assessing its applications and accuracy. The earlier studies assessed the use 
of compression ultrasonography for the detection of DVT. However accuracy has 
improved over the last two decades as the technology has advanced with the 
introduction of colour Doppler ultrasound in the mid 1980's and with the more recent 
addition of enhanced computer software and power Doppler (colour Doppler 
energy). Today, state of the art ultrasound machines now provide high levels of 
accuracy when compared to venography and isotopic fibrinogen scans for the 
detection of DVT. For some time the detection of proximal (popliteal, femoral and 
iliac vein) DVT has reached good levels of sensitivity and specificity with additional 
safety employed by repeated scanning within one week. The duplex detection of calf 
vein DVT however, has been controversial. The perceived minor relevance of the 
calf vein DVT together with inferior diagnostic imaging from early ultrasound has 
often led to this pathology being ignored. More recently the improved software for 
pre and post processing of the B mode image, such as high definition zoom, together 
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with Doppler and now power Doppler, has enabled good visualisation of small calf 
veins and low flow scenarios can reliably be assessed. The accuracy has been 
reported to reach between 94 and 97.9% for detecting acute isolated calf DVT and 
97% (confidence interval (CI) 96-98%) for the diagnosis of proximal DVT 
(Baumgartner et al 1998 & Keearon et al 1998). The sensitivity has been reported to 
reach one hundred percent, specificity 71%, positive predictive value 71%, achieved 
with 100% of scans completed successfully (Forbes & Stevenson 1998). Colour 
duplex scanning for DVT is non-invasive, time efficient, acceptable to patients, 
harmless and repeatable. Contrast venography on the other hand, is expensive, 
uncomfortable to the patient, occasionally painful, technically difficult to perform 
and is inadequate or impossible to perform in up to ten percent of patients. In 
addition, disagreements over the interpretation of venographic results for diagnosing 
DVT have been reported to occur in approximately ten percent of cases. Therefore, 
although in the past this test has been considered the gold standard for the detection 
of DVT, it is not ideal to use in the clinical environment. Isotopic fibrinogen 
scanning suffers similar set backs to venography as it is invasive, uncomfortable for 
the patients, technically difficult to interpret and in patients it has limited ability to 
image proximal DVT in patients with knee and hip replacements due to artefact. 
Bum et al (1997) reported how duplex ultrasonography has become increasing 
prevalent as a first line diagnostic instrument for the diagnosis of lower limb DVT in 
UK hospitals and that venography is used in only a minority of departments as the 
principal diagnostic technique. 
The accuracy of detecting postoperative DVT by duplex scanning is dependent on a 
number of factors: 
N The ultrasound machine and its capabilities 
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a The ultrasonographer and techniques employed 
m The use of a 'serial strategy' of colour Doppler scanning before and after the 
surgery and within one week after an equivocal DVT scan. 
The colour Doppler ultrasound (CDU) machine that was used for this study was an 
ATL/HDI (High Definition Imaging) 5000 (Advanced Technology Laboratory, 
USA), which is a state of the art colour Doppler machine with power Doppler and 
high definition zoom capabilities. All of the ultrasound scans for this study were 
performed by myself after completing a venous duplex training course of three 
months duration. Scanning for DVT with ultrasonography is known to be operator 
dependent, however errors can be limited if the operator is trained to perform a strict 
scan protocol. I was trained by our principal clinical vascular technological scientist 
(acknowledgements) to perform scans in this manner (see methods 6.2.4). 
In the diagnosis of postoperative DVT, it is important to scan all of the patients for 
the presence of DVT before their operation to ensure that the patients have not 
recently suffered an undiagnosed acute DVT just prior to surgery and to record any 
deep venous scarring or occlusions secondary to previous 'old' DVT, that could 
potentially be mistaken for acute venous thrombosis after the surgery. All of the 
three factors - hypercoagulability, vein wall damage and venous stasis - described by 
Rudolph Virchow (1858) in the pathogenesis of venous thrombosis, are potentially 
present during and immediately after a surgical procedure. These are secondary to 
the stress response, calf vein wall distension and muscle paralysis, respectively. The 
development of an 'early' surgical DVT is thought to begin during the surgical 
procedure, with any clinical manifestations becoming evident during the first 
postoperative week, where as prolonged immobility in the convalescing patient may 
lead to the formation of a 'late' DVT' that may not be directly related to the 
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operation itself Hence, the second postoperative duplex scan should be carried out 
at five to seven days after the surgery. If the patient has not developed a DVT by 5-7 
days after surgery then any venous thrombosis that develops after this time can be 
assumed to be related to thrombogenic factors taking effect to produce a 'late' DVT. 
However, for follow up purposes, I duplex scanned any patients who experienced 
any symptoms of DVT up to six weeks after their operation. 
6.1.7 Sample size and statistical analysis 
Studies provide evidence for improved venous haemodynamic properties of thigh 
over knee-length stockings (Benko et al 1999,2001 & Berridge et al 1999). Sample 
size calculations for detecting a theoretical difference between thigh and knee-length 
GCS enabled the recruitment numbers to be estimated. Therefore, sample size 
calculations were based on detecting a possible difference in postoperative DVT 
rates of 20% in the knee-length stocking group and 5% in each of the thigh-length 
stocking groups. These calculations - based on 90% power at the 5% significance 
level - required 114 patients per group (342 patients in total). 
The sample size calculations for equivalence of above-knee GCS to below-knee 
stockings for the prevention of DVT, based on hypothetical assumptions taken from 
the limited evidence from small trials in the published literature showing minimal 
differences between the stocking lengths in terms of efficacy. After testing for 
equivalence of treatment it was assumed that pi(l)=pi(2) for all practical purposes 
although they may differ by a small amount. In conducting such a test for 
equivalence to show, with a given probability I -beta (power in table), that the trial 
will rule out any difference in proportions greater tharl some prespecified, usually 
small, difference epsilon. Sample size calculations based on testing for equivalence, 
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to detect a difference of 7% in a one-sided test, at the 0.05 significance level and 
with 90% power, recruitment required 315 patients per group. The table I e, gives the 
sample sizes for differences in an equivalence study. 
Statistical analysis was performed using STATA 6.0 statistical package (Stata 
Corporation, College Station, USA). Logistic regression analysis was used to 
estimate crude odds ratios (ORs) between Medi thigh-length and Medi knee-length 
and between Kendall thigh-length and Medi knee-length stocking groups. These 
crude ORs were also adjusted for the use of preoperative LMWH. 
Difference Sig level=0.1, Sig level=0.05, Sig level=0.1, Sig level=0.05, 
(epsilon) power = 0.9 power=0.9 
0.02 n=2956 per n=3854 per 
group group 
0.05 n=473 per n=616 per 
group group 
0.06 n=328 per n=428 per 
group group 
0.07 n=242 per n==3 15 per 
power--0.8 
n=2029 per 
group 
n=3 25 per 
group 
n=225 per 
group 
n= 166 per 
power--0.8 
n=2782 per 
group 
n=445 per 
group 
n=309 per 
group 
n=227 per 
group group group group 
Table le - The sample sizes for certain differences in an equivalence 
study. Sig level - significance level, n= number of patients. 
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6.2 Patients and methods 
6.2.1 Patients and data collection 
All patients were recruited from the surgical departments of Charing Cross hospital, 
the specialities included breast and oncology, ENT, gastrointestinal, neurosurgery, 
orthopedic, urology and vascular surgery. Patients were given trial information 
sheets on the day before their proposed surgery (Appendix). A record of patient 
details were recorded on a trial baseline sheet (see below) in order to gain 
information for DVT risk categorisation and stratified randomisation. Data sheets 
were compiled to made a trial booklet for each patient. Other sheets recorded 
information from each stage of the patients' participation in the trial, these included a 
randomisation, surgery and post-surgery, venous duplex scan findings, patients' 
stocking satisfaction questionnaire and compliance assessment (Appendix). 
All completed patient trial booklets were stored and not inspected until the 
completion of the trial. At the end of the trial, all patient data was entered and stored 
in secure offline computer databases. The risk factors for venous thrombosis were 
recorded on the 'baseline' sheet, these factors included: 
m Age 
n Male/Female 
m Past medical history of: 
Deep vein thrombosis 
Pulmonary embolus 
Coagulopathy 
o Coagulopathy family history 
Smoking 
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Obesity 
o Varicose veins (CEAP classification) 
History of leg fracture or joint prosthesis surgery 
Mobility at time of trial (bed bound/chair bound/housebound/full) 
Recent - last six weeks - aeroplane flight (duration/date) 
o Malignancy (type, date of diagnosis) 
Medications (warfarin, aspirin, oral contraceptive pill, hormone replacement 
therapy, steroids, others). 
The stratified randomisation details of each patient were recorded. The treatment 
data was recorded regarding the length of the surgery (greater or less than 45 minutes 
as recommended by the international consensus, and the type of surgery. A record of 
peri-operative prophylaxis complications was made for each case. 
The findings from colour Doppler scanning, clinical assessment for DVT and PE and 
the compliance of patients wearing stockings and receiving LMVM injections were 
recorded. The compression profiles of each of the stocking designs were assessed 
randomly on patients throughout the duration of the trial. External pressure 
(compression profile) applied by the stocking was measured with an Oxford pressure 
monitor equipped with three skin/stocking interface pressure transducers. The 
transducers were positioned at specific points on the patients' limbs between the skin 
and the stocking; the level of the maleoli of the ankle joint in the midline, on the 
lateral aspect of the lower leg at the midpoint between the maleoli and the tibial 
tuberosity and at the level of the tibial tuberosity (as described in the operator 
instructions). Care was taken not to position the transducers over boney prominences 
as this may produce falsely elevated readings. After the wearing of GCS for 5-7 
days, the patients were asked to complete an HRQL 'stocking satisfaction 
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questionnaire' developed for the assessment of patient acceptability using lower limb 
compression t erapies (chapter 7). 
6.2.2 Recruitment and randomisation 
Patients were interviewed at surgical pre-admission clinics or on admission to 
surgical wards at Charing Cross Hospital for planned elective surgery, before entry 
into the study, patients were checked to ensure they fitted the entry criteria as 
detailed in table 6a. 
Inclusion criteria 
.......... I ........ .................... A random allocation of all patients 
undergoing any elective surgical 
procedure whilst admitted as an in- 
patient at Charing Cross hospital. 
Exclusion criteria 
1. Patients unable to give 
informed consent 
2. Patients unable to receive 
LMVY'H or anti-embolic 
stockings 
3. Patients receiving full oral or 
intravenous anticoagulation 
4. Patients undergoing surgery 
in the Day Surgery Unit 
Table 6a Entry and exclusion criteria for the study 
The interview provided verbal information and ethics-committee-approved 
information sheets describing deep vein thrombosis, the study protocol and ethics 
approval. Informed consent (Appendix) was gained after the patient had had 
sufficient time to digest the information and ask further questions. 
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426 Patients 
Assessed for Eligibility 
to Commence Trial 
11 patients did not 
meet inclusion 
criteria 
39 patients refused 
to participate 
376 Patients Randomised 
to Commence Trial Protocol 
All Patients Received LMNVH 
Kendall T. E. D. 
Thigh-length 
AFS 
127 Patients 
NMDI 
Thrombexin 
Thigh-length AES 
121 Patients 
NIEDI 
Thrombexin 
Knee-length AES 
128 Patients 
Figure 6a Recruitment consort diagram. Low molecular weight 
heparin (LM)VH), Antiembolic Stockings (AES) 
The patients that volunteered to take part in the trial were randomised via computer 
into one of the three stocking groups (figure 6a): 
1. Kendall T. E. D. (Tyco Healthcare, Gosport, England) thigh-length stockings. 
2. Medi ThrombexinS ClimaXTM(Medi UK, Hereford, England) thigh-length 
stockings, 
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3. Medi Thrombexing ClimaXTM(Medi UK, Hereford, England) knee-length 
stockings. 
Computer randomisation was stratified for surgical speciality and thromboembolic 
risk, in line with the International Consensus Statement for the Prevention of Venous 
Thromboembolism (Nicolaides et al 200 1). 
6.2.3 Patient information and informed consent 
Trial information sheets were provided to all patients, these were developed in 
accordance to the recommendations of the Riverside ethics committee (London). 
General information describing deep vein thrombosis, its development in relation to 
surgical procedures and potential complications of a lower limb DVT. Specific 
information describing the randomised controlled trial and the influence that 
enrolment in the trial may have on the patients' surgical care in hospital. Patients 
were interviewed during admission to surgical pre-admission clinics and surgical 
wards, infon-nation sheets were provided with a verbal explanation of the trial, 
sufficient time was allowed to assess the information and ask further questions. The 
patients who were interested in taking part in the study signed an informed consent 
sheet prior to taking part in any trial procedures. Patients who were unable to 
understand the trial information fully due to illness or otherwise were unable to give 
informed consent and therefore were unable to take part in the study. 
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6.2.4 Colour duplex scanning for deep vein thrombosis in trial 
patients 
The incidence of DVT was assessed by colour Doppler ultrasound scanning as 
described previously in this chapter (6.1.6 Colour duplex scanning). All duplex 
scans were performed by myself with an ATL/High definition imaging 5000 
(Advanced Technology Laboratory, USA) ultrasound machine with power Doppler 
and high definition zoom capabilities. All patients received a pre-operative venous 
duplex scan on the evening before surgery and a further duplex assessment on the 
fifth to seventh day after the surgical procedure. The preoperative scan was 
performed in order to check for clinically silent DVT or old post-thrombotic scarring 
or occlusions. As an undiagnosed preoperative DVT would potentially produce a 
false positive result during the second duplex after surgery. Any patients with 
preoperative DVT had their operations cancelled for safety reasons and rescheduled 
to a time that it was deemed appropriate to carry out the required elective surgery. 
Due to the long time delay and the possibility of the patient no longer undergoing 
their planned operation these patients were removed from the study. However if the 
patients returned for surgery during the trial period then these patients would then be 
enrolled with the patients' pennission. 
A postoperative venous duplex was performed on all patients, the results of this 
second scan were compared to results from the preoperative CDU scans taking into 
account any preoperative detection of 'old' prothrombotic scarring or occlusions. 
The vascular department's principal vascular technology scientist supervised and 
verified the venous duplex scans. Prior to commencement of the trial, I underwent a 
three-month period of training to learn the techniques for venous duplex scanning of 
the lower limb for diagnosing DVT, this training was carried out under the guidance 
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of the principal vascular technology scientist. During this training I achieved a high 
standard of DVT duplex scanning and thereafter during the trial venous scans were 
regularly supervised and checked by the principal vascular technology scientist, Mrs 
Mary Ellis. The DVT scans were frequently graded for accuracy by the principal 
vascular technologist. During this assessment, my scan results were not revealed to 
the principal vascular technologist until she had completed and finalised the outcome 
of the scan that she performed on the same patient. 
Scanning for DVT with ultrasonography is known to be operator dependent, however 
errors can be limited if the operator is trained in a strict scan protocol. I was trained 
by our principal clinical vascular technological scientist to perform scans in the 
following manner: 
1. With the patients in the supine position with the knee slightly flexed, 
longitudinally scan the iliac to the distal popliteal veins of both legs with 
. V--- frequency-based colour coded duplex ultrasound 
2. Valsalva manoeuvre is performed by the patient whilst insonnating over the 
femoral triangle to ensure free venous flow from the inferior vena into the 
iliac veins 
3. Scan in cross-section the iliac to distal popliteal veins with compression non- 
colour ultrasound. 
4. In the sitting patient with the lower legs dependent, scan the proximal 
popliteal (to ensure an overlap of scanned areas) to the distal ends of the calf 
veins, namely the anterior tibial, posterior tibial, peroneal, gastrocnemius and 
soleus veins, in longitudinal CDU and cross-sectional non-colour 
compression ultrasound. 
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5. Power Doppler was used for small veins with low flow 
6. Magnified imaging with high defirtition zoom mode was used for areas of 
suspected abnormality 
7. Six criteria were required to be fulfilled for all areas of the deep venous 
circulation in order to exclude acute DVT - 
i. Colour fill 
Spontaneous flow 
iii. Phasic flow 
iv. Augmentation 
v. No visible thrombus 
vi. Complete venous compression 
8. If all of the six above criteria were not adequately fulfilled or if poor images 
were produced secondary limb pathology such as oedema, cellulitis, 
lymphoederna or obesity; the duplex scans were checked during that current 
scan by the principal vascular technology scientist and repeated within 7 days 
with the principal vascular technology scientist in attendance, as part of a 
serial scanning strategy. 
Power Doppler and high-resolution zoom imaging modes were used for areas of 
suspected abnormality and for small veins with low flow rates. 
For follow up purposes, any patients who experienced any symptoms of DVT up to 
six weeks after their operation were duplex scanned. 
6.2.5 Commencement and maintenance of trial prophylaxis 
Subcutaneous LMWH and graduated compression stockings were prescribed and 
administered to the patients on the evening before surgery (see figure 6b for a flow 
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diagram of the trial methodology). Stockings were expertly fitted to patients using 
the manufacturers guidelines; measurements with a tape measure were performed at 
the necessary points on the leg to achieve the best possible fit. All patients received 
stockings on the evening before surgery unless the surgical intervention involved the 
lower extremity and for these cases the stocking was fitted to the leg undergoing 
surgery on the first postoperative day. 
Ol 110. -% 
t stj 
Informed Preoperative 
CFitting 
of 
Consent venous stockings 
Uduplexuscan 
z 
LMWH 
prescribed 
z 
Postsurgery Compliance 
venous Ibb- questionnaire Operation 
duplex scan) 
PP- 
( 
completed 
Figure 6b - Flow diagram of the trial methodology 
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Patients were checked each day to ensure that stockings were being worn and 
maintained there fit, patients also completed diary cards to record stocking 
compliance. Patients were free to chose whether they wore their allocated stockings. 
A record of complications associated with the use of stockings and LMWH was 
made for all patients. A complication was classified as significant if it caused death, 
required surgical correction or other morbidity such as infection or wound 
dehiscence. Minor complications were regarded as those that were uncomplicated 
and resolved without additional treatment. Patients were allowed to leave the trial at 
any point is they wished as a result of complications secondary to a trial intervention 
or for other personal reasons. 
6.2.6 Treatment of patients who developed DVT 
All patients who developed a DVT during the trial were treated with full 
anticoagulation, initially using subcutaneous LMWH (Tinzaparin 175 Units/kg/day) 
until daily oral anticoagulation (Warfarin) achieved an International Ratio (INR) 
level of greater than two. Patients were also prescribed level-two compression 
hosiery to wear on a daily basis and referred for haematological follow-up care with 
a planned six months period of warfarin treatment. 
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6.3 Results 
6.3.1 Patient series 
A total of 426 patients were interviewed for introduction into the trial, thirty-nine 
refused and eleven were medically unable to wear AES or receive subcutaneous 
heparin prophylaxis, because they suffered from peripheral vascular disease or 
received other anticoagulation such as intravenous heparin or warfarin. The 
remaining three hundred and seventy six patients were randomised into the three 
stocking groups, the overall mean age was 58 years (range 16-88) and forty-two 
percent were males. The recruitment of patients during the trial is shown in figure 
6c, limitations to the rate of recruitment were found to be due to the following: 
m Patients admitted to hospital on the aftemoon/evening before surgery still 
required multiple medical investigations 
E Many patients were admitted on morning of surgery 
w Shortage of hospital beds for elective surgery led to many cancellations 
m Foreign and very elderly patients had difficulty understanding trial 
information 
E Some patients were not prepared to return for 2nd duplex scan. 
Patients were recruited from a variety of surgical specialities that included: breast 
and oncology (n=73), ENT (n=13), gastrointestinal (n=122), neurosurgery (n=34), 
orthopaedic (n=62), urology (n=5 8) and vascular surgical patients (n= 14) (table 6b) - 
Thromboembolic risk assessment in accordance with the International consensus 
(Nicolaides et al 2001) revealed 291 patients were high risk, fifty-nine patients were 
moderate risk and twenty-six patients fell into the low risk category. Stratified 
randomisation allocated patients into three similar stocking groups (see table 6c) 
consisting of Patients wearing Medi Thrombexin thigh-length stockings (n= 12 1), 
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Medi Thrombexin knee-length stockings (n=128) and Kendall T. E. D. thigh-length 
stockings (n= 127) (figure 6d). 
Fgm 6c - Rate of reenfifiment of hial patients 
(Dee 2000 - Jum 2002) 
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Precise stratified randomisation resulted in each group being statistically very similar 
in terms of age (P=0.850), gender (P=0.998) (table 6c), thromboembolic risk 
(P=0.230) (figure 6e) and surgical speciality (figure 6f). There was no significant 
difference between groups for compliance with the trial protocol i. e. receiving 
injections of LMWH and wearing stockings (P=0.277). 
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Surgical Speciality Number of Patients 
Breast 73 
ENT 13 
Gastro-intestinal 122 
Neurosurgery 34 
Orthopedic 62 
Urology 58 
Vascular 14 
Table 6b - Surgical specialities of recruited patients 
Kendall Medi Thigh Medi Knee 
Thigh Stocking Stocking 
k 
Stocking 
Number 127 121 128 
Sex (male) 42% 41% 42% 
[Pearson Ch i2 
P=0.99] 
Age (years) 
EMean 58 58 57 
wMedian 60 60 58 
ERange 16-85 17-88 22-87 
mStd Dev 15.3 16.2 15.4 
[Kruskal-Wallis 
Test; P=0.851 
1 1 1 11 
Table 6c - The demographic details of the trial patients 
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426 Patients 
Assessed for Eligibility 
to Commence Trial 
Kendall T. E. D. 
Thigh-length 
AES 
127 Patients 
11 patients did not 
meet inclusion 
criteria 
39 patients refused 
to participate 
376 Patients Randomised 
to Commence Trial Protocol 
All Patients Received LMWH 
NWDI 
Thrombexin 
Thigh-length AES 
121 Patients 
MEDI 
Thrombexin 
Knee-length AES 
128 Patients 
102 (80%) Patients 
Completed Trial 
Protocol 
6 Patients with 
Postoperative DVT 
(5 unilateral and I 
bilateral DVT) 
93 (77%) Patients 
Completed Trial 
Protocol 
2 Patients with 
Postoperative DVT 
(2 unilateral DVT) 
99 (77%) Patients 
Completed Trial 
Protocol 
11 Patients with 
Postoperative DVT 
(10 unilateral and I 
bilateral DVT) 
Figure 6d - Trial consort diagram. Low molecular weight heparin 
(LMWH), Antiembolic Stockings (AES), Deep vein thrombosis (DVT) 
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Figure 6e - Similarity of stocking groups for DVT risk 
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Figure 6f - Similarity of stocking groups for surgical 
speciality 
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Kendall Thigh Medi Thigh Medi Knee 
Stocking Type 
Kendall Thigh Medi Thigh Medi Knee 
Table 6d - Similarity of stocking groups for 'DVT risk factors' 
Risk factor 
Previous DVT/PE 
History of Thrombophilia 
Smoking 
Aspirin 
OCP/HRT 
Varicose Veins 
Recent flight 
Malignancy 
Kendall Thigh 
Stockings 
(% patients) 
7 
2 
23 
14 
3 
26 
10 
51 
Medi Thigh 
Stockings 
(% patients) 
2 
0 
26 
5 
3 
30 
8 
55 
Medi Knee 
Stockings 
(% patients) 
2 
0 
26 
11 
6.5 
26 
10 
48 
Figure 6g - Similarity of stocking groups for aspirin 
usage X 
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Aspirin Users 
M Kendall Thigh N Medi Thigh N Medi Knee 
As previously mentioned the WE risk category for each patient was calculated using 
the guidelines in the International Consensus Statement (Nicolaides 2001). However, 
separate WE risk factors for patients in each stocking group were very similar (table 
6d). Aspirin usage was found to statistically similar [Pearson Chi2; p>0.05] for each 
group (figure 6g). Malignancy is thought to be an important risk factor and 
interestingly the Medi thigh GCS group had the highest malignancy rate (see later). 
6.3.2 Colour Doppler ultrasound scanning for DVT 
The accuracy of the trial scans with colour Doppler was assessed by the principal 
vascular technologist, these were graded out of a total score of five. All scanned 
diagnosed by myself as positive for DVT were checked by a vascular scientist, 
additional scans were checked randomly each week of the trial and any scans found 
difficult to interpret by myself and the vascular scientist were brought back for a 're- 
scan') after four days. My results were scored as follows; half a mark was awarded 
for each of the six factors required for the diagnosis of a DVT; colour fill, 
spontaneous flow, phasic flow, augmentation, no visible thrombus and complete 
venous compression. 
One mark was awarded for correctly assessing the anatomical extent of the DVT and 
a final mark for detecting or excluding other synchronous DVT at all sites of the 
deep venous system. The recorded scores are shown in figure 6h, there were no 
scans in which the overall diagnosis of DVT made by Mary Ellis, the chief vascular 
technologist, was different from the DVT diagnosis by my scans. In summary, all 
scans checked proved to be correct in their diagnosis of lower limb DVT. 
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Figure 6h - Accuracy of duplex scanning for DVT 
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6.3.3 Trial results 
6.3.3.1 Postoperative deep vein thrombosis 
No DVT occurred in the low or moderate DVT risk patients (n=85) using this 
protocol. All postoperative DVT occurred in the patients from the high-risk group, 
nineteen patients developed DVT from two hundred and ninety one high-risk 
patients; two of these suffered bilateral DVT. 
There were two patients wearing Medi Thrombexin thigh-length stockings that 
developed unilateral postoperative DVT with significantly more, eleven patients 
i2. from the Medi Thrombexin knee-length group developed DVT (Fisher's Exact Ch I 
P=0.039), one with bilateral DVT. Kendall thigh-length stockings were associated 
with five patients with unilateral DVT and one with bilateral DVT, neither 
significantly more than Medi Thrombexin thigh nor less than Medi Thrombexin 
knee-length stockings (Fisher's Exact Chi2; p-0. Igo) (figure 6i). Although 
significant differences were found with Chi2, clearer interpretation of the results was 
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possible with logistic regression analysis. Logistic regression found an 81% 
reduction in DVT with Thrombexin thigh-length stockings (OR 0.18 [95% Cl 0.04 - 
0.82] p=0.026) and a 50% reduction with Kendall thigh-length (OR 0.5 [95% CI 0.18 
- 1.4 1] p= 190), when compared to Thrombexin knee-length stockings. The DVT 
that developed with the thigh-length stockings were all found in the posterior tibial 
and peroneal veins of the calf. The knee-length stockings were associated primarily 
with calf vein DVT, however one DVT was found in the superficial femoral vein of 
the thigh (figure 6j). 
Age and malignancy were found by logistic regression analysis to be positive risk 
factors for DVT, the average age of the nineteen patients with DVT was 68 years 
(range 45-83) and twelve of these had a history of malignancy. The patients with 
postoperative DVT included, six orthopaedic patients, six patients from 
gastrointestinal surgery, five urology patients and two neurosurgical patients. The 
DVT were associated with two main types of surgery, firstly 'bone cutting' 
operations which included hip (n=3) and knee replacements (n=2), spinal surgery 
(n=3) and craniotomy (n=l). And secondly with major abdominal surgery: upper 
gastrointestinal operations (n-3), lower gastrointestinal operations (n=3), 
nephrectomy (n=2), cystectomy (n=3) and radical prostatectomy (n=1), (figure 6k). 
The specific surgical procedures that resulted in the patient suffering a postoperative 
DVT are detailed in figure 61. 
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Figure 6i - Postoperative DVT rates for each stocking 
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Figure 6j - Anatomical distribution of DVT with each 
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Figure 61 - Operation associated with DVT 
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The VTE risk factors of the patients who developed post-operative DVT were 
minimal apart from twelve or nineteen patients (63%) had a history of malignancy. 
Otherwise, none of the patients had previously suffered VTE, only two had a family 
history of DVT, three were smokers, five had varicosities, three had previous joint 
replacements and six had limited mobility. However, most interestingly six patients 
with DVT had deep venous scarring on preoperative duplex scanning, but this factor 
and all others were spread evenly across the stocking groups. 
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6.3.3.2 LMVVH prophylaxis commenced before and after 
surgery 
Thirteen percent of the patients that underwent neurosurgical and orthopaedic 
surgical procedures, who all received their LMWH twelve hours after surgery, 
developed postoperative DVT compared to only five percent of the patients from the 
other specialities; breast, ENT, GIT, urology and vascular, who all commenced the 
LMWH prophylaxis preoperatively on the evening before surgery. This difference 
was found to be statistically borderline but not significant (OR 0.41 [95% Cl 0.16 - 
1.06] P=0.066), (figures 6m), however this possible trend was reciprocated across 
each stocking group (figure 6n). 
Figure 6m - DVT rates with and without 
preoperative heaprin 
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Figure 6n - DVT rates with and without preoperative 
heparin for each stocking group 
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6.3.3.3 Complications resulting from the blanket use of LMWH 
and stockings 
A record of complications associated with the use of subcutaneous LMWH and AES 
showed that only one significant bleeding complication occurred, other 
complications included minor haematomas (n=2) not requiring further management 
and minor foot abrasions from stockings (n=3), (figure 6p). The significant bleeding 
complication developed when a drain was removed on the second day after parotid 
surgery, the resultant haematoma required further general anaesthesia for evacuation. 
The patient made a rapid and uncomplicated recovery before discharge back to 
community. 
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Figure 6p - Complications associated with LMWH 
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6.3.3.4 The compression profiles of the stockings 
The compression profiles of the stockings showed that the Medi designs produced a 
greater mean external pressure at all three measurement points on the lower limbs of 
a total of thirty-one patients. All three types of stocking produced graduated pressure 
profile reducing from distal to proximal in the lower limb (figure 6q). 
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Figure 6q - Stocking compression profiles 
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6.3.3.5 Clinical aspects of deep vein thrombosis 
Deep vein thromboses of the calf have a range of non-specific clinical symptoms and 
signs that makes the simple clinical diagnosis historically unreliable. The advent of 
venography for the diagnosis of DVT highlighted the inaccuracies of clinical 
examination alone (Barnes et al 1975). However, if risk factors are present in 
combination with consistent symptoms and signs, then the probability of a correct 
clinical diagnosis is increased (Wells et al 1997, Wells & Anderson 2000). Authors 
have developed 'clinical prediction indexes' to improve the diagnosis of DVT to help 
physicians with limited access to objective diagnostic means such as venography or 
duplex. There are four published clinical prediction indexes by Vine et al (1981), 
Landefeld et al (1990), Wells et al 1995, and a revised version by Wells et al (1997) 
The latter index has been reported to be the most useful, however none of these 
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indexes can safely replace the need for diagnostic testing (Kahn 1998). It is 
important to successfully diagnose a DVT, because if left untreated the patient can 
suffer a fatal PE. Proximal extension of calf vein DVT occurs in approximately 20- 
30% of cases and PE (symptomatic and asymptornatic) have been detected in as 
many as 50% of the cases with proximal DVT (Huisman et al 1989 & Kakkar et al 
1969) 
I recorded the clinical findings in the lower extremities of all of our trial patients in 
order to investigate further the relationship between clinically diagnosed DVT and 
those DVT diagnosed by Duplex ultrasound. The criteria for the clinical diagnosis of 
DVT was based on the presence of lower limb swelling confinned by calf 
circumference measurement, calf/thigh pain confin-ned by tenderness on palpation 
and a change in discolouration confirmed by the presence of erythema. The 
proportion of symptomatic and asymptomatic DVT (detected by duplex ultrasound 
after surgery) were approximately equal (figure 6r), around fifty percent. 
A small proportion of patients from the total recruitment of 376 patients entered into 
the trial experienced one or more of the symptoms or signs mentioned above in one 
or two legs. The distribution of clinical findings and there relationship to DVT 
diagnosed by duplex is displayed in figure 6s. Of the original 376 patients (752 legs) 
recruited into the trial, 79 patients did not attend their postoperative duplex scan 
because their operation was cancelled or they chose to decline. Of the remaining 297 
patients (594 legs), 62 patients (64 limbs) experienced limb swelling, eleven patents 
(twelve limbs) suffered calf or thigh erythema and 43 patients (44 limbs) had calf or 
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Figure 6r - The incidence of symptomatic DVT 
and those detected by duplex ultrasound 
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thigh pain and tenderness and 287 patients (574 limbs) did not have any symptoms. 
One patient experienced all three symptoms of swelling, erythema and pain in both 
legs. 
Of these symptomatic limbs (total 78), 10 legs suffered DVT diagnosed by duplex 
and the remaining 68 symptomatic limbs had no duplex evidence of DVT. Of the 
516 asymptornatic limbs, II legs suffered DVT by duplex (505 limbs had no 
evidence of DVT by duplex). 
The accuracy of clinical diagnosis can be assessed by calculating the specificity, 
sensitivity, positive and negative predictive values (assuming duplex DVT diagnosis 
as the gold standard). The values required for the calculations are displayed in table 
6e. 
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Figure 6s - The distribution of clinical findings and there 
relationship to DVT diagnosed by duplex 
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Test Disease Value 
Shows Status Type 
Trial 
Value (legs) 
++ True Positive 10 
False Positive 68 
+ False Negative II 
True Negative 
. ...... - -------------- - 
505 
Table 6e - The values required for the calculation of specificity, 
sensitivity, positive and negative predictive values of clinical 
diagnosis of DVT 
The specificity, sensitivity, positive and negative predictive values of clinical 
diagnosis using one or more symptoms is calculated as follows: 
Specificity = True Negatives 505 98% 
True Negatives + False Positives 505+ 10 
Sensitivity = True Positives 10 48% 
True Positives + False Negatives 10+11 
Positive True Positives 10 13% 
Predictive True Positives + False Positives 10+68 
Negative = True Negatives 505 98% 
Predictive True Negatives + False Negatives 505+11 
The combination of all three clinical findings, the triad of swelling, pain and 
erythema were present in only nine legs (eight patients), however only one patient 
(one limb) ftom this group suffered a post-operative DVT. However, of the legs 
186 
without the complete clinical triad (n=586 legs), 20 were diagnosed with DVT by 
duplex and 573 legs were free of thrombosis. The specificity, sensitivity, positive and 
negative predictive values of clinical diagnosis using the 'clinical triad' of swelling, 
pain and erytherna are as follows: 
Specificity 
_ 
573 98% 
573+8 
Sensitivity 
-1 
5% 
1+19 
Positive 
-1 Predictive 1 +8 
Negative 
_573 
97% 
Predictive 573+20 
Clinical diagnosis by examination alone is specific but not sensitive for the diagnosis 
of DVT. These calculations indicate that clinical diagnosis of DVT is moderately 
accurate at detecting those without DVT, with improved specificity if a clinical triad 
model is applied. However, clinical appraisal alone is poor at diagnosing patients 
with DVT and will miss a large proportion of patients with DVT if the clinical triad 
is used alone. 
6.4 Conclusions 
Although numerous investigators have provided evidence to show that prophylaxis 
against venous thromboembolism is effective by reducing the incidence of DVT and 
PE by as much as two-thirds, there is still a lot of confusion and controversy over the 
correct prophylactic methods for surgical patients (George et al 1998). This 
uncertainty has led to the frequent occurrence of inadequate compliance of 
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thromboembolic prophylaxis in many centres globally (George 1998, Jones 199 1, 
Stephens et al 1995, Audet et al 1998, Fletcher et al 1992). Hence, we may not be 
alone in our regional centre where the use of prophylaxis in surgical patients was 
alarmingly disparate (Howard et al 2002). There was no single policy for any of the 
departments, specialities or even consultant firms. The doctor initiating a patient's 
treatment in hospital usually prescribed the DVT prophylaxis, which was more often 
than not the mostjunior member of the team. Low molecular weight and 
unfractionated heparins and antiernbolic stockings of thigh-length and knee-length 
designs were prescribed to surgical patients in an incongruent manner. 
In our establishment the poor adherence to thromboembolic prophylaxis was 
generally not realised until audit presentations to each speciality were given to 
explain the existing deficiencies. Education has proved beneficial to prophylaxis of 
venous thromboembolism (Howard et at 2002, George et at 1998, Jones 199 1, 
Stephens et al 1995, Audet et al 1998, Fletcher et al 1992, Anderson et al 1994) and 
is required on a regular basis with support from frequent audit. A general consensus 
between departments would not have been reached without this education and audit. 
Any information conveyed to the medical staff has to be based on evidence-based 
principals. Unfortunately, the complexity of the abundant recommendations for 
surgical thromboembolic prophylaxis in the literature adds to the general uncertainty 
and consequent loss of coordinated and agreed practice. A clear and simple plan for 
venous thromboembolic prophylaxis was proposed in order to improve its 
application and therefore overall efficacy. This plan was based on our audit findings 
that most surgical 'in-patients' are of high or moderate thromboembolic risk. And 
despite the copious methods available for the prevention of venous 
thromboembolism, low-dose heparin and AES are the most frequent combination in 
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use (Conti & Daschbach 1982). Antiernbolic stockings have proved effective in the 
surgical patient with a reduction in the incidence of postoperative DVT to 
approximately eleven percent and subcutaneous low dose heparin is slightly more 
effective, reducing the DVT incidence to around nine percent (Wille-Jorgensen et al 
2002). Furthermore, the combined effects of GCS and subcutaneous heparin are 
thought to be synergistic (Kalodiki et al 1996, Nurmohamed et al 1992, Leyvraz et al 
199 1, Nicolaides et al 2002). The efficacy, safety and acceptability of these two 
methods have led to their popularity in surgical practice. 
It was proposed that LMWH should be given to all patients undergoing surgery with 
general anaesthesia, bar those with medical contraindications. This policy was 
accepted throughout the surgical specialities. However the orthopaedic and 
neurosurgery specialities feared bleeding at the time of surgery and insisted on 
delayed heparin administration for their patients. 
The question arose as to which type of stocking and heparin is best in combination. 
Until our randomised controlled trial, no conclusive evidence was available to 
distinguish between knee and thigh-length GCS to guide practitioners on their 
prescription (Hui et al 1996, Porteus et al 1989, Williams et al. 1996, Williams et al 
1988). Our study has provided level one evidence that the thigh-length version of 
GCS is better at preventing postoperative DVT than the knee-length design with the 
same graduated compression profile. We have also demonstrated that the 
manufacture specifications of the stocking are important, but there is no significant 
difference between the two thigh-length stockings. Certainly, we can be sure that the 
full thigh length stocking is a vital factor. 
Low molecular weight heparin has been heavily investigated over the last decade to 
establish its efficacy and safety when compared to LDUH and placebo. A large 
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number of trials and meta-analyses have demonstrated that LMWH is undoubtedly 
no worse and in many instances better at preventing thromboembolic complications 
than LDUH (Handoll et al 2002, Koch et al 1997). On the balance of published 
evidence we felt that it was right to attempt to convince all surgical specialities to use 
LMWH for all patients and they did. We believed that we could investigate which 
stocking was optimal, but on current evidence LMWH should be given to every 
surgical patient undergoing general anaesthetic except in day surgery, and continued 
daily till discharge. In addition to efficacy, LMWH has other advantages in terms of 
patient acceptability, practicality and cost. Patient acceptability is improved with 
only one daily subcutaneous injection compared to a possible three injections with 
LDUH. The fact that LMWH requires only a once daily dose, permits the injection 
to be given on the evening before surgery, which allows the peak plasma anti-Xa 
activity that occurs one to four hours after the injection to pass during the night, 
therefore reducing further any risk of pero-operative bleeding. Many anaesthetists 
also prefer LMWH prophylaxis to be given up to twelve hours before placement of 
spinal and epidural anaesthesia (Bergqvist et al 1997); the preoperative 'evening' 
LMWI injection allows these patients safely to receive regional anaesthesia with 
heparin prophylaxis. The cost effectiveness of DVT prophylaxis has been reported 
(Oster et al 1987, Dunn et al 1996, Freedman et al 2000), and because the cost of 
LMWH has reduced since its conception it is now the cheaper option, making it more 
economically acceptable than unfractionated heparin (Freedman et al 2000). 
Very few complications were associated with the combined use of LMWH and GCS. 
The potential side effect of postoperative bleeding has been a frequent criticism of 
LMWH, especially by orthopaedic and neurosurgery consultants who fear the 
devastating postoperative complications ofjoint prosthesis infection and intracranial 
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haemorrhage. The controversy surrounding heparin prophylaxis is evident from the 
large number of studies investigating the fine balance of the reduction in 
thromboembolic complications opposed to the potential increase in perioperative 
bleeding. However, in the majority of studies, of which many are from orthopaedic 
and neurosurgery specialities, LMVM does not increase the incidence of operative 
bleeding when compared to placebo, let alone LDUH (Freedman et al 2000, Howard 
et al 1998, Palmer et al 1997, Levine et al 199 1, Menzin et al 1994). Operative 
bleeding complications have a number of causes and distinguishing those due to 
heparin coagulopathy maybe difficult and for this reason the clinical trials required 
randomisation. Randomised controlled trials, some with double-blinding have shown 
rates of bleeding complications for LMWH, LDUH and placebo in orthopaedic 
surgery that ranged between 1.5-6%, 6-9% and 2.4-8% respectively (Turpie et al 
1986, Agnelli et al 1998, Macdonald et al 1999, Nunnohamed et al 1996, Raabe et al 
2001). Likewise, in neurosurgery bleeding complications occurred at 2-3%, 0-1.8% 
and 0-3% respectively, and results from gastrointestinal surgery studies were very 
similar (Gallus et al 1993, Ockelford et al 1989). fn our study, the orthopedic and 
neurosurgical teams at least had the reassurance that the major bleeding problems 
they feared did not occur. For them to allow LMWH to be given twelve hours before 
surgery could potentially increase this complication but the balance could be a lower 
DVT rate. Surgery requiring 'bone cutting' and turnour resection are at high risk of 
thromboembolic complications and therefore require optimal prophylaxis. The 
surgical procedure initiates the thromboembolic process and therefore we feel that 
starting the heparin prophylaxis after surgery is suboptimal and interestingly in our 
study, the neurosurgery and orthopaedic patients suffered the highest rate of 
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postoperative DVT (figure 6m), approximately twice that of the other specialities 
whose patients received LMWH prior to their surgery. 
The combination of a good quality thigh-length stocking and LMWH for hospitalised 
patients requiring surgery produced a low postoperative DVT rate of two percent in 
the high-risk patients and no DVT in the moderate and low-risk patients. We have 
recommended a simple and safe protocol for DVT prophylaxis in a busy university 
hospital by prescribing LMWH and GCS to all surgical in-patients. To have a 
hospital protocol means that prophylaxis against DVT is less likely to be forgotten 
and its simplicity improved compliance (chapter 4). If a speciality insists on a 
LMWH delay, this can be accommodated. Those patients with medical 
contraindications to heparin or stockings would receive their permitted prophylaxis. 
A 'blanket' treatment of perioperative LMWH and good quality thigh-length AES is 
safe and effective to use in surgical patients for the prophylaxis of postoperative 
DVT, with very few disadvantages. 
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7.1 Background - Health outcome assessment 
With the advent of clinical governance, practitioners are now increasingly 
accountable for the quality of health care provision. This chapter outlines the 
importance of the measurement of health outcomes and summarises the currently 
available outcomes measures in surgery. The development of an outcome measure 
for patients using lower limb compression treatments is described. 
There are many ways to measure outcomes of care. An improvement in a patient's 
condition needs to be demonstrated in order to determine the benefit of a surgical 
treatment or intervention. In surgery, audit and follow-up appraisals are used to 
record a number of outcome variables such as: improvement in symptoms, survival, 
specific and general changes in morbidity, for example in vascular surgery; patency 
of vessel or graft, heated or non-healed, amputation and stroke rate. Patient 
satisfaction and quality of life outcome measurements represent an essential adjunct 
to these largely objective 'standard' outcomes measures. Many patients have been 
found to grade symptom relief higher than healing on their list of treatment priorities. 
For example, in patients with near intractable venous ulceration, which are 
commonly treated by compression, improvements in the patients' quality of life - 
which is closely related to patient acceptability and satisfaction with therapy - is as 
important as achieving healing (Harmer et al 1994). Any treatment with the 
capability to cure and improve quality of life would be the ideal therapy. In order to 
prove whether a new or established treatment is optimal; a valid, responsive, 
acceptable and reliable health outcome measure is required alongside the 'standard' 
outcomes measures. 
Until recently, health outcome assessment has been slow to permeate clinical 
surgical principles. The popularity of health outcome assessment was minimal in the 
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1970's (Bardelli & Saracci 1978). In the 1980's a review of surgical trials showed 
that only 3% mentioned quality of life (O'Young & McPeek 1987). In the early 
1990's the importance of health outcome assessments was recognised, it has taken 
many years to infiltrate into surgical practice: 
"It is important that wejoin with colleagues in other disciplines to develop 
measures of the outcome of surgery, 'Quality of Life'and 'patient 
satisfaction' after surgery are important outcome measures and in our daily 
work we should attempt to measure our success in these ways. Many of the 
technical decisions in clinical surgical management are based on the 
weighting of different outcomes, and we should ensure that these 
incorporate patient values. Patient opinions are important in determining 
these relative values. " (Devlin 1990) 
The reporting of health outcomes has increased from 0.63% in 1980 to 4.2% in 1997 
for trials of all disciplines (Sanders et al 1998). Currently, the majority of surgical, 
medical and pharmaceutical trials measure quality of life and treatment acceptability 
or satisfaction as an outcome variable alongside morbidity and mortality. 
7.1.1 Health outcomes measurement 
Traditionally, the assessment of health outcomes in care involved the use of 
objective biomedical measures that focused on the disorder, where the outcome is 
defined as the presence or absence of the disease. At the population level the 
influence of disease is defined in terms of morbidity, incidence and prevalence and 
mortality. Although simple, these measures are now thought to be incomplete 
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measures of health outcome due to improvements in general living standards and 
health care (McDowell & Newell 1987). The many different aspects of a patient's 
life, such as cultural, economic, social and environmental factors are taken into 
account in the measurement of health outcomes. Objective biomedical 
measurements are easier to measure than the complex influences of these factors. 
Surgical interventions may functionally improve the affected organ or the overall 
physical state of the patient, however with a detrimental effect on the quality of life. 
The goal of medical care for most patients is the achievement of a more effective life 
and the preservation of function and well-being (McDermot 198 1). In this new era 
of clinical governance and applying evidence-based medicine, the sole use of 
biomedical measures is no longer adequate and information about quality of life, 
patient satisfaction as well as functional status is required to fully assess a 
treatment's success. Over the last fifty years, the introduction of numerous 
treatments for each disease has lead to many studies comparing new treatments to 
established treatments. Chronic conditions are rarely cured, hence health care 
commonly focuses on limiting or improving the impact of the condition on the 
patient's life by improving the health related quality of life (HRQL). The patient's 
subjective perceptions of their health are therefore an important measure of health 
outcome along with the objective measures. The approach to assessing the 
subjective outcomes is grounded in the theory that the patient is the best judge of 
their health and can accurately report these subjective outcomes (Fitzpatrick 1984, 
Albrecht 1994). There are a number of health outcome measures and their 
development has increased over recent decades. These now include measures of 
patient satisfaction, functional disability, psychological well-being, social health and 
HRQL (McDowell & Newell 1987). 
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Health related quality of life is a concept that assesses the patient's perceptions 
relating to health care, rather than the influences on health of environmental factors. 
The measurement of HRQL is now recognised as a core component in the 
assessment of health care outcomes (Albrecht 1994, Geigle & Jones 1990). A 
Medline search over the last two decades using 'health outcomes' or 'HRQL 
measurement' as key words in the titles of articles demonstrates a gradual yearly 
increase in related articles. Furthermore health care reforms in the UK now require 
the use of health outcome measures. 
Measurement of HRQL - The World Health Organisation defined health as a state of 
"complete physical, mental and social well-being, and not just the absence of 
disease" (1958). HRQL helps to complete the assessment of a patient's health by 
focusing on the person and their experiences of the disease and treatment. Price 
offered a simple but clear definition of HRQL as "the impact of an illness an its 
treatment on disability and daily living" (Price 1996). 
Early attempts to size quality of life were primitive in comparison to their present 
day equivalents, for example: they recorded the numbers able to 'resume paid 
employment' or 'perform household duties' (Ebbs 1989). A comprehensive HRQL 
instrument must have multiple dimensions; these usually assess physical, mental or 
cognitive, emotional or psychological, social and role functions, disease symptoms 
and perceptions of well-being. The applicability of HRQL instruments are diverse 
and numerous. HRQL can be used to improve health outcome evaluation of- 
1. The efficacy of a new or established treatment. 
2. Results in research and clinical studies. 
3. Cost-benefit ratio of a treatment. 
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4. Clinical decisions, prioritising waiting lists, treatment guidelines and health 
policies (Coons & Kaplan 1993), 
5. Symptoms that are otherwise difficult to assess objectively, for example 
fatigue in sarcoidosis (Wimsberger et al 1998), 
6. Health care delivery to the wider community (Martin & Stockler 1998), 
7. Finally to help individual patients with difficult clinical choices over there 
treatment options offering different outcomes in quality of life (Casali et al 
1997). 
Beattie et al described the 'ideal' HRQL measure as one that produced constant 
validity when used by any healthcare employee, in any location and for any disease 
or treatment (Beattie et al 199). 
7.1.2 Measuring health outcomes in surgery 
The concurrent assessment of the clinical outcomes and HRQL in patients 
undergoing a surgery provides a complete overall assessment of the benefits of that 
treatment. The recognised way of assessing the quality of life is by using a generic 
and specific measure of health outcome (Garratt 1993, Ware et al 1993). The 
properties of these outcome measures are surnmarised in table 7a. 
7.1.2.1 Types of HRQL 
A wide range of instruments for measuring HRQL have been developed during the 
last decade that fall into two broad categories: generic and disease specific tools. 
The selection of an instrument depends upon its measurement properties but also 
upon the particular context in which the instrument is to be used. 
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GENERIC 
INSTRUMENTS 
SPECIFIC 
INSTRUMENTS 
Advantages 
Disadvantages 
Examples 
Health Profiles utility Condition-specific 
Measures Disease-specific 
Function-specific 
Population-specific 
Problem-speciflc 
Single instrument Single index Focuses on primary 
May detect different representing disease area 
aspects of HRQL HRQL Relevance to clinical 
Enable comparison Can be used for management 
across different cost-utility May be more 
conditions analysis responsive 
Can be used for cost 
effectiveness analysis 
May not focus Attribution Not comprehensive 
adequately on the disease problems of and may miss side- 
area single index effects/compl i cations 
May not be responsive May not be Cannot compare 
Do not take account of responsive across conditions 
values attached to levels 
ofHRQL 
Sickness impact profile EuroQoI Aberdeen back pain 
Nottingham health scale 
profile Asthma quality of life 
Short form 36 item health questionnaire 
survey Sabbatsberg sexual 
Short form 12 item health rating scale 
survey Child health 
questionnaire 
Pain perception 
profile 
Table 7a - Summary of properties for quality of life assessments 
Generic instruments are designed to assess multiple conditions and measure 
generalised effects. These characteristics lend to the ability to assess a new 
intervention or treatment for which the medical outcomes are uncertain. Generic 
instruments can measure the broad range of effects and co-morbidity of multiple 
diseases which enables comparisons of quality of life between different population 
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groups, normal and those with disease (Stewart et a 1989, Ware & Sherbourne 1992). 
The age and sex matched population 'normal scores' are available for such 
established tools as the Medical Outcomes Study SF-36 (Ware & Sherbourne 1992), 
the Nottingham Health Profile (NHP) (Hunt et al 1985) and the Sickness Impact 
Profile (SIP) (Bergner et al 1976). The SF-36 and NHP have been used to gauge 
outcomes in many conditions in many different countries. The SF-36 continues to be 
validated for use in more countries, languages and conditions (Ware 1999, Chang et 
al 2000). 
There are two major classes of generic instruments: Health profiles that measure 
HRQL across a number of designated dimensions and Utility measures that take 
account of values or preferences attached to HRQL states (Davies et al 1999). The 
36 item short form (SF-36) is a health profile that was designed for use in clinical 
practice and research, health policy evaluation and general population health surveys. 
The SF-36 assesses eight health domains: limitations in physical activity, social 
activity, role activities due to physical and emotional health problems, bodily pain, 
general mental health (psychological distress and well-being), vitality (energy and 
fatigue) and general health perceptions (Ware & Sherbourne 1992). Another 
commonly used generic instrument is the 12-Item Short-Form Health Survey (SF- 
12), which was developed from the SF-36 to form the Physical Component Summary 
and Mental Component Summary measures (Ware et al 1996). The wide-range of 
applications of health profiles enables their use in assessing cost-effectiveness in the 
treatment of disease, however cost-utility assessment requires utility instruments for 
this purpose. Utility instruments take account of preferences associated with HRQL 
states. Through weighting of HRQL states and their durations the quality adjusted 
life years (QALYs) can be calculated (Williams 1985). A commonly used utility 
202 
instruments for cost-benefit analysis is the EuroQol (EuroQol Group 1990), which 
assesses the health effects of all interventions in units of utility via five items 
(mobility, self care, main activity, pain/discomfort and anxiety/depression). 
Specific HRQL instruments have a more restricted application, the focus of the 
assessment is specific to a certain condition, disease, function, population or problem 
which in-turn produces greater responsiveness or sensitivity to clinical changes 
associated with that particular disease (Davies et al 1999). Specific instruments can 
be designed or selected to assess specific areas of interest in the quality of life of a 
population, for example venous ulceration (Smith et al 2000), varicose veins (Gaffat 
1993), back pain (Ruta 1994), asthma (Juniper 1992). Disease specific tools have the 
advantage of being more responsive to small changes in health produced by the 
disease under investigation, for example: the Dutch questionnaire for Klippel- 
Trenaunay syndrome (van der Ploeg et al 1995) and the Diabetes Quality of Life 
Measure (Jacobson et al 1994). 
Both specific and generic measures have their strengths and weaknesses, which are 
products of their design; generic tools can detect changes in comorbidity but are less 
specific, whereas specific HRQL instruments may fail to detect changes occurring 
outside the primary interest. However, generic and specific HRQL instruments when 
used in combination may compliment each other by joining their general and specific 
attributes, which has now become a recognised process (Garratt 1993, Ware 1993). 
Whatever HRQL tool is employed, particular attention needs to be paid to the 
translation and validation of instruments for use in different countries, cultural 
contexts and diseases (Holcik 1999). The increasing appreciation of the need for 
disease specific measures in surgery, especially in vascular surgery when 
maintaining the quality of life is of great importance amidst incurable chronic disease 
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processes. Quality of life measures have been and are now frequently employed to 
assess outcomes in chronic venous disease. Outcomes after treatment of deep vein 
thrombosis (DVT) have been assessed by HRQL for short term benefits such as: after 
catheter directed thrombolysis of iliofemoral DVT (Comerota 2000) and for long 
term follow-up of post-thrombotic syndrome for up to eight years (Beyth et al 1995). 
The SF-36 has been applied in combination with a specific instrument (Hicken et al 
2000) for simultaneous assessment of common conditions including varicose veins 
(Ruta et al 1999). 
Recent reviews of quality of life assessments in vascular disease came to the 
conclusion that the SF-36 (Beattie 1997, Howard & Davies 2001) or its shorter 
version the SF- 12 was the best generic tool for 'vascular' patients particularly as it is 
translated for use in a number of different countries. The combined use of generic 
and specific instruments is required to achieve an overall assessment of health 
outcome. In this study the patients were asked to wear anti-embolic stockings for 
prophylactic reasons rather than for the treatment of a specific condition. We needed 
to assess the acceptability of the trial stockings for each patient and not their quality 
of life in relation to their disease for which they were undergoing surgery. Patient 
stocking satisfaction measurement would help to understand compliance variations 
and chose the 'best' of two functionally similar GCS. Until this study there was not 
available tool to access patient satisfaction with compression stockings, therefore I 
needed to develop a questionnaire to measure patient satisfaction with lower limb 
compression therapies which could be used in this study and in future studies 
comparing compression treatments. This new specific HRQL tool was developed for 
use alongside a generic instrument; hence the Charing Cross Stockings Satisfaction 
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Questionnaire (CSSQ) was employed with the SF-12 to ensure that the measure of 
stocking acceptability and not influenced by the patients' illness. 
7.1.2.2 Medical Outcomes Study Short Form 12 Item Health 
Survey 
The 12-Item Short-Form Health Survey (SF-12) was developed from the SF-36 by 
regression methods to form the Physical Component Summary and Mental 
Component Summary measures (Ware et al 1996). The SF-12 is a generic 
instrument that provides an overall assessment of HRQL. The SF- 12 has been 
employed in combination with the SF-36 (Hawk et al 1998, Besette et al 1998) and 
individually (Johnson & Coons 1998). The SF-12 is a general health survey with a 
shorter respondent time and improved respondent acceptability compared to SF-36. It 
generates physical and mental health summary scores equivalent to SF-36. The SF- 
12 was also more sensitive than the EuroQol EQ-513 in low morbidity conditions 
(Johnson & Coons 1998). 
7.2 Developing and testing a specific health outcome questionnaire 
The methods described below explain the development and validation of a specific 
health outcome measure to assess the patient satisfaction associated with the wearing 
of lower limb compression therapies, such as GCS. The development of a health 
outcome instrument relies on item selection through the empirical testing in relation 
to the objectives and proposed application as recommended by Streiner and Norman 
(Streiner & Norman 1990). There are a number of approaches to develop a specific 
instrument, either by the modification of a generic instrument, addition of specific 
qualities to a generic measure or development of a separate specific instrument 
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(Patrick & Deyo 1989). The modification of a generic instrument requires the 
adjustment of the content or removal of items to make the measure more specific to 
the area of concern (Temkin et al. 1989). Specific supplements to generic 
instruments add specific domains to the existing domain of the generic instrument, 
this approach reduces the effort of the patient by negating the simultaneous use of a 
generic and specific instrument and by reducing the repetition found in any overlap 
between domains. Separate specific instruments aim to assess specific areas of a 
condition (Juniper et al 1992, Ruta 1994), however if the specific instrument is used 
alongside a generic instrument there may be areas of repetition. 
The assessment of patient satisfaction for lower limb compression therapies is a 
small and very specific area of health outcome to investigate, prior to the 
development of our instrument in this study there was no existing measure generic or 
specific for this health outcome. Therefore it was necessary to develop a new 
specific health outcome measure. 
7.2.1 Development of instrument 'questions' (items) 
The selection of items for an HRQL instrument should be guided by theories of 
HRQL measurement taken from the literature, clinical practice, and interviews with 
health professionals and patients (Streiner & Norman 1990). The first stage involves 
a detailed search of the literature to investigate previous similar assessments. 
Following this, interviews with patients using the treatment highlights the areas of 
patient interest to form items in the health outcome questionnaire. 
These interviews 
should be composed of open and closed questions. There 
is no set number of 
interviews required, the criteria often used is 'sampling until redundancy', 
in other 
words until no new subject are uncovered. Interviews should also 
be carried out with 
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a number of health professionals in the field such as doctors and nurses. Again there 
is no set rule as to how many and who is interviewed from the medical staff. Clinical 
observation alone may be enough to establish the items for an instrument in a new 
area or field, this can be attained through preliminary research in the specialist area. 
The number of domains or items construed from these sources described above will 
usually be more than what is required in the final questionnaire. In the process of 
reducing the number of items to a suitable number, one must ensure that the 
remaining items cover the specific area being measured. This is known as 'content 
validity' and will be discussed in more detail later in this chapter. The simplest 
method of assessing the content is by the matrix method (see table 7b). The left 
hand column of the matrix contains the questions and the row at the top contains the 
areas to be assessed, each question should address one or more of the areas otherwise 
the questionnaire will not be comprehensive. 
Table 7b - Matrix method for content validity 
Once the subjects for the questions have been decided, then the method of obtaining 
an accurate response to each question must be decided. A large amount of research 
into this area has been performed (Streiner & Norman 1990). The questions can be 
in two forms, categorical or continuous. Categorical answers 'yes' or 'no' produce a 
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nominal scale for the questionnaire. The simple binary answer provides a definite 
positive or negative but may miss detail available from a continuous scale. There are 
many varieties of continuous scales such as visual analogue, likert scales and 
adjectival scales. 
The scales should be of a reading age of twelve years unless the questionnaire is 
planned for use in specific population whose reading level is known, hence technical 
terminology should be avoided. Microsoft word has a useful application to assess 
the reading age of the any document. The questions should not be ambiguous. The 
questions should also ask one question only, double-barrelled questions asking for 
the answers to more than one subject within the same question can produce 
inconsistent answers. The length of the questions should be short as possible without 
losing the comprehensibility. 
Once a pilot format of the questionnaire has been formulated with the chosen 
questions and answer scales, the questionnaire can tested for simple understanding 
on a population comparable to intended population. 
7.2.2 Selection of the items for use in the questionnaire 
The pilot instrument is tested and adjusted when necessary in order to meet a number 
of requirements necessary for the final development of a fully effective and validated 
questionnaire. 
7.2.2.1 Face validity 
Face validity refers to the ability of items to measure 'on the surface' what they aim 
to ask. In other words does the question make sense when read. If the respondent 
does not fully understand the question this may lead to the person answering 
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incorrectly or omitting the question completely. Open face validity makes the 
questioWs meaning and relevance clear to the respondent and this can be easily be 
subjected to the patient making a 'fake' answer in order to influence the doctor's 
management of that patient. 
7.2.2.2 Frequency of endorsement 
The endorsement frequency provides a discriminatory value for a question. The 
endorsement value (p) is the number of people (n) who answer yes or no (for a 
dichotomous question) over the total number of people answering the questionnaire 
(q). 
P= 
q 
In other words; the proportion of people that answer the question with a particular 
response. If a question has an endorsement frequency greater than 80% then the 
majority of subjects are answering yes to that question, and likewise if the value is 
less than 20% then few are answering no, this indicates that the question has little 
discriminatory value. However if the question has a number of answer choices then 
the endorsement values will be lower due to the spread, in these cases lower 
endorsement values but not higher endorsement values may be accepted. In some 
questionnaires it may be necessary to include questions with high endorsement 
values (p>0.95) if it is suspected that patients are faking their answers or not reading 
the reading the questions correctly. These questions should be predictable and the 
scores from these questions should not be included in the overall scale 
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7.2.2.3 Homogeneity of items 
In order to assess a specific condition or patient's behaviour, the instrument should 
be homogeneous with regard to its items, in other words the items assess different 
parts but be moderately correlated to each other and the total scale score. Too high a 
correlation between items could result in redundancy of questions, or conversely 
poor correlation could result in the items assessing different traits. There are a 
number of statistical tests that can be available for the assessment of internal 
consistency that provides a measure for the homogeneity of the instrument. 
7.2.2.3.1 Cronbach's Alpha 
Cronbach's Alpha determines the reliability of a scale using dichotomous responses 
and when more than two response options are available. Cronbach's Alpha assesses 
the average level of reliability between all of the items that make up the 
questionnaire (Cronbach 195 1). If all of the items are focused on measuring the 
outcome for a specific problem then a moderate to high level of correlation should be 
attained; alpha should exceed 0.7 for a reliable instrument (Cronbach 195 1). 
Generally, the greater the reliability of a questionnaire the higher the coefficient. If 
the questions are too diverse and measure more than one trait then the reliability 
coefficient will be poor. However, if the alpha is too high it can indicate that there 
are too many redundant and similar repetitive questions (Boyle 1991). Thus alpha 
should be greater than 0.7 (Nunally 1975, Cronbach 195 1) and approximately below 
0.9. The equation for Cronbach's alpha is as follows: 
Or 
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The value n is the number of items, (yj is the standard deviation of the item and (y, is 
the standard deviation of the total score. 
7.2.2.3.2 Split-half homogeneity 
Another approach to testing the homogeneity of a scale is called split-half reliability. 
Here the items are divided into two halves, also refeffed to 'odd-even' homogeneity, 
if the scale is internally consistent then the split-halves should be very similar. This 
form of test should not be applied to a timed achievement test or to an instrument in 
which the items are serially linked in a 'chain', where the next answer is dependent 
on the former. 
7.2.2.3.3 Item-total correlation 
This is the correlation of the item with the scale total not including the score from 
that item, it is best calculated using statistics (Nunally 1975), using the formula: 
at 
2- 2ai(Ttrit) 
The value ri (t -i) 
is the correlation of the item i with the total, with the effect of the 
item I removed. The value rit is the correlation of item I with the total score. The 
value (Tj is the standard deviation of i and at is the standard deviation of the total 
score. Items with lower correlation than 0.20 should be discarded. 
The corre ation 
used depends on the distribution of data, if parametric - Pearson's coefficient - or 
non-parametric - Spearman's coefficient - tests should 
be applied (Kline 1986). 
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7.2.3 Multifactor inventories 
More sophisticated analysis -factor analysis - is required of a scale that is part of an 
inventory that contains a number of scales. Factor analysis looks for relationships 
within a set of questions, using the method of 'principal components' where the first 
component describes the maximum variance and successive components describe 
further the smaller portions of variance that are not correlated with each other (Joliffe 
1986, Joliffe & Morgan 1992 & Stewart et al 1988). The total variance explained by 
each component is expressed in tenns of an Eigenvalue. If the Eigenvalue is greater 
than one then this component is considered important (Joliffe & Morgan 1992). The 
Eigenvalues express the variance in a standardised form with a mean of zero and a 
standard deviation of one. Those factors with Eigenvalues greater than one will 
explain the majority of the variance, as the number of factors increases the total 
variance will decrease. The questions with the highest loadings within these latter 
factors have poor face validity then they are discarded. The overall aim of this 
analysis is not to reduce the number of questions, however this commonly is the end 
result. This process of instrument assessment is for an inventory and not a single 
questionnaire, and therefore is not required for the assessment of our instrument. 
7.2.4 Summary of item selection 
The requirements for the selection of questionnaire items are as follows: 
9 Thorough literature review for initial questions 
o Patient and expert interview 
o Pre-test the questions for comprehensibility and lack or ambiguity 
9 Elimination of any items without face-validity and not fulfilling the necessary 
endorsement criteria (described above). 
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* Pretest again after any eliminations 
* Check for internal consistency 
Once the above stages have successfully been completed then method of scoring the 
scale will need to be developed. 
7.2.5 Scale construction 
The development of a scoring system for the questionnaire will allow the results to 
be compared, for example, between populations or before and after an intervention or 
treatment. The simplest method of scoring is to assume that each question has an 
equal 'weight' and to simply add the scores of each question to produce a final 
overall score. If it is deemed necessary to weight the scoring system then two 
methods are available, theoretical or empirical. Theoretical weighting adjusts the 
scores of the questions, thought by a panel of experts, to be the most important. 
Emprical weighting relies on multiple regression to produce weighted scores for the 
questions. The equation is as follows: 
PO + PIXI + P2X2 + P3X3 
The value 'Y' is the predicted score that is based on the product of the items 'X' with 
the weights 'P', where Po is a 'weight' constant. 
Weighting has potential problems by changing the 'true' outcome of the instrument 
and some authors have shown that weighting makes little difference to the 
final 
outcome (Steiner et al 1981). In questionnaires with less than 40 questions, 
weighting may have some benefit (Nunally 1975). 
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In order to allow scores of different questionnaires to be comparable the final score 
can be transformed. Transformation of the score can be performed using percentiles 
or by using the formula for standardised scores: 
X-X 
SD 
Where z is the transfon-ned score, X is the total questionnaire score by an individual, 
X, n is the mean score for the sample and SD the standard deviation for the sample. 
This results in the scale having a mean of zero and a standard deviation of one. A 
simpler method of transformation is to convert the score to range from 0- 100 by 
using the formula: 
z=I 00(x) 
y 
Where 'x' is the individual's score and the maximum questionnaire score of is 'y'. 
7.3 Testing a specific health outcome questionnaire 
A questionnaire of any practical use must be valid, reliable, responsive and 
acceptable to the population being questioned. Validity refers to the ability of the 
questionnaire to assess what it is meant to assess. Reliability refers to the ability of 
the questionnaire to consistently measure an outcome over repeated testing. 
Responsiveness is the ability to measure the important changes in the outcome. 
Questionnaires should be easy to administer and easy for the patient to complete, in 
other words they should be acceptable. 
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7.3.1 Validity 
A health outcome measure must assess the health related outcome in order to be 
valid. Validity is defined as the ability of a test to measure what it is intended to 
measure (Streiner & Non-nan 1990). There are many types of validity, these are 
usually classified under content, criterion and construct validity. Not all forms of 
validity are required for the assessment of questionnaires validity. 
Content validity refers to the adequacy of the items in the questionnaire. Simple 
observation of the questionnaire assesses the adequacy of the items for content 
validity. The more representative the items are with respect to the condition, the 
more valid the conclusions that can be drawn from the questionnaire outcome. 
Criterion validity refers to the instrument's direct comparison to another instrument 
that has been deemed to be the 'gold standard' or criterion. The comparison can be 
made concurrently (concurrent validity) or in the future (predictive validity). 
Criterion validity is rarely applied to health outcome measures as more often than not 
they are novel instruments assessing new areas of medicine. Criterion validity is 
more commonly used in health instruments to validate a shorter version of the same 
instrument to ensure that its performance is equivalent. 
Construct validity is used in the absence of a 'gold standard'. Construct validity is 
further subdivided into trait, discriminant and convergent validity. The 'constructs' 
are variables that are not directly observable, in medicine these are usually known as 
'hypothetical constructs' due to their often subjective nature. Construct validation 
assesses the question for measuring a health outcome in line with a predicted theory. 
It can be assessed by comparison to 'extreme groups' and convergent and 
discrimmant validation. Statistically the groups can be assessed by the simple 
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parametric and non-parametric tests however correlation may be employed if 
necessary. 
7.3.2 Reliability 
Reliability is calculated by internal consistency, (which assesses the level of 
correlation or 'agreement' between questions), and test-retest which demonstrates the 
questionnaire's stability during repeated application. For outcome measures, test- 
retest assessment is recommended as the most appropriate assessment of reliability 
(Kirshner & Guyatt 1985). Reliability testing provides the evidence for the ability of 
the questionnaire to produce consistent results during different occasions or with 
different observers - reproducibility. Internal consistency is measured using item- 
total correlations, Cronbach's alpha or Split-half homogeneity as described 
previously in this chapter. It is not adequate to use internal consistency alone as an 
indicator of reliability and testing should also involve the use of 'test-retest' (Streiner 
& Norman 1990, Kirshner & Guyatt 1985). Internal consistency will assess the 
questionnaire at any one time and therefore cannot take into account any variations in 
the patients' health on a day-to-day basis, therefore test-retest is required to assess 
stability of the questionnaire over a period of time. A sample of the population is 
given a second questionnaire after a period of time and the scores from the two tests 
are compared for their similarity. This period of time should be long enough to 
prevent the patient from simply remembering the answers and short enough so that 
the patient's health has not significantly changed. Two weeks is thought an 
appropriate period of time (Streiner & Norman 1990). Statistical analysis allows the 
level of similarity between the scores before and after the lag period to be formally 
assessed. 
216 
7.3.3 Responsiveness 
Until recently the need for the assessment of responsiveness was underestimated in 
comparison to the appraisal of reliability and validity (Tuley et al 199 1). This may 
be due partly to the lack of formal assessments for responsiveness (Deyo, et al 1991). 
Responsiveness measures the questionnaires ability to detect important changes in 
health outcome (Deyo & Centor 1986, Guyatt et al 1987), A number of methods 
exist; firstly by using transition questions that ask patients to rate their current health 
compared to a period in the past. Other methods include using mean differences and 
significance levels (Guyatt et al 1989), receiver operating characteristic curves 
(Mackenzie et al 1986), index of responsiveness, effect size and standard response 
means (Laing 1992). The standard response mean is a form of effect size 
measurement, which is calculated by dividing the standard deviation of score 
differences by the mean change in scores. A standard response mean equal to or 
greater than 0.2,0.5 and 0.8 imply small, moderate or large health changes 
respectively (Liang et al 1990). The standard response mean has the advantage over 
the other methods described above as it is a standardised measure that can analysed 
statistically and used for comparison between different instruments. 
7.3.4 Acceptability 
The ease of use for the patients and the observer together with acceptability to 
patients ensures good response rates and reliable outcomes. A lengthy and difficult 
questionnaire reduces the acceptability to patients which in turn reduces its use in 
routine clinical situations restricting the use of the instrument to research situations. 
There are numerous different modes of administration of the questionnaire; self- 
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completion by the patients results in a lower response rate compared to interview 
administration using face-to-face or telephone techniques. 
7.4 ' The development and testing of a questionnaire to assess 
patients' satisfaction with thigh and knee length stockings 
The application of compression hosiery and bandaging is an integral part of 
conservative treatments for a variety of venous disorders, such as: 
9 Superficial and deep venous insufficiency 
* Post-phlebitic syndrome 
* Venous ulceration 
o Prophylaxis against deep vein thrombosis 
To date there is no health outcome measure to assess the patient acceptability of 
different compression treatments that are commonly used in patients with chronic 
venous insufficiency (and lymphoedema). The patient acceptability of this treatment 
modality is important to assess as many patients have chronic disease requiring long 
term treatment. Although many patients understand that compression treatment is an 
integral part of their therapy, some patients find stockings and bandaging restricts 
their normal daily activities and are cosmetically unappealing,. The effectiveness of 
any external compression treatment is critically dependent on whether it is worn or 
tolerated by the patient. The influence of external compression treatments on quality 
of life can be assessed by a specific assessment of patient satisfaction. Quality of life 
data together with the evaluation of clinical efficacy would provide an overall 
appraisal to establish which is the best GCS for prevention of postoperative DVT. 
Therefore, a validated a specific questionnaire to formerly assess patient satisfaction 
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and quality of life in patients receiving compression treatment for venous disease 
was developed. 
7.4.1 Methods and patient series 
7.4.1.1 Development of instrument 'questions' 
Questionnaire items were developed via interviews with patients and experts in 
venous disease. Thirty interviews with patients were carried out and expert opinion 
was obtained from vascular consultants and stocking manufacturers. Patients were 
asked which characteristics of compression stockings and bandaging they 'liked' or 
'disliked' and, were 'important' or 'unimportant'. The experts were asked to give 
their opinions on the factors that they believed made up an effective and acceptable 
stocking. 
The comprehension and ease of completing the questions was assessed by pre-testing 
of pilot questionnaires in two formats; visual analogue scale and Likert scale format. 
Face validity was assessed by questioning the patients about their understanding of 
the questions. All of the patients who answered the questionnaire during its 
development were recruited during their treatment at Charing Cross hospital as 
outpatients and/or inpatients. 
7.4.1.2 Selection of the items for use in the questionnaire 
7.4.1.2.1 Frequency of endorsement 
One hundred and eighty three surgical in-patients, wearing GCS, were ask to 
complete the questionnaire for the purposes of assessing the endorsement of the 
questions. A number greater than 50 subjects is required for this assessment. No 
patients refused to answer the questionnaire. 
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7.4.1.2.2 Homogeneity of items 
The internal consistency of the questionnaire was assessed by statistically comparing 
the means and total scores from the 'odd' and 'even' questions of the questionnaires 
(Split-half homogeneity) answered by a cohort of 127 surgical in-patients wearing 
GCS. No patients refused to answer the questionnaire. 
7.4.1.3 Scale construction 
Thirty patients wearing GCS admitted to hospital for surgical care were asked to 
complete the questionnaire and rate the questions in order of importance. Patients 
were asked to indicate the four most important items out of the total of eight. The 
'importance' of a question was graded by the patients depending on how important 
they believed the item to be with regard to the properties of the stockings. 
7.4.1.4 Testing for use as a satisfaction measure 
7.4.1.4.1 Validity 
The stocking satisfaction questionnaire was assessed for content and construct 
validity. The content validity was assessed by applying the question to a cohort of 26 
patients wearing different types of compression stockings. Construct validity was 
assessed by applying the questionnaire to 'extreme' groups of compression therapy 
in 80 patients wearmg extremes of compression stocking and 24 wearing Charing 
Cross four layer or three layer bandaging (4LB and 3LB). Criterion validity was not 
possible to assess with no similar questionnaires or health outcome measures 
currently published for comparison as a 'gold standard'. However the stocking 
satisfaction scores of 31 patients wearing compression stockings or bandages, were 
correlated with the scores in the same patients who completed the general health 
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outcome measure SF-12, in order to assess the effect of the status of their general 
health on stocking satisfaction scores. 
7.4.1.4.2 Reliability 
Reliability was assessed by calculating the test-retest assessment and internal 
consistency (Split-half homogeneity and Cronbach'sAlpha). The questionnaire's 
test-retest stability was assessed over a period of two weeks before the repeat 
assessment. 
7.4.1.4.3 Responsiveness 
The formal assessment of responsiveness for this new health outcome instrument was 
not possible as this involves testing the instrument for its ability to measure changes 
of health outcome over a period of a patient's treatment. The use of transition 
questions and the comparison of previous and current scores to evaluate standard 
response means and effect size was not applicable to a new questionnaire that 
investigates stocking satisfaction and not a disease process. 
7.4.1.4.4 Acceptability 
The acceptability of the questionnaire was assessed by two criteria, firstly the time 
for completion and secondly the response rate of the patients asked to answer the 
questionnaire. Twenty patients were timed without warning whilst answering the 
questionnaire and the number of patients who refused to complete or failed to return 
a completed questionnaire during this study was recorded. 
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7.4.1.5 Use of the questionnaire assessing patient satisfaction with 
thigh and knee length stockings 
All patients recruited to the study RCT for comparing thigh to knee-length GCS 
(chapter 6) were asked to complete the stockings satisfaction questionnaire at the 
time of the second postoperative duplex DVT scan. By this time in the study, the 
patients had wom their stockings for 5-7 days. 
7.5 Results 
7.5.1 Development of instrument 'questions' (items) 
The results of patient interviews provided information for the development of the 
domains or items for the questionnaire. A combination of the most frequently 
mentioned characteristics and 'most important' factors together with the experts' 
opinions were used to produce the following domains: 
o Discomfort 
0 Tightness 
* Temperature 
o Itch 
Falling down 
o Hygiene 
o Unsightliness 
* Difficulty of application 
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The domains were found to express negative experiences with compression. In 
general, patients did not enjoy wearing their compression stockings or bandaging and 
they preferred the therapies that caused less of the symptoms described in these 
domains. The questionnaire items were designed to be simple to read and understand 
without ambiguity and asked the patients to grade their experiences. The Likert scale 
format proved to be fully comprehensive and face validity (correct understanding of 
the items) was good. The visual analogue scale format proved to be inadequate due 
to poor understanding of the mechanism of completing the answer, especially by the 
elderly patients. Table 7c summarises these results: 
Patients Responses Visual Analogue Adjectival Scale 
Scale (n=12) (n=10) 
Number of patients correctly completing 
questions 2 10 
Number confused by questionnaire 
layout 70 
Number unable to complete due to 
illness 30 
Table 7c - The assessment of questionnaire for comprehension using 
visual analogue and Likert scales. 
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The item questions and their 'likert scale' layout to make up the questionnaire were 
as follows: 
Question 1- Do you feel the stockings cause you discomfort? 
Not at all I Slightly I Moderately I Quite a bit I Extremely 
questIOD L- UO ou ieei ine sioc Kings maKe you iegs nen.,, 
Not at all Slightly Moderately Quite a bit Extremely 
I 
Question 3- Do ou leel tne stoc Kings maKe you iegs wei not., 
Not at all Slightly Moderately Quite a bit Extremely 
I I --- I I--I 
Question 4- Do you feel the stockings are too tight? 
Not at all Slightly Moderately Quite a bit Extremely 
P- irk- r--i 4iL- m. i,,,. n araund vnitr thiph or knee? vuvbtlun Y-" 
None of the 
time 
J%YqLa A %, a W-- --- 
A little of the 
time 
---ý -- - 
Some of the 
time 
Most of the 
time 
All of the 
time 
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Question 6- Do you feel the stockings are unhygienic to wear? 
Not at all Slightly Moderately Quite a bit Extremely 
III-II 
Question 7- Do you feel your stockings look unsightly to wear? 
Not at all Slightly Moderately Quite a bit Extremely 
Question 8- Do you feel your stockings are difficult to remove and put back on, 
(if performed by yourself without the help of another person)? 
Not at all Slightly Moderately Quite a bit Extremely 
IIII 
The questionnaire was accompanied by simple introductory instructions. Patients 
were asked to answer questions by placing a single mark in the box that most 
accurately described their experience whilst wearing the trial stockings for each 
question. As this questionnaire was intended for use compression bandage therapies 
as well as stockings, the term 'stockings' was interchanged with bandages if 
assessing compression bandaging - as general term for both therapies such as 
compression appliance was found to be poorly understood by patients. Each question 
was scored without weighting from 0-4 for 'Not at all' to 'Extremely' respectively. 
The minimum questionnaire total score was zero and the maximum was 32. The 
questionnaire total scores were transformed into percentages, where zero percent 
coffesponded to no satisfaction and 100% to maximal satisfaction. 
225 
7.5.2 Selection of the items for use in the questionnaire 
7.5.2.1 Frequency of endorsement 
The endorsement of the questions answered by a cohort of 183 patients is represented 
by the endorsement value: the percentage of questions answered in a particular 
manner by the patient group. This group of patients (n=l 83) was approximately 
equal for gender (53% female) and the mean age was 60 years (range 21-86). The 
endorsement values (%) demonstrated that the items were answered with the most 
negative choice, 'extremely' by less than eighty percent of patients and answered 
positively, i. e. 'not at all' by greater than twenty percent of the patients for all items 
(figure 7a). These values indicated that all questions were satisfactory with regard to 
patient endorsement. 
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10 
0 
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M'Not at all'answers O'Extremely' answers 
7.5.2.2 Homogeneity of items 
The questionnaire was completed by 144 patients staying in hospital wearing GCS 
for homogeneity (or internal consistency) assessment with Split-half homogeneity 
and Cronbach's alpha. The population was approximately equal for gender (52% 
female) and the mean age of the group was 60 years. 
7.5.2.2.1 Split-halve homogeneity 
The statistical comparison (t-test) of the means and totals of the 'odd' and 'even' 
questions from the questionnaire were very similar (figures 7b and 7c) (p=0.698). 
which implies good internal consistency for the questionnaire. This was also 
confirmed by split-halves rreliability analysis using SPSS@ (SPSS Inc, USA). 
Statistics for 
Part I 
Part 2 
Mean 
6.6597 
8.2778 
Scale 14.9375 
Reliability Coefficients 8 items, 
Guttman Split-half =. 5396, 
Variance 
6.9114 
7.4188 
19.6254 
Equal-length Spearman-Brown =. 5399, 
Unequal-length Spearman-Brown =. 5399. 
Std Dev 
2.6289 
2.7237 
4.4301 
Number of 
Variables 
4 
4 
8 
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Figure 7b - Mean Scores for Odd and Even 
Questions 
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Figure 7c - Sum of Questions Scores for Odd and 
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M Odd Questions N Even Questions 
975 968 
7.5.2.2.2 Cronbach's alpha 
Cronbach's alpha calculated for the eight item questionnaire achieved borderline 
reliability of 0.6, an alpha value between 0.7 and 0.9 is optimal and a level of greater 
than one indicates some redundant items and less than 0.5 demonstrates an 
unsatisfactory reliability. Cronbach's alpha calculated using SPSS software is 
displayed below: 
Mean Std Dev Cases 
1. Ql 1.6875 . 9998 144.0 
2. Q2 1.4861 . 7754 144.0 
3. Q3 1.9306 1.1072 144.0 
4. Q4 1.5556 . 8753 144.0 
5. Q5 1.9306 1.1566 144.0 
6. Q6 1.5694 . 9727 144.0 
7. Q7 1.9028 1.2079 144.0 
8. Q8 2.8750 1.4430 144.0 
N of Cases = 144.0 
Statistics for Mean Variance Std Dev N of Variables 
Scale 14.9375 19.6254 4.4301 8 
Item Means Mean Minimum Maximum 
1.8672 1.4861 2.8750 
Range Max/Min Variance 
1.3889 1.9346 . 1983 
Item Variances Mean Minimum Maximum 
1.1772 . 6012 
2.0822 
Range Max/Min Variance 
1.4810 3.4633 . 2160 
Inter-item 
Covariances Mean Minimum Maximum 
. 1823 -. 
0223 . 5026 
Range Max/Min Variance 
. 5250 -22.5000 . 
0170 
Inter-item 
Correlations Mean Minimum Maximum 
. 1646 -. 
0239 . 49 55 
Range Max/Min Variance 
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. 5193 -20.7722 . 0157 
Reliability Coefficients 8 items 
Alpha = . 5944 Standardized item alpha = . 6119. 
7.5.3 Scale construction 
The patients who completed and graded the questions in order of importance 
numbered thirty, twelve were male and the mean age was 52 years (range 22-83). 
The relative importance of each of the questions is displayed in figure 7d, with 
question eight assessing application regarded as the most important and question 
seven assessing unsightliness of the stockings as the least important to the patients. 
Although this investigation together with patients endorsement, provided an 
indication of the usefulness of the questions, it was not considered necessary to 
weight the scores of individual items as this may alter the 'true' outcome. Empirical 
weighting was deemed unnecessary when discussed with two experts in quality of 
life and health outcome measures. 
7.5.4 Validity 
The content validity was found to be satisfactory, indicated by the different scores 
produced by the questionnaire of three different types of compression therapy when 
worn by 26 patients. 
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Figure 7d- Patients' Weighting by Importance 
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The theoretical assumption that patient acceptability of stockings would decrease 
with increase compression and length of the stocking was reflected in the better 
scores for the lower compression class one (CCL 1) knee length compared to the 
longer higher compression class two (CCL2) thigh length stockings (figure 7e). 
Construct validity, was assessed by applying the questionnaire to eighty patients 
wearing extremes of compression stocking or bandaging, i. e. 'extreme' groups. The 
4 extremes' of GCS that are frequently used in clinical practice are GCS and CCL2 
stockings. A 'zero' compression (cosmetic) stocking was also assessed by the 
questionnaire as an extreme (figure 7f). The satisfaction scores reduced with the 
stockings of greater compression. 
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Figure 7e - Satisfaction Scores for Compression Hoisery 
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Figure 7g - Satisfaction scores for three and four layer 
bandaging 
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The questionnaire was also applied in order to assess the 'extremes' of compression 
bandages, in twenty-four patients wearing three and four layer banclaging. The 
satisfaction scores decreased similarly with increased compression (figure 7g). 
The questionnaire scores from patients (n=3 1) who also simultaneously completed 
the SF- 12 health outcome assessment showed that there was no correlation between 
these two health outcome measures (p=0.6, r--1.04) (figures 7h & 7i). The SF-12 
assessed the general health quality of life of the patients, but not the acceptability or 
satisfaction with compression stockings or bandages. Therefore the lack of 
correlation indicates that the stocking satisfaction questionnaire scores are not a mere 
reflection of the overall health of the patients. 
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Figure 7h - Correlation between physical SF-12 scores and 
stocking satisfaction scores 
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Figure 7i - Correlation between mental SF-12 scores and 
stocking satisfaction scores 
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7.5.5 Test-Retest reliability 
Test-retest assessment and reliability expressed as a product of the questionnaire's 
homogeneity or internal consistency was found to be good. The internal consistency 
of the questionnaire was described previously. The test and retesting of the 
questionnaire by 39 patients wearing GCS separated by a two-week period proved to 
be very similar with no significant difference (paired t-test) between mean scores of 
the first 'test' and the second 'retest' assessment (figure 7j). 
Figure 7j - Reliability test-retest assessment 
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7.5.6 Acceptability 
n=39 
p=0.185 
This instrument was developed as a self-completion questionnaire, which is 
theoretically less responsive than telephone or interview completion questionnaires. 
However the acceptability of the questionnaire was found to be more than adequate 
because: 
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0 First Score 0 Second Score 
i. The mean completion time was less than the recommended five 
minutes. The mean time for completion was 3 minutes and twenty 
seven seconds (range 54 to 634 seconds). 
ii. The number of patients who voluntarily completed the questionnaire 
was excellent,, no patients refused. 
7.5.7 Patient satisfaction with thigh and knee length stockings 
All 376 patients in the trial were asked and successfully completed the questionnaire. 
No patients refused. The median satisfaction scores for each stocking group (figure 
7k) 
Figure 7k - Stockings Satisfaction Questionnaire 
Assessment 
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demonstrated a greater patient satisfaction score of 90% with the 
Medi thrombexing 
climaXTm knee-length stockings compared to 78% satisfaction with 
Medi 
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thrombexinS climaXTM thigh-length (Kruskal-Wallis Test, p=0.00 1) and 78% 
satisfaction with Kendall T. E. D. TMthigh-length stockings (Kruskal-Wallis Test, 
p=0.001). There was no significant difference between Medi and Kendall thigh- 
length stockings (Kruskal-Wallis Test, p>0.05). 
The median of question scores (range 0-4) from each questionnaire item for each 
stocking type demonstrated that the thigh length stockings scored higher (worse) for 
all items (questions) when compared to knee-length stockings (figure 71 & table 7d). 
Figure 71 - Median item scores for each stocking group 
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Both thigh length stockings scored particularly badly with 'Unsightliness' and 
'Application difficulty' and Kendall thigh-length stockings produced a markedly 
high (bad) score for falling down. The worse scores for application with Medi thigh 
and falling down with Kendall thigh may be related to the greater and lesser 
compression profiles of these stocking respectively (chapter 6). 
Questionnaire Item Mean Item Scores 
Kendall Thigh Medi Thigh Medi Knee 
(n=101) (n=92) (n=95) 
Discomfort 0.57 1.04 0.35 
Tightness 0.46 0.75 0.25 
Temperature 1.18 1.01 0.77 
Itch 0.65 0.82 0.44 
Falling down 1.74 0.84 0.32 
Hygiene 0.50 0.74 0.46 
Unsightliness 1.04 1.04 0.24 
Difficulty of application and removal 2.13 2.69 0.8 
Table 7d - Mean item scores for each stocking group 
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7.5.8 Conclusions 
This stocking satisfaction questionnaire was found to be a valid and useful tool for 
the specific assessment of satisfaction in patients with lower extremity compression 
appliances. Its use in clinical practice and future research will enable practitioners to 
assess patient acceptability of new or alternative compression treatments. This 
health outcome measure may be used in conjunction with a generic 14RQL 
instrument to investigate clinical or trial patients receiving treatments involving 
compression therapy. The necessity for this satisfaction questionnaire is based on the 
theory that the efficacy of a compression device is highly dependent on patient 
compliance. The stocking compliance of the patients in this study is discussed in the 
next part of this chapter. The stockings effectiveness has been shown to dependent 
on the length of the stocking (chapter 6), the thigh length stockings reduced 
postoperative DVT significantly more than the knee-length variety of the same 
compression profile. The DVT prevention by the Kendall thigh stockings fell 
approximately half way between the two Medi stockings (thigh and knee-length), 
this may be related to finding of the Kendall stocking falling down markedly more 
than the Medi thigh stocking. As expected, the stocking satisfaction questionnaire 
revealed overall a significantly improved satisfaction with knee-length stockings, but 
the breakdown into individual domains showed much better scores for unsightliness 
and difficulty of application compared to the thigh stockings. The next part of this 
chapter reveals whether these differences in satisfaction are associated with 
differences in stocking compliance. 
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7.6 The assessment of patient stocking compliance 
Compliance is defined as the consistency and accuracy with which a patient follows 
the regimen prescribed by a physician or other health professional. There are 
numerous methods of assessing the compliance of a regimen depending on the nature 
of the treatment. Patients can either be asked to record there use of the therapy or a 
timing device may be used ter record the actual use of the treatment. In clinical trials, 
bias can be introduced with both of these methods; the patient may increase their use 
of the therapy or adhere more to a specific regime if they know their perfon-nance or 
behaviour is recorded by the physician. Some timing devices have the advantage 
that compliance can be recorded unknown to the patients, however in many instances 
this is not possible with simple mechanical therapies such as GCS. The effectiveness 
of GCS is heavily dependent on the actual use of the stocking by the patients, hence 
in a randomised controlled trial such as this, it was important to ensure that each 
stocking group received the same instructions regarding stocking use. 
7.6.1 Methods and patient series 
To all 376 patients, infonnation regarding the DVT and the purpose and use of 
stockings was given in the ethically approved trial information sheets and verbally at 
two stages in the trial; initially when the stockings were first applied and 
subsequently after the postoperative duplex scan. All patients were given the 
following advice: 
1. To wear their allocated stockings day and night during the trial until the 
postoperative duplex scan. Patients were free to remove their stockings 
if 
they wished for any reason. 
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ii. After the postoperative duplex scan, the patients were advised that the 
continued wearing of stockings for approximately four weeks after surgery 
had been shown to be beneficial in the prevention of DVT. Their decision to 
continue wearing their stockings or not would not affect the trial results. 
They were also informed that they were free to remove their stockings at any 
time for any reason. 
If the patients wished to continue wearing their stocking then a compliance diary 
sheet with a stamped addressed envelope and another pair of GCS was supplied for 
wash-and-wear purposes. All patients were shown how to apply and remove their 
stockings. 
Patient compliance diary sheet was developed for the purposes of the trial, this 
involved a literature search for similar instruments (none was found), expert opinion 
and a trial of pilot compliance assessment sheets with ten patients. The patients' 
compliance diary sheets consisted of a different sheet for each postoperative week. 
In the event of any difficulties with compliance sheet completion, patients were 
given a telephone number to call for advice. 
7.6.2 Compliance diary sheets 
The pilot version of the compliance diary sheet proved easy to use with a maximal 
response rate - no patients refused to answer the questions and all successfully 
completed the compliance assessment. The layout of the compliance is shown in the 
appendix. The total approximate number of hours that the stockings were worn could 
simply be summated from the compliance sheet entries. The compliance score was 
calculated as a percentage of the total time available for the stockings to be worn. 
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This was divided into hospitalised in-patient stay and time in the community after 
discharge from hospital. 
7.6.3 Results 
All trial patients who attended their postoperative duplex scan completed their 
compliance sheets for the first week of the trial. Eighty five percent of patients who 
chose to wear their stockings after the postoperative scan, returned the completed 
compliance sheets. There was no significant difference for stocking in-patient 
compliance for each stocking group (Chi2 p>0.05), the percentage of time worn was 
99% for Kendall thigh, 92% for Medi thigh and 98% for Medi knee (figure 7m). 
Figure 7m - Stocking compliance in hospital and after 
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7.7 Conclusion 
The compliance for the knee length stockings was significantly better than for the 
thigh-length stockings after the patients had left hospital (Chi2 p>0.05). The greater 
patient acceptability and comfort of knee over thigh-length stockings has been 
reported before by a number of authors (McNally et al 1995, Porteus et al 1989, 
Benko et al 2001). However the formal comparison of the thigh to knee-length 
stocking satisfaction and compliance has not been previously carried out. This health 
outcome and compliance study has confirmed a number of important characteristics 
of thigh and knee-length stockings: 
m The patients' satisfaction with knee length stockings was better than with 
thigh-length. Thigh stockings differed most markedly in the characteristic of 
'falling down', unsightliness and difficulty of application. 
A similar trend of stocking compliance was shown after discharge from 
hospital, with the knee-length stockings performing considerably better. 
The stockings compliance of patients while staying in hospital was not 
significantly different. This may be due to influence of nurses and doctors 
enforcing stockings prophylaxis. 
The stocking satisfaction and compliance was very similar for the two 
different brands of thigh-length stocking, implying that it is the length of 
stocking that is important to patients and not the different materials of 
manufacture. 
Stocking efficacy in the reduction of DVT is dependent on the stocking being wom 
by the patient. Despite improved acceptability to patients of the knee-length design, 
the thigh-length is the preferred GCS due to the fact that patient compliance is 
equivalent for thigh and knee stockings in hospital and thigh-length stockings were 
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proven to be more effective. The optimal in-patient GCS is the thigh-length, 
however the knee-length stocking could be considered for use as a 'post-hospital- 
discharge stocking' in view of its better compliance outside of hospital. 
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8.1 The need for change in DVT prophylaxis practice 
In Charing Cross hospital, a large university multidisciplinary hospital, and in many 
other centres in the developed world, continued reports of poor thromboembolic 
prophylaxis have occurred (George et al 1998, Jones 1991, Stephens et al 1995, 
Audet et al 1998, Fletcher et a] 1992, Conti et al 1982). In Charing Cross hospital, 
the proportion of surgical patients who effectively received GCS was only 44%, 
subcutaneous heparin was 54%, and overall optimal prophylaxis was found to be 
present in only 47%. The dangers of protecting only 'half of the surgical patients 
against DVT or PE are substantial. Without prophylaxis, the incidence of DVT in 
unprotected general surgical patients ranges from 25 to 30 per cent and up to 70 
percent in orthopaedic patients (Colditz et al 1986, Hull et al 1986, Clagett & Reisch 
1988, Stamatakis et al 1976). Optimal prophylaxis using a combination of 
mechanical and pharmacological agents, most commonly GCS and subcutaneous 
heparin, reduces the risk of DVT by 60-80 percent in general surgery and 50-64 per 
cent in orthopaedics patients (Stulberg et al 1984, Jeff-rey & Nicolaides 1988, Parker- 
Williams & Vickers 1991, THRIFT consensus group 1992). Most lower extremity 
thromboses are subclinical and some may resolve, although a significant amount do 
produce permanent valvular damage and chronic venous insufficiency. A small 
number of these DVT extend proximally and embolise to the lungs and depending on 
the amount of pulmonary circulation obstructed may produce mild, moderate or fatal 
effects. Pulmonary embolism accounts for a substantial proportion of postoperative 
deaths (Berqvist & Lindblad 1985). Pulmonary embolism and DVT may be difficult 
to detect before the patient clinically deteriorates and treatment may be unsuccessful, 
hence prophylaxis is the best means of reducing complications and death from VTE 
disease. 
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With over forty years of research highlighting the dangers and the need for the 
prevention of thromboembolic disease, it is unacceptable to find inadequate and 
disparate thromboembolic prophylactic practice in a modem hospital. Especially 
with an abundance of guidelines and numerous effective, safe and cheap methods of 
prophylaxis available. Therefore an investigative process was commenced in order to 
find out where, why and how the prophylaxis was lacking in Charing Cross hospital. 
The plan was to use this information to rectify and improve the overall status of 
thromboembolic prophylaxis in surgical patients. 
8.2 Preliminary argument for a single protocol 
Poor prophylactic practice continues despite continued efforts by consensus bodies to 
provide the optimal regime guidelines (Nicolaides et al 2001, THRIFT 1992, Haas 
1993). These authors went to great lengths to publish consensus statements 
containing accurate and up to date evidence-based recommendations for the 
prevention of postoperative DVT. However, the reported insufficient use of 
prophylaxis may represent a breakdown in the intended and actual implemented 
prophylaxis. The published guidelines utilize the process of obligatory 
categorisation of patients into risk groups prior to prescribing the appropriate 
thromboembolic prophylaxis. This process has two main weaknesses with regard to 
DVT prophylaxis: 
i. Preoperative thromboembolic risk-factors that decide the thromboprophylaxis 
may change intra- and post-operatively with a resultant change in the 
prophylactic requirements of that patient that are not met. Surgery and 
complications that increase DVT risk need to have optimal prophylactic 
cover in place at the time of these events. 
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11. One of the three risk category patient groups - low risk - has minimal 
randornised controlled evidence to support clinical or economic prophylactic 
recommendations, thus evidence-based practice for this group is difficult to 
apply. 
Our new protocol is based on the guidelines produced by these consensus groups, 
which are based on years of collated evidence and expert opinion that recommend 
subcutaneous heparin and GCS (or IPC) for high and moderate-risk patients. In a 
large university hospital such as Charing Cross, the majority of patients are of high- 
risk, some moderate and only a small proportion of patients undergoing surgery are 
low risk. Therefore, this permits 'stockings and heparin use across the board' and 
negates the need for risk categorisation in our hospital. In this era of clinical 
governance, health professionals are increasingly encouraged to perform evidence- 
based practice and maintain the quality of the care. The best way of unifying the 
practice of the many different health professionals is via the implementation of 
guidelines, healthcare frameworks or protocols. George et al (1998) demonstrated 
that the number of thromboprophylactic protocol violations increased with the 
complexity of the protocol. The questionnaire audit assessing prophylactic practice 
of surgical doctors (chapter 5) demonstrated that complex guidelines, that are readily 
available in the literature, were either not being used or used with incorrect risk 
assessment (with resultant incorrect prophylaxis prescriptions). Hence it was 
concluded that in order to achieve successful compliant DVT prophylaxis in Charing 
Cross hospital, the new recommendations needed to be simple, evidence-based, 
without risk assessment, and laid out in a clear protocol that was the same 
for all 
patients (unless medically contraindicated) undergoing surgery by all surgical 
specialities -a single blanket protocol. 
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8.3 Achieving a hospital consensus for a large randomised clinical 
trial investigating a single protocol and the optimal stocking 
length 
In general, as demonstrated by the questionnaire survey in chapter five, the junior 
doctors were keen to improve and simplify the surgical DVT prophylaxis in their 
hospital, however their practice was govemed by the wishes of their surgical 
consultants in charge. A small number of surgical consultants, from a variety of 
specialities, showed enthusiasm for updating their practice as long as the 
recommendations were evidence-based; these consultants were influential in 
arranging meetings and instigating change within each department. In order to set up 
a hospital consensus for an area of practices such as DVT prophylaxis, the agreement 
by all heads of departments, surgical consultants, trainee doctors, nursing sisters, 
pharmacists and management staff is required for a consensus to be reached. If a 
collection of any of these professionals - as experienced in this study - are opposed to 
the consensus then the whole process becomes hindered. In the early stages only 
nominal interest was shown for improving the overall status of DVT prophylaxis by 
a large proportion of surgical consultants. Details of the opinions and reactions of 
individual consultants will not be detailed as part of this thesis. The nursing sisters 
and chief phannacists were in favour of a hospital protocol that would unify surgical 
prophylactic practice in the hospital. Management expressed their wishes to use 
evidence-based and proven cost-effective means of DVT prophylaxis. A number of 
different approaches were employed to reach an agreement between consultants and 
departments, namely by personal meetings, letters and departmental presentations. 
The latter proved to be the most effective method for communicating information 
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and commencing debate on important issues. Presentations containing audit results 
and literature reviews were prepared and presented to each surgical department 
(chapter 5). The main points that were raised against achieving a surgical consensus 
during these meetings were as follows: 
n In general, the surgical consultants assumed that the their own DVT 
prophylaxis regimes were adequate. 
a Consultants were unaware of the overall disparity of the DVT prophylaxis in 
the hospital and how prophylaxis overall was made up of unstructured 'firm- 
led' regimes. 
m Orthopedic consultants were in favour of not using subcutaneous heparin at 
all in spinal surgery and only post-operatively in hip and knee replacements. 
They were in favour of using LDUH rather than LMWM due to suspected 
increased risk of bleeding complications with the latter. 
m Neurosurgeons were not in favour of using subcutaneous heparin 
preoperatively in any cranial or spinal surgery. They also preferred 
unfractionated heparin to LMWH for the bleeding risk. 
Some consultants preferred to use either no GCS or knee length types for 
certain patients and operative procedures 
w Many varieties of GCS were in use in the hospital, many of which had no 
randomised clinical trial evidence to support their use. 
A second round of presentations provided the evidence from the literature for the use 
of LMWH rather than LDUH, in terms of improved efficacy, lower cost and safety 
from bleeding and other complications. These presentations also outlined the need 
for a randomised controlled trial to investigate the best length of stocking and the 
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efficacy and safety of a 'single LM" with stockings protocol' for all surgical 
patients. 
An agreement was reached to allow the trial to commence with LMWH in trial 
patients only, postoperatively in orthopaedic and neurosurgical patients, and 
preoperatively in the remaining specialities with randomisation to either knee or 
thigh length GCS. Attaining a consensus on prophylaxis for all surgical patients in 
the hospital would then depend on the evidence provided by this trial. 
8.4 The optimal length of stocking 
The best length of stocking was investigated by the means of a large randomised 
controlled trial with 376 patients randomised into three stocking groups. Two groups 
with Medi thrombexint climaXTMstockings, one with thigh length and the other 
with knee-length GCS. The third group wore Kendall T. E. D. TM, the original and 
most frequently prescribed graduated compression anti-embolic stocking used in the 
NHS and the stocking with the most level one evidence demonstrating its efficacy in 
the prevention of postoperative DVT (Holford 1976, Scurr et al 1977, Turner et al 
1984). These stockings groups were investigated for incidence of postoperative 
DVT by serial pre- and post-operative duplex scanning, stocking acceptability with a 
validated stocking satisfaction health outcome assessment, and patient compliance. 
The Medi thigh-length stockings proved to be significantly better at reducing 
postoperative DVT than the Medi knee-length stocking with an equivalent 
compression. This was found to be in the order of a five-fold reduction (ORs=O. 18 
[95%C1 0.04-0.82] P--0.026). The Kendall T. E. D. TMstockings were found to be 
nether significantly better than the knee-length or significantly worse than the Medi 
thigh-length stockings. However, this study did not have sufficient power to show 
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differences between the two types of thigh stockings. The two lengths of Medi 
thrombexinS climax(V are manufactured from the same materials and produced 
comparable compression to the calf, the dissimilarity in DVT prevention between 
these stockings can therefore be assumed to be due to the differences in their length. 
The health outcome findings (discussed later in this chapter) of stocking satisfaction 
and compliance also revealed significant differences and important similarities to 
support the use of thigh length stockings as part of a single protocol. 
8.5 LMWH for all patients undergoing surgery 
The use of LMWH for thromboprophylaxis was controversial at the time of its 
introduction - over a decade ago -to clinical practice due to the lack of true evidence 
and use of anecdotal evidence regarding bleeding complications, efficacy and 
expense. Some of these old beliefs were found to remain at Charing Cross hospital, 
however a simple review of the recent literature and published prophylaxis 
guidelines clearly demonstrates that LMWH is the heparin of choice for the use in 
the majority of surgical patients. Compared to unfractionated heparins, low 
molecular weight heparins have been shown to perform equally and in many 
instances better at preventing postoperative DVT and PE with less ee ing 
complications when used at the optimal dosage. And as far as cost, it is now the 
cheaper option when administered once daily compared the twice or thrice daily 
injections with unfractionated heparin regimes. The once daily subcutaneous 
LM" injection has the added benefit of improved patients acceptability. Even with 
the abundance of evidence in the literature, many surgeons at Charing Cross hospital 
still required reassurance that LMWH was safe and effective to use across the 
board 
in a blanket protocol. This study verified that daily enoxaparin (20mg) given on the 
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evening efore surgery, and postoperative in orthopaedic and neurosurgery patients, 
was effective and safe when used across the board for the prevention of postoperative 
DVT. In the RCT, no DVT occurred in the low and moderate risk patients and with 
the best thigh-length stockings the DVT rate was only two percent. Only one 
significant bleeding complication occurred from which the patient made a full 
recovery. The timing of administering LMWH in this trial was on the evening before 
surgery for a number of important reasons: 
m Firstly, the peak activity of LMWH is at one to four hours after subcutaneous 
injection. Therefore if administered on the morning before surgery, may 
increase bleeding during surgery. This may explain many surgeons dislike of 
LMWH with regard to bleeding. However if given on the evening before 
surgery this allows the peak activity to pass and the prophylactic activity to 
continue during surgery. 
m Secondly, the evening dose permits the required twelve hours to pass before 
anaesthetists are happy to insert epidural or spinal catheters for regional 
anaesthesia. The evening dose is therefore part of the single protocol regimen 
making LMWH available for use in all patients undergoing surgery. 
There are a number of different LMWH dosage regimes that have been investigated 
in the literature. These involve doses adjusted to the weight of the patient and 
increased doses for high-risk patients. However, studies have shown that increasing 
the dose of LM" increases the risk of bleeding without added efficacy in DVT 
prevention (Koch et al 1997). In order to avoid complex prescribing regimes in the 
'single blanket protocol', a single dose of 20mg of enoxaparin was investigated for 
efficacy in this study. The low incidence of DVT (2%) in only high risk patients 
proved this to be a reliable and effective dose in line with similar results 
from the 
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Cochrane reviews (Wille-Jorgensen et al 2002). If a speciality or health professional 
insists on a LMWH delay or increased dosage for certain patients, this can be 
accommodated. The single protocol is the basis for DVT prophylaxis in patients 
undergoing surgery in this university hospital, it should encompass the prophylactic 
requirements of all surgical patients. It can be 'upgraded' or 'added to' in specific 
cases but not 'downgraded' or omitted unless there is a medical contraindication to 
stockings or LM". Those patients with medical contraindications to LMWH or 
stockings would only receive appropriate safe prophylaxis. 
In summary, a simple and safe new protocol for DVT prophylaxis in a busy 
university hospital is recommended. The combination of a good quality thigh-length 
stocking and LMWH for hospitalised patients requiring surgery produced a low 
postoperative DVT rate in the high-risk patients and no DVT in the moderate and 
low-risk patients. To have a single hospital protocol means that prophylaxis against 
DVT is less likely to be forgotten; confirmed by the audited improvement (p<0.05) 
in prescribing optimal prophylaxis to 88% of surgical patients (chapter four). This 
study provides evidence that a single 'blanket' protocol of LMWH and a good 
quality thigh-length anti-embolic stockings is safe and effective to use all surgical 
patients (bar medical contraindications) for the prophylaxis of postoperative DVT, 
with very few disadvantages. 
8.6 Health outcome assessment of stocking satisfaction and 
compliance 
Prior to this study the evidence to support the choice of stocking for general DVT 
prophylaxis and for use in a new protocol was limited, only three randomised clinical 
trials assessing DVT prevention comparing knee to thigh length stockings were 
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available in the published literature. These studies as previous mentioned in chapter 
three contained small numbers of patients and failed to show any differences in the 
efficacy between knee and thigh-length stockings. Despite these limitations, the 
study primary hypothesis was based on the available published evidence, 
'Provided all patients received LMWH, 
thigh-length anti-embolic stockings are equivalent to knee-length of the same design 
in the prevention ofpost-operative deep vein thrombosis'. 
If this hypothesis had been shown to be correct then the stocking with the greater 
patient acceptability and compliance would be the stocking of choice. This principle 
also applies to other compression therapies with similar efficacies used to treat 
venous and lymphatic disorders of the limb. Hence a validated instrument to assess 
patient satisfaction with lower limb compression therapies has uses outside of this 
study in clinical practice and other research. 
Stocking acceptability assessed with a new validated instrument demonstrated that 
patients were more satisfied (p<0.05) with knee-length stockings (satisfaction score 
90%). The satisfaction levels for the two types of thigh length stocking were very 
similar (satisfaction score 78%) and at an acceptable level so as not to prevent their 
use. The similarity in the scores achieved by the two different thigh-length stockings 
brands suggested that it was the length of the stocking and not the materials of 
manufacture that was important to the patients. 
The trends discovered in stocking acceptability were mirrored in the compliance 
scores achieved by each stocking type when used after discharge 
from hospital, with 
256 
the knee-length stocking performing considerably better than the thigh-length 
stockings. However, the compliance was good and not significantly different for 
each stocking type when worn by patients staying in hospital. These findings 
provide guidance on the GCS to use in a new single protocol - the most efficacious 
thigh-length stocking with equal in-patient compliance and acceptable levels of 
patient satisfaction. 
8.7 The impact of this study on clinical practice at a large 
university hospital 
In the early stages of this research, the status of thromboprophylaxis in this hospital 
was disparate and inadequate. Only about one half of the patients were receiving 
optimal prophylaxis and only a quarter the better LMWH, as recorded by a hospital 
wide audit of surgical patients (chapter 4). Many different brands and regimes of 
subcutaneous heparin were prescribed. The use of GCS was also in disarray with a 
variety of unproven brands and an inconsistent use of knee and thigh-length 
stockings on many of the surgical wards. 
Since this time, the use of audit, surveys, reviews of the literature, and a large 
randomised controlled trial has provided evidence to instigate change in a large 
university hospital with many surgical specialities and academic surgical consultants. 
With the approval of the surgical and medical directorates and the help of the 
consultants in charge of clinical governance, the new Charing Cross single protocol 
was implemented in October 2003 for use in all surgical patients staying in hospital 
to undergo surgery. The medical consultants have used the latest evidence from the 
medical literature and extrapolated these findings concerning the benefits of thigh- 
length stockings to develop a similar single protocol for all medical patients. In 
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summary the status of thromboprophylaxis practice in Charing Cross hospital is as 
follows: 
m All consultants from all specialities have agreed a consensus to use a single 
blanket protocol of thigh-length stockings (Kendall and Medi) and LMWH 
(enoxaparin) in all surgical in-patients undergoing surgery (and all medical 
patients) 
m The LMWH used, is subcutaneous enoxaparin 20mg prescribed in the 
evening at 6pm, as prescribed during the RCT. A single type and dose of 
LMWH was chosen to maintain the simplicity of the single protocol. 
a Thigh stockings used, are either Medi thrombexinS climaXTMor Kendall 
T. E. D. TM 
m LMWH/thigh stockings prophylaxis is given preoperatively in all surgical 
specialities, except in certain specific procedures that require LMWH to be 
commenced postoperative, namely spinal surgery, intracranial surgery and 
joint replacements. However, some orthopaedic and neurosurgery consultants 
have agreed to use preoperative LMWH in all of their patients. 
mA list of specific contraindications to the use of either LMWH or GCS is 
available on all wards and on the hospital intranet. 
0 The published hospital single protocol 'LMWWthigh stockings' is published 
on the Hammersmith Hospitals NHS Trust intranet. 
The single LMWH/thigh-stockings protocol published on the intranet gives clear and 
simple instructions for thromboprophylaxis with guidance for relative and absolute 
contraindications. The thromboprophylaxis practice in Charing Cross hospital will 
be audited at regular intervals by the department of clinical governance. 
These audits 
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will record and report the future influence of this study on prophylactic compliance 
at Charing Cross Hospital. 
8.8 Future research 
The use of the single protocol needs to be audited to complete the assessment of the 
changes made as a result of this work on DVT prophylaxis in Charing Cross hospital; 
this was not possible during this study due the prolonged time taken to achieve a 
consensus and to establish the new single protocol in all surgical departments. 
However the significant improvements to 88% optimal prophylaxis in surgical 
patients achieved by using the 'single protocol' in the breast and oncology, 
gastroenterology, urology and vascular surgery specialities (chapter four) indicates 
that a simple single DVT protocol improves overall prophylactic compliance. 
Future work is required to find if this protocol is applicable to other similarly sized 
hospitals that would probably have similar patient populations. However the 
thromboembolic risk of the patient population would require formal assessment 
through similar audit processes, to confirm that the majority of patients were of high 
and moderate risk. The evidence based recommendations for the DVT prophylaxis 
of these patients is LM" and GCS (Nicolaides et al 2001) and therefore the single 
protocol would be indicated. 
A 'grey' area in the prophylactic recommendations published in the literature is the 
optimal prophylactic requirments of low risk patients. Currently there is no good 
evidence to guide practitioners and this evidence may not become readily available 
due to the large numbers of these patients that would be required in a randomised 
study. Many protocols simply recommend no prophylaxis apart from early 
mobilisation. However even if the incidence is low, this group of patients are at risk 
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e__ - trom fatal PE and debilitating DVT after surgery. The protocol developed in this 
study recommends the same prophylaxis for these patients as the other patients in 
higher risk groups on the basis of their small proportion of the total in-patient 
population and the ease at which these low-risk patients may become higher risk 
during their hospital stay. There is certainly no evidence in the literature to suggest 
that these patients should be withheld DVT prophylaxis. However more evidence is 
required for this low risk group in terms of DVT prophylaxis requirements and cost- 
effectiveness. 
The protocol developed in this study recommends the use of preoperative 
prophylaxis when safe, however the evidence comparing the efficacies of 
prophylaxis implemented before or after surgery needs to be improved. 
The actual mechanism(s) by which GCS achieve prophylaxis of DVT has never been 
fully evaluated. Stockings are known to counteract two parts of Virchow's triad by 
increasing venous velocity and reducing vein wall distension. However is this their 
actual mechanism of action? Further work is required in this area to explain the 
differences in efficacy of knee to thigh-length stockings. 
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Appendix A Ethical committee approval 
RIVERSIDE RESEARCH ETHICS COMMITTEE 
Pharmacy Offices Lower Ground Floor 
CHELSEA & WESTMINSTER HOSPITAL 
369 Fulham Road London SW10 9NH 
Tel: 020 8846 6855 Fax: 020 8846 6860 
Cý, 
ýJQ , --týao 
Professor R Greenhalgh 
Department of Vascular Surgery 
Imperial College of Science, Technology and Medicine 
4th Floor 
Charing Cross Hospital 
Fulham Palace Road 
London, W6 8RF 
Dear Pro 
. 
Nssor7G-reenhalgh, 
J5V(, ticv 
RREC 2447 - The development of Charing Cross guidelines for the prevention of 
venous thrombosis after surgery with subcutaneous low dose heparin and anti- 
embolic stockings in high, medium and low risk patients 
Thank you for sending us this submission. Following your response to the four points 
raised, I am pleased to inform you that approval has now been granted by the 
Committee. 
Please note the following conditions which form part of this approval: 
This approval is for one year only. For projects with an expected duration of 
more than one year, a letter from the principal investigator will be required in 
order to further extend consent. This will enable the Committee to maintain a 
full record of research. 
[2] Any changes to the protocol must be notified to the Committee. Such changes 
may not be implemented without the Committee's approval. 
[3] The Committee should be notified immediately of any serious adverse events 
that are believed to be study related or if the entire study is terminated 
prematurely. 
[4] You are responsible for consulting with colleagues and/or other groups who 
may be involved or affected by the research, e. g., extra work for laboratories. 
Approval by the Committee for your project does not remove your responsibility 
to negotiate such factors with your colleagues. 
Cont/2.. 
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Cont/2... RREC 2447 - The development of Charing Cross guidelines for the 
prevention of venous thrombosis after surgery with subcutaneous low dose 
heparin and anti-embolic stockings in high, medium and low risk patients 
[5] You must ensure that nursing and other staff are made aware that research in 
progress on patients with whom they are concerned has been approved by the 
Committee. 
(6] Pharmacy must be told about any drugs and all drug trials, and must be given 
the responsibility of receiving and dispensing any trial drug. 
[7] The Committee must be advised when a project is concluded and should be 
sent one copy of any publication arising from your study, or a summary if there 
is to be no publication. 
[8] All documents relating to the study, including Consent Forms for each patient (if 
applicable), must be stored securely and in such a way that they are readily 
identifiable and accessible. The Committee will be conducting random checks 
on the conduct of studies, and these will include inspection of documents. 
May I take this opportunity to wish you well in your research. If any doubts or 
problems of an unexpected nature arise, please feel free to contact me at any time. 
Yours sincerely 
LO 
CG Mackworth-Young MA MD FRCP 
Chairman - RREC 
I 
Seen and Approved 
Submission 20 July, 2000 
Protocol As part of submission 
Information Sheet Version I- 18/7/2000 
Consent Form Yes 
Questionnaires 
Letter of Indemnity 
CTX/DDX/Licence 
Appendix B Audit proforma 
Consultant 
Speciality: Ward 
Operation: In-patient stay= 
Day post-op 
Patient details 
Age: years 
Male Female 
Risk Factors 
Previous Deep vein thrombosis Yes No 
Previous Pulmonary embolus Yes No 
Coagulopathy Yes No Type: I 
FHx Coag Yes No Type: 
Smoker Yes No 
Hx of VVs Yes No 
Hx of # leg/Sx Yes No Surgery type 
Recent flight Yes No Duration 
Malignancy Yes No Diagnosis Date: 
Obese Yes No Kg= Ht BMI: 
Medication Warfarin= Aspirin = 
Stockings 
Heparin 
HRT OCP 
Steroids 
Others: 
None = One Both legs 
Suitable Size Fitted Yes = No 
Known contra-indication: Yes/No I 
Prescribed Yes No 
I Nil I 
s No 7 
Given Yes No vý Yes No 
Type 
Time (BD=I, OD= 2, Noctez---. 3) 
Pre-op 
Post-op 
Mobility level attained Bed Chair 
Walking with aid Walking unaided 
Other DVT Prophylaxis Yes = No E---7 Typej 
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Appendix C 
VERSION 2 
I- Study title 
DATE 1/8/2001 
THE DEVELOPMENT OF CHARING CROSS GUIDELINES FOR THE 
PREVENTION OF 
VENOUS THROMBOSIS AFTER SURGERY WITH ANTI-EMBOLIC LEG 
STOCKINGS 
AND LOW DOSE HEPARIN 
2. Invitation 
You are being invited to take part in a research study. Before you decide to take part, 
it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with friends, relatives and medical staff if you wish. Ask us if there is anything that 
is not clear or if you would like more information. Take time to decide whether or 
not you wish to take part. 
Consumers for Ethics in Research (CERES) publish a leaflet entitled 'Medical 
Research and You'. This leaflet gives more information about medical research and 
looks at some questions you may want to ask. A copy may be obtained from 
CERES, PO Box 1365, London N16 OBW. 
3. What is the purpose of the study? 
In patients who have had an operation there is a risk of developing a thrombosis in 
the deep veins of the leg. There are a number of measures, which can be used to help 
prevent this from occurring; these include using anti-embolic leg stockings and an 
injection of low dose heparin just under the skin once a day. However the exact type 
of stockings that are best for this purpose is not yet known. 
The Department of Vascular Surgery of Imperial College of Science, Technology 
and Medicine, led by Professor R. M. Greenhalgh has set up a study to compare the 
Patient information sheets 
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effectiveness of different types of leg stockings, used to stop deep vein thrombosis 
(DVT) occurring after surgery. 
A second part of the study will also involve a testing two small samples of blood 
These blood tests will not require any additional 'needles' or 'injections', the 
samples will be taken at the same time as your routine blood tests on admission to 
hospital and in the operating theatre anaesthetic room before your surgery. The 
analysis of the blood samples will help us to develop a test that may be able to 
predict if you are going to develop a deep vein thrombosis after your surgery and 
therefore help to prevent D VT in the future. 
With the information from the trial, we will develop guidelines for the prevention of 
deep vein thrombosis; to be used in our trust for every surgical procedure performed 
under general anaesthetic involving at least one night stay in hospital. Subcutaneous 
heparin will be recommended for all, but type of stocking is under scrutiny. 
4. Why have I been chosen? 
You are due to have an operation in the next few days, and as part of the usual post 
operative treatment, you would normally be asked to wear leg stockings and receive 
daily injections of low dose subcutaneous heparin. If you agree to take parý we 
would like to decide for you which of the three types of stocking to wear after the 
operation. You would still receive the standard heparin injections. 
It is up to you to decide whether or not to take part. If you decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without giving 
any reason. This will not affect the standard of care you receive. 
5. What will happen to me if I take part? 
Before your operation, a specialist vascular nurse will measure and 
fit your new 
stockings, which you should then wear day and night until seven 
days after your 
operation. The stockings that you receive will be one of three types, 
Kendall 'TED' 
thigh length anti-embolic stockings, Medi thigh length anti-embolic stockings or 
Medi knee length stockings. This is a 'Randomised trial', which means that people 
will be put into one of three groups and then compared. 
As we do not know which 
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are the best stockings to use, patients are randomly assigned by computer to wear one 
of the stocking types and then each group is compared. The computer has no 
information about the individual, so that each patient is assigned by chance. At this 
stage we would like to take a small blood sample (I ml) when your routine pre- 
operative blood tests are taken and another just before your operation when the 
anaesthetist is routinely required to insert a needle for venous access. 
On the 5-7th day after your operation the vascular research fellow or a vascular 
technician will carry out an ultrasound scan on the veins in your legs, looking for 
deep vein thromboses. This test is completely painless, and is not dangerous to you 
at all, but it will require you to lie still for approximately 30 minutes. If you have left 
hospital before the fifth day after your operation, we would give you an appointment 
to come to have the ultrasound scan in the Department of Vascular Surgery at 
Charing Cross Hospital as part of your post operative management. 
When an adult patient wears stockings and receives low dose heparin injections after 
an operation, the risk of developing a deep vein thrombosis is between I and 10%. 
This depends on whether your are in the low, medium or high risk category for post 
operative deep vein thrombosis. If you are found to have a deep vein thrombosis, we 
would then start you on the standard hospital treatment for deep vein thrombosis. 
This would involve having a daily injection of another type of heparin, called 
Tinzaparin and starting warfarin tablets which, you would need to take for six 
months. The treatment of a deep vein thrombosis does not mean that you need to 
stay in hospital any longer than normal, as a district nurse can administer the 
Tinzaparin injections daily at your home. A specialist anti-coagulation outpatient 
clinic would then see you on a regular basis to monitor the dose of your warfarin. 
The information above is surnmarised in a flow diagram as follows: 
ýkDMISSION TO HOSPI 
m 
ýEXPLANATION OF TRIA 
m 
FSýIG-NING OF -TRIAL CONSENT FOýM 
m 
ýLINICAL ASSESSMENT 
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ýLLOCATION TO STOCKING G 
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ýLOOD SAMPLE TAKEN WITHROUTTNE VENOUS 
OPERATION PERFORME 
R 
ýONTINUED WEARING OF STOCKINGS AND TWICE DAILY MECTION 
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m 
PUPLEX ULTRASOUND SCAN OF LEG VEINS AND A SINGLE kL-7: 0:: Oýp 
ýEST F 
O-DIMER ON 5-7'H DAY AFTER SURGER 
m 
ýND OF ýýD 
PATIENTS FOUND TO HAVE DEEP VEIN THROMBOSIS WILL RECEIVEI 
ýINZAPA 
[AND WARFARIN TREAT 
(* You may be excluded from the study if the doctors running the trial feel that the 
use of stockings and/or heparin may be dangerous to your health. ) 
6. What do I have to do? 
There will be no change to management of your care during your hospital stay as 
each surgical patient receives stockings and heparin after surgery. We will only alter 
the type of stockings worn by patients, because we wish to know which our patients 
like the best. 
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It will not affect any current treatments that your are receiving. You can continue to 
take any current medications and a normal diet as directed by your surgical team. 
You will be asked to fill in a Health Related Quality of Life Questionnaire at the end 
of the study to help us know your views on the stockings. 
7. What is the appliance being tested? 
As described above, we aim to compare different types of leg stockings used to 
prevent post operative deep vein thrombosis after a surgical procedure and blood 
sample will tested with Thromboelastograph analysis which gives an overall clotting 
picture of the blood. 
8. What are the side effects of taking part? 
Stockings, heparin injections and blood tests are all part the routine surgical 
treatment before and after any operation, this study will not change your treatment 
or subject you to any additional risk. There are no side effects from wearing leg 
stockings; they rarely cause itching and minor discomfort. 
Low dose subcutaneous heparin injections are given to all patients on trial or not and 
rarely cause side effects. It is used in most adult patients in the post operative period. 
However, the side effects that heparin can cause are as follows: 
" Irritation or damage to the skin at the injection site. 
" Bruising or increased bleeding. 
"A lowering of platelets in the blood. Platelets are cells which, help to form blood 
clots. 
"A rise in the blood level of potassium. 
" Allergic reactions. 
Every patient will be closely observed to the check that side effects are avoided or 
treated immediately. 
9. What are the possible disadvantages and risks of taking part? 
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There will be no additional risk to your health by taking part in this study. All the 
interventions carried out in this study such as: stockings, low dose heparin injections 
and blood tests are usually perfonned on all surgical patients. The additional duplex 
ultrasound scan is painless and risk free. The only disadvantage is to let us know 
your views by questionnaire. 
If we diagnose a deep vein thrombosis, then the appropriate treatment will be 
commenced in accordance with the Hammersmith Hospitals Trust's Protocol (as 
described above). Any other condition that is diagnosed as a result of this trial will 
be treated by your surgical team or result in a referral to another team for treatment. 
10. What are the possible benefits of taking part? 
We do not know if the new stocking types used are better than the currently used 
stockings. In the post operative period you would be followed more closely than 
normal for the detection of a deep vein thrombosis as a result of the additional tests 
implemented for the study. 
We hope that all treatments will benefit patients. However, this cannot be 
guaranteed. The information we get from this study may help us to prevent future 
patients from developing a deep vein thrombosis. 
11. What happens when the research study stops? 
We shall provide the preferred stockings to all of our patients. 
12. What if something goes wrong? 
Any complaints about the treatment you receive as part of this trial can be discussed 
with the clinical research fellow. 
It is very unlikely that any harm should come to you as a result of wearing a different 
type of leg stocking. If taking part in this research project harms you, there are no 
special compensation arrangements. If you are harmed due to someone's negligence. 
then you may have grounds for legal action but you may have to pay 
for it. 
Regardless of this, if you wish to complain about any aspect of the way you 
have 
been approached or treated during the course of this study, the normal 
NHS 
complaints mechanisms may be available to you. 
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13. Will my taking part in this study be kept confidential? 
All information, which is collected, about you during the course of the research will 
be kept strictly confidential. Any information about you that leaves the hospital wi II 
have your name and address removed so that you cannot be recognised from it 
(unless it is necessary to send information to your GP). 
14. What will happen to the results of the research study? 
The results of the study will be used to formulate the 'Charing Cross Guidelines for 
Post Operative Deep Vein Thrombosis Prevention'. These guidelines will help to 
prevent DVT in future post operative patients. The results of the trial will be 
published in leading medical journal after completion of the study, a copy of this will 
be available to you from the Department of Vascular Surgery at the Charing Cross 
Hospital. You will not be identified in a report or publication. A copy of the results 
will available to Medi UK who have supplied the stockings for this study. 
15. Who is organising and funding the research? 
This study has been organised by the Professor R. Greenhalgh and Mr A Davies in 
the Department of Vascular Surgery of Imperial College of Science, Technology and 
Medicine. This is not a sponsored study, the department or doctors involved will not 
be paid for including you in this study. The research is funded by a charitable trust 
via Imperial College. 
16. Who has reviewed this study? 
This trial has been reviewed by the Riverside Research Ethics Committee, Chelsea 
and Westminster Hospital, 369 Fulham Road, London SWIO 9NH. 
17. Contact for further information. 
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If you require further information, please contact Mr A Howard, Clinical Research 
Fellow or Mrs A Williams, Specialist Vascular Nurse, at the Department of Vascular 
Surgery, 0' Floor, Charing Cross Hospital, Fulham Place Road, London. 
We would like to thank you if you have decided to help by taking part in our study. 
You will be given a copy of the patient information sheet and a signed consent form 
to keep. 
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Appendix D 
OVT 
patient Consent Form 
November 2000 
Mr Howard, Professor RM. Greenhalgh 
Direct Line: 020 8846 7301 
E-Mail: a. howard@lc. ac. uk 
Patient consent form 
Patient Consent Form 
STOCKINGS Trial Co-ordinatcw 
Departmerif of Vascular Surgery 
Charing Cross Hospital 
London W6 8RF 
Comparing Anti-Embolic Stockings for the Prevention of Deep Vein Thrombosis 
Patient Name: ................................................ Patient ID Numberd 
I 
The patient must complete the whole of this sheet by initiallinq the boxes 
I have read the patient information sheet F-I 
I have had the opportunity to ask questions 
and discuss the study 
17 
I understand that my participation is voluntary and that I am 
free to withdraw at any time without giving reason, without my 
medical care or legal rights being affected 
I understand that sections of my medical notes may be looked 
at by doctors from Charing Cross hospital and possibly by members 
from regulatory authorities where it is relevant to the research. 
I give permission for these individuals to have access to my 
records F1 
Do you give permission for your General Practitioner (GP) 
to be notified of your participation in this trial? 1: 1 F71 
YES NO 
I fully agree to take part in the study. 
Signed by patient: ....................................................... 
Name in block letters: ....................................................... 
Date of consent: ....................................................... 
Copy of consent to be placed in patients hospital notes. 
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Appendix E Trial baseline sheet 
Recruiting Consultant 
Speciality: 
Planned operation: 
Date: Admission: Operation: Ward 
First Scan: Time Day Bkd Y/N EJ 
Final Scan: 
9 Time Day Bkd YIN EJ 
Patient details 
Name/address in full: 
Hospital number: 
Weight: 
Height: 
BMI: 
Past Medical History 
Deep vein thrombosis 
Pulmonary embolus 
Coagulopathy 
Coag FHx 
Smoking 
HxofVVs 
Hx of # leg/Sx 
Mobility 
Recent flight 
Malignancy 
Medication 
Pre-operative duplex 
Normal 
Thrombus Scarring 
Recannalised 
Obstruction 
Venous anomaly 
Tel: 
kg/st 
cm/ft 
Yes No 
Yes No 
Yes No 
Yes No 
Yes No 
Yes No 
Yes No 
Bed bound 
Housebound 
Yes No 
Yes No 
Warfarin 
HRT 
Steroids 
Others: F- 
Baseline Form 
Age: years 
Male Female 
Left/Right Date: 
Date: // 
Type: I 
Type: I 
Number of ears: I 
CEAI 
Ei 
Surgery type 
Chair bound 
Full 
Duration Date: 
Diagnosis Date: 
Aspirin O= na= 
name: 
name: 
(Attach copy of duplex diagrammatic findings) 
Yes = No 
Site F- 
- Yes No 
Yes No 
Yes No 
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Appendix F 
Patient details 
Name in full: 
Checklist 
Randomisation sheet 
Read patient information sheet Yes No 
Signed consent form Yes No 
Pre-operative duplex Yes No 
Baseline sheet completed Yes No 
Stratification 
Risk category High Moderate 
Speciality Neuro Ortho 
Date of randomisation 
Outcome Kendall thigh length stockings 
Medi thigh length stockings 
Medi knee length stockings 
Low = 
Other = 
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Appendix G Surgery and post-surgery sheet 
Patient details 
Name in full: 
Hospital number: 
Prophylaxis 
Stocking type KTL = MTL = MKL 
Enoxaparin Time: 12hrpre-op = 12hr post-op = 
Heparin complication: Bleeding - Wound: Yes No 
- Major: Yes No 
GCS complication: F- 
Operative details 
Date of operation: Time: =: = am/pm 
Type of operation: 
Duration of operation hours 
Post operative period 
Mobilisation Post-operative day I 
-1- -2- -1- -4- --S- -6- -7- 
Limb swelling Yes* = No Day Site 
Limb erytherna Yes = No Day Site 
Limb pain Yes = No= Day Site 
Sepsis Yes = No = Day S ite 
Calf size Pre-op cm Post-op I j cm 
Post operative duplex (Attach copy of duplex diagrammatic findings) 
Date performed 
Post operative day 
Post operative DVT 
[ i/i /II 
56=7 Other 
Yes No= Day = 
DVT site Right Proximal 
E=3)istal 
Left Proximal istal 
-------------- 
lVC 
------------ -------------------- 
P. FemorisV 
------ 
C. IliacV S. FemoralV 
E IliacV Popliteal V . C. FemoralV Deep Calf V 
Pulmonary embolus Clinically: Yes =No 
= Day 
VQ: Yes = No = Equivocal 
275 
Appendix H DVT duplex sheet 
affix label 
Vascular Surgical Service 
gXH 1QVT Charing Cross Hospita 
Name .......................................... 
EaRggE-V 
Vascular Laboratorý 
Stu Study 0 
__ENTION TRLAAL Duplex of Lower Limb Venbus Systerr, Hosp. No ...................................... y Study No 
ý7 
D. O. 8 .......... / ........... / ............ Assessed by .......................................... 
Date ......... / ........... / ........ Aorto-fflac RIGHT LEFT Aorto-iliac 
Common Femoral vein 
Sapheno-fernoral junction 
PFV 
Long saphenous vein 
SFV 
Profunda Femoral vein 
Superficial Femoral vein 
Perforators 
Popliteal vein 
Short saphenous vein 
Tibial veins 
Perforators 
Date: ink colour: 
PRE-OP SCAN R L 
DVT DIAGNOSIS N Y N Y 
Augmentation Y N Y N 
Colour Fill Y N Y N 
Compression Y N Y N 
Thrombus Visible N Y N Y 
Spontaneous Flow Y N Y N 
Phasic4 
y N y N 
Common Femoral vein 
Sapheno-fernoral junction 
PFV 
Long saphenous vein 
'-, QFV 
SFV 
LS Profunda Femoral vein 
Superficial Femoral vein 
Perforators 
POP 
k 
v 
Popliteal vein 
POP 
Short saphenous vein 
SS 
Tibial veins 
Perforators 
Date: ink colour: 
POST-OP SCAN R L 
DVT DIAGNOSIS N Y N Y 
Augmentation Y N Y N 
Colour Fill Y N Y N 
Compression Y N Y N 
Thrombus Visible N Y N 
- 
Y 
Spontaneous Flow Y N 
Y7 
N 
Respiratory 
Phasicity 
Y 
I 
N Y 
I 
N 
-i 
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Appendix I Patient stocking satisfaction questionnaire 
This questionnaire asks you for your views about your stockings or bandages. 
Please read the questions carefully, and then place a tick in one box below the 
statement that best describes your answer. If you are unsure about how to answer. ) please give the best answer you can. 
In order help us assess the types of stockings or bandages used, please be as frank 
with your answer as possible. 
Patient Name: I Sex: F-1 Age: 
Pressure Level: TED 3LB Full Length 
4LB Knee Length 
Fý 
Duration worn: Fj monthsF] days Date: 2002 
Please do not tick more than one box per question. 
1. Do you feel the stockings/bandages cause you discomfort? 
Not at all Slightly Moderately Quite a bit Extremely 
2. Do you feel the stockings/bandages make your legs itch? 
Not at all Slightly 
_ýjoderately 
Quite a bit Extremely 
3. Do you feel the stockings/bandages make your legs feel hot? 
Not at all Slightly Moderately Quite a bit Ext, mely 
4. Do you feel the stockings/bandages are tight? 
Not at all Slightly Moderately Quite a bit xtremely 
5. Do you feel the stockings/bandages slip down? 
None of the 
time 
A little of the 
time 
Some of the 
time 
Most of the 
time 
All of the 
time 
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6. Do you feel the stockings/bandages are unhygienic to wear? 
Not at all Slightly Moderately Quite a bit Extremely 
7. Do you feel your stockings/bandages look unsightly to wear? 
Not at all Slightly Moderately Quite a bit xtremely 
8. Do you feel your stockings/bandages are difficult to remove and put back on, 
if performed by yourself without the help of another person? 
Not at all Slightly ModeratýýIy Quite a bit Extremely 
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Appendix J Patient stocking compliance diary sheet 
The compliance diary sheet was laid out as follows*: 
How many days did you stay in hospital? = Days 
Please fill in the date of leaving hospital. Date I 
Please place a single mark for each day and night in a box to record the number of hours that 
your stockings have been wom: 
WEEK , DAYTIME 
Days of None of A little Some Most of 
the week the of the of the the 
that time time time time 
stockings (0 (less 
are worn hours) than 4 (betwee (8 to I" 
hours) n4 to 8 hours) 
hours) 
Monday 
--/--/2002 
Tuesday 
Wednesd 
ay 
Thursday 
Friday 
Saturday 
Sunday 
*Table reduced in size to fit page layout for thesis binding 
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Abbreviations 
AES Anti-embolic stockings 
aPTT Activated partial thromboplastin time 
ATIH Anti-thrombin III 
CDU Colour Doppler ultrasound 
C1 Confidence interval 
DVT Deep vein thrombosis 
ENT Ear nose and throat surgery 
GCS Graduated compression stockings 
G1 Gastrointestinal 
GIT Gastrointestinal surgery 
ics International consensus statement 
INR International Normalised Ratio 
IPC Intermittent pneumatic compression 
LDUH Low dose unfractionated heparin 
OR Odds ration 
LMNVH Low molecular weight heparin 
PE Pulmonary embolism 
PTS Post-thrombotic or post-phlebitic syndrome 
RCT Randomised controlled trials 
RR Relative risk 
SNAD sodium N-[ I 0-(2-hydroxybenzoyl)amine decanoate 
TF Tissue factor 
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TFPI Tissue factor pathway inhibitor 
THRIFT Thromboembolic Risk Factors Consensus Group 
3LB Charing Cross three layer bandaging 
4LB Charing Cross four layer banclaging 
WE Venous thromboembolism 
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List of presentations and publications resulting from this study 
Presentations at national and international meetings 
'A simplified approach to the prophylaxis of deep vein thrombosis. ' A Howard, 
N Salooga, F Barrack, T Beresford, D Zaccagnini, J Cockburn, A Rodway, AH 
Davies, RM Greenhalgh. Presented at the European Venous Forum, Berlin, June 
2002. 
'Evaluation of satisfaction in patients with lower leg compression appliances. ' 
A Howard, T Beresford, CD Rodd, RM Greenhalgh, AH Davies. Presentation at the 
European Venous Forum, Berlin, June 2002. 
'Patient satisfaction with compression appliances used for the treatment of 
venous disease. ' A Howard, T Beresford, CD Rodd, RM Greenhalgh, AH Davies. 
Presentation at the Royal Society of Medicine Venous Forum, Cardiff, September 
2002. 
'A protocol of low molecular weight heparin and antiembolic stockings 
abolishes deep vein thrombosis in low and moderate risk patients and reduces it 
in high risk patients. ' A Howard, D Zaccagnini, A Williams, M Ellis, N Salooja, 
AH Davies, RM Greenhalgh. Presented at the ASGBI Annual Meeting, Manchester, 
May 2003. 
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'A teaching hospital audit: errors of DVT prophylaxis at the bedside. ' A 
Howard, WL Mo, T Beresford, RM Greenhalgh, AH Davies. Presentation at the 
European Venous Forum, Lisbon, June 2003. 
'A single protocol for the prevention of postoperative deep vein thrombosis'. A 
Howard and RM Greenhalgh. Presentation at the Charing Cross International 
Symposium, Vascular and Endovascular Challenges, London, April 2004. 
'A protocol to abolish postoperative beep vein thrombosisT A Howard, A 
Williams, D Zaccagnini, M Ellis, L Brown, N Salooja, AH Davies, RM Greenhalgh. 
Presented at the The Charing Cross International Symposium, Vascular and 
Endovascular Challenges, Nurses Forum, London, April 2005. 
'A single protocol for the prevention of postoperative deep vein thrombosis. ' 
A Howard, D Zaccagnini, A Williams, M Ellis, N Salooja, AH Davies, RM 
Greenhalgh. Presented at the UIP Symposium, Rio, Brazil, Oct 2005. 
Invited chapters 
'A new single protocol for the prevention of postoperative deep vein thrombosis' 
A Howard, RM Greenhalgh. Association of Surgeons In Training Yearbook 2004 
'A single protocol for the prevention of postoperative deep vein thrombosis'. 
A 
Howard and RM Greenhalgh. Invited book chapter for the International Charing 
Cross Vascular and Endovascular Symposium 2004. 
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Publications 
Abstracts 
'A simplified approach to the prophylaxis of deep vein thrombosis. '. A Howard, 
N Salooga, F Barrack, T Beresford, D Zaccagnini, J Cockburn, A Rodway, AH 
Davies, RM Greenhalgh. Abstract published in International Angiology, June 
2002; 3: 288 
'Evaluation of satisfaction in patients with lower leg compression appliances. ' 
A Howard, T Beresford, CD Rodd, RM Greenhalgh, AN Davies. Abstract published 
in International Angiology, June 2002; suppl. 
'Patient satisfaction with compression appliances used for the treatment of 
venous disease. ' A Howard, T Beresford, CD Rodd, RM Greenhalgh, AH Davies. 
Abstract publication in Phlebology, September 2002. 
'A protocol of low molecular weight heparin and antiembolic stockings 
abolishes deep vein thrombosis in low and moderate risk patients and reduces it 
in high risk patients. ' 
A Howard, D Zaccagnini, A Williams, M Ellis, N Salooja, AH Davies, RM 
Greenhalgh. Abstract published in BJS. Vol. 90, Suppl. 1, June 2003. 
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'A teaching hospital audit: errors of DVT prophylaxis at the bedside. ' A 
Howard, WL Mo, T Beresford, RM Greenhalgh, AH Davies. Abstract published 
Abstract published in International Angiology, June 2003; suppl. 
Papers 
'Randomised clinical trial of low molecular weight heparin with thigh-length 
and knee-length antiembolism stockings for patients undergoing surgery. ' A 
Howard, D Zaccagnini, A Williams, M Ellis, AH Davies, RM Greenhalgh. BJS 
2004; 90: 842-847. (copy included) 
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patients undergoing surgery 
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Background: This was a randomized clinical trial to determine the efficacy and safety of a 'blanket' 
protocol of low molecular weight heparin (LNIWH) and the best length of antiembolism stocking, for 
every patient requiring surgery under general anaesthesia. 
Methods: Of 426 patients interviewed, 376 agreed to be randomized to receive one of three types of 
stocking: thigh-length Medi thrombexin' climax TM (Medi M Hereford, LTK), knee-length thrombexin ý' ' 
climax TM and thigh-length Kendall T. E. D. TM (Tyco Healthcare M Redruth, LTK). All patients received 
IAIV; H thromboprophylaxis. Duplex ultrasonography was used to assess the incidence of postoperative 
deep vein thrombosis (DVT). 
. 
Results: No postoperative DVT occurred in 85 patients at low or moderate risk. Nineteen DVTs 
-occurred, all in the 291 high-risk patients: two with the Medi thigh-length stockings, 11 with the Medi 
knee-length stockings (odds ratio 0.18 (95 percent confidence interval 0.04 to 0.82); P=0.026) and 
six with the Kendall T. E. D TM thigh-length stockings. No patient developed a pulmonary embolism. 
Stocking groups were similar for age, sex, thromboembolic risk, type of operation and compliance. One 
significant bleeding complication occurred. 
Conclusion: A single protocol comprising LNIVVH and thigh-length stockings abolished DVT in low- 
and moderate-risk patients, and reduced the rate of DVT to 2 per cent in high-risk patients. 
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Introduction 
Currently, the most appropriate means of preventing 
deep vein thrombosis (DVT) in surgical patients are 
subcutaneous heparin and antiembolism stockings 1,2 
which offer increased benefit when used in combination 3 
Other pharmacological and physical prophylactic methods 
exist, but are less effective, less safe or impractical3. 
An audit was conducted in this university hospital 
of the status of thromboprophylaxis to investigate areas 
for improvement. Of 106 patients who had undergone 
surgery, heparin prophylaxis was omitted in 43 .0 per cent. 
The use of "antiembolism stockings was also disparate 
and underprescribed to only 46-2 per cent of patients. 
A variety of stocking brands and lengths was used with 
COPyright (D 2 004 British journal of Surgery Society Ltd Published byjohn Wiley & Sons Ltd 
inadequate fitting. The combined use of subcutaneous 
heparin and stockings was evident in only 24.3 percent 
of patients. These findings are similar to other reports 
in the literature describing poor compliance of DVT 
4-6 thromboprophylaxis 
In order to correct the poor compliance of thrombo- 
prophylaxis in the hospital, junior doctors and nurses were 
tutored in the merits of a single 'blanket' protocol of hep- 
arm and stockings for all surgical patients. A repeat audit 
showed a significant improvement in optimal thrombo- 
prophylaxis to 88.1 per cent of patients (P = 0.003). The 
majority of surgical specialties considered low molecular 
weight heparin (LMNM to be the best choice for a single- 
protocol regimen as it is generally more effective3, more 
acceptable to patients owing to the single daily injection, 
Br7'tisb Journal of Surge7y 2 004,91: 842 - 84 7 
I-protocol thromboprophylaxis in surgical patients 
and now cheaper than low-dose unfractionated hep- 
However, surgeons and nurses remained uncertain 
it what length and design of antiembolism stocking to 
Y. 
he aim of the study was determine the optimal length 
, ocking for use in a safe single 'blanket' protocol to 
'ent postoperative DVT, suitable for all patients at low, 
lerate or high risk 3 undergoing any surgical procedure 
I ormed by a wide range of specialties including breast 
oncology, ear, nose and throat (ENT), gastrointestinal, 
rosurgery, orthopaedic, urological and vascular surgery. 
ent Cochrane reviews gave encouragement for the 
ibined use of subcutaneous heparin and antiembolism 
kings 1,2 - 
'he study hypothesis that, provided LMVVH is given 
11 patients, knee-length antiembolism stockings are as 
ctive as thigh-length stockings of the same graduated 
ipression in the prevention of postoperative DVT, was 
,d on the limited evidence in the literature comparing 
ýh-length with knee-length stockings. The primary 
point of the study was the rate of postoperative DVT 
ýssed- by duplex imaging. A secondary endpoint was 
incidence of bleeding complications associated with 
WH. 
tients and methods 
-andomized clinical trial was approved by the local 
erside Ethics Committee (London, UK) to compare 
efficacy and safety of thigh-length and knee-length 
ýembolism stockings on a background of LMWH 
)mboprophylaxis. Patients were inter-viewed to gain 
)rmed consent and for randomization to one of three 
ups: thigh-length Kendall T. E. D. TM (Tyco Healthcare 
Redruth, UK), thigh-length Medi thrombeXin 
lax TM (Medi LTK, Hereford, UK) and knee-length 
di thrombexin (g) climax TM stockings. Randomization was 
dfied for surgical specialty and thromboembolic risk in 
with the international consensus statement for the 
vention of venous thromboembolism 3. 
I he incidence of DVT was assessed by duplex 
asonography; each patient had preoperative venous 
ýlex imaging on the evening before surgery and a second 
ýlex assessment on postoperative day 5-7. A principal 
lar technologist supervised and verified the venous 
lex scans. 
tockings were expertly fitted to patients on the evening 
)re the operation, unless the surgical intervention 
)Ived the leg; in these patients the stocking was fitted 
he first postoperative day. 
right @ 2004 British Journal of Surgery Society Ltd 
shed bYJohn Wilev S, Sons Ltd 
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A single daily subcutaneous injection of 20 mg LAIIN-H, 
enoxaparin sodium (Clexanee; Aventis Pharma, West 
Malling, UK), was given to patients on the evening before 
surgery, except for neurosurgical and orthopaedic patients 
whose surgeons insisted that they receive the LAIWH 
within 12 h after completion of the operation. Enoxaparin 
injections were iven daily until discharge from hospital. 91 111 
A record of complications associated with the use of 
stockings and LMWH was kept. All patients Nvho developed 
a DVT were treated with fall anticoagulation with 
daily LMVvH until adequate warfarinization and class-2 
compression hosiery, and were referred for haematological 
follow-up. 
Sample size and statistical analysis 
Sample size calculations were based on detecting a possible 
difference in postoperative DVT rates of - in '0.0 per cent i 
the knee-length stocking group and 5.0 per cent in each of 
the thigh-length stocking groups. These calculations, based 
on 90.0 per cent power at the 5.0 per cent significance 
level, required 114 patients per group (342 patients in 
total). 
Statistical analysis was performed using the STATA", 
version 6.0 statistical package (Stata Corporation, College 
Station, Texas, USA). Logistic regression analysis was used 
to estimate crude odds ratios (ORs) between the three types 
of stocking. These ORs were also adjusted for the use of 
preoperative LMVv'H. 
Results 
A total of 426 patients were interviewed for entry into 
the trial; 39 refused and 11 were medically unable to 
wear antiembolism stockings or to receive subcutaneous 
LMVVH prophylaxis. Three hundred and seventy-six 
patients were randomized; their mean age was 58 (range 
16-88) years and 218 (58.0 percent) were women. Throm- 
boembolic risk assessment 3 revealed that 2 91 patients were 
at high risk, 59 at moderate risk and 26 at low risk. 
Patients were recruited from a variety of surgical spe- 
cialties: breast and oncology (73 patients), ENT (13), 
gastrointestinal (12 2), neurosurgery (3 4), orthopaedic (62), 
urology (58) and vascular venous surgery (14). The patients 
were randomized into three stocking groups: thigh- 
length Kendall T. E. D TNI (127 patients), thigh-length 
Medi thrombexin@ climax TM (121) and knee-length Med, 
thrombexin@ climax 
TAI (12 8) stockings. Randomization was 
stratified by thromboembolic risk 
3 (high, moderate and 
low) and surgical specialty (breast and oncolop-, ENT, 
gastrointestinal, neurosurgery, orthopaedic, urological and 
NN-w%v. bJs. co. uk- British 
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vascular), which produced three similar groups matched 
for age (P = 0.850), sex (P = 0.998), time of commence- 
ment of LNIVM (P = 0.280) and thromboembolic risk 
(P =0-23 0). For each stocking group a statistically similar 
number of patients did not undergo surgery or postopera- 
tive venous duplex imaging (P = 0.277) (Fig. 1). 
Trial results 
None of the 85 patients at low or moderate risk developed 
a DVT when this protocol was used. All postoperative 
DVTs occurred in patients from the high-risk category. 
Some 19 (6-5 per cent) of 291 high-risk patients developed 
a DVT; two were bilateral (Fig. 1). No patient developed 
pulmonary embolism during the trial. 
The Medi thrombexin@ climax TM thigh-length stock- 
ings were significantly better at preventing postoperative 
dall TE. D. TM thig 
AES 
127 patients 
Kendall TIED TM thigh-length 
AES 
102 patients (80.3 per cent) 
completed trial 
postoperative DVT 
(5 unilateral and I 
bilateral DVT) 
DVT than the knee-length stockings (two z: ersus 11; OR 
0.18 (95 percent confidence interval (c. i. ) 0.04 to 0.82); 
P=0.026). Five patients developed unilateral DVT and 
one a bilateral DVT in the Kendall T. E. D. "'" thigh-length 
group (OR 0.5 (95 percent c. i. 0.18 to 1.41) versus Medi 
thrombexint chmaXT. " knee-length stockings; P=0.190). 
Although data for Kendall T. E. D TM thigh-length stock- 
ings were not significantly different from those for either of 
the other two types of stocking, the results were inconclu- 
sive owing to a lack of power between the groups. All the 
DVTs that developed in patients with thigh-length stock- 
ings were found in the calf veins (posterior tibial and per- 
oneal veins). The knee-length stockings were also associ- 
ated primarily with calf-vein DVT, although one proXimal 
DVT was found in the superficial femoral vein of the thigh. 
The patients With postoperative DVT included six 
having orthopaedic surgery, six gastrointestinal surgery, 
376 patients randomized to 
commence trial protocol 
All patients received LMWH 
Medi thrombexine climaxTm 
thigh-length AES 
121 patients 
Medi thrombexins clima)Jm 
thigh-length AES 
93 patients (76.9 per cent) 
completed trial 
2 patients with 
postoperative DVT 
(2 unilateral DVT) 
Medi thrombexinaDclimaxTm 
knee-length AES 
128 patients 
a TM Medi thrombexin climax 
knee-length AES 
99 patients (77.3 per cent) 
completed trial 
11 patients with 
postoperative DVT 
(10 unilateral and I 
bilateral DVT) 
Fig. I Trial Consort diagram: patient outcome. LMWH, low molecular weight 
heparin; AES, antiembolism stochings; DVT, deep vein 
thrombosis 
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gle-protocol thromboprophylaxis in surgical patients 
- urology and two neurosurgery. The DVT occurred 
:h two main types of surgery: 'bone cutting' operations 
,h as 
hip (n = 3) and knee (n = 2) replacements, 
nal surgery (n = 2) and craniotomy (n - 1); and 
tjor abdominal surgery including upper gastrointestinal 
erations (n == 3), lower gastrointestinal operations 
= 3), nephrectomy (n = 2), cystectomy (n = 2) and 
Dstatectomy (n = 1). Of patients undergoing bone- 
tting operations, 11 per cent developed a postoperative 
VT compared with 5.2 per cent of those undergoing 
ijor abdominal surgery; the latter all commenced 
AVVH prophylaxis before surgery. 
The value of preoperative LAIVVH in reducing the 
te of postoperative DVT was investigated by means of 
gistic regression, which showed similar significance when 
justed for the use of heparin before and after surgery, for 
e Medi thigh-length versus Medi knee-length stockings 
)R 0.19 (95 per cent c. i. 0.04 to 0- 88); P=0.034) and for 
-ndall thigh-length versus Medi knee-length stockings 
)R 0.5 (95 per cent c. i. 0.18 to 1.42); P=0.192). There 
is weak evidence suggesting that preoperative LAIVVH 
is protective in reducing postoperative DVT (OR 0.41 
5 per cent c. i. 0.16 to 1.06); P=0.066). However, this 
vel of significance was diminished when adjusted for 
ndomized groups (P =0- 110). Approximately one-half 
. the patients with postoperative DVT in each stocking 
oup had relevant clinical signs of swelling, tenderness 
- erythema. Age and malignancy were positive risk 
ctors for DVT; the mean age of the 19 patients with 
VT was 68 (range 45-83) years, and 12 of these 
id a history of malignancy. All patients who developed 
VT were treated with full anticoagulation. Warfarin was 
intinued for 6 months under haernatological outpatient 
inic surveillance. 
A record of complications associated with the use of 
bcutaneous LMVVH and antiembolism stockings showed 
at only one significant bleeding complication occurred; 
her complications included two minor haernatomas 
at did not require further management, and minor 
ot abrasions from stockings in three patients. The 
, nificant bleeding complication developed when a 
drain 
is removed on the second day after parotid surgery; the 
sulting haematoma required further general anaesthesia 
r surgical evacuation. The patient made a full recovery. 
scussion 
though numerous investigators have provided evidence 
show that prophylaxis against venous thromboembolism 
effective in reducing the incidence of DVT and pul- 
)nary embolism by as much as two-thirds, there is 
)Yright @ 2004 British joumal of Surgery Society Ltd 
lished byjohn Wiley & Sons Ltd 
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still controversy over the correct prophylactic methods 
and regimens for surgical patientS5 . 
This uncertainty has 
frequently led to the inadequate application of thromboem- 
bolic prophylaxis in many centreS4-8 , 
despite guidelines in 
the literature. 
A single protocol was deemed appropriate and nec- 
essary because findings from previous audits had shown 
that the majority of surgical patients staying in hospi- 
tal were at high or moderate risk of thromboembolism. 
Second, existing protocols prescribe prophylaxis according 
to risk assessment, which relies on preoperative predic- 
tions that may change unexpectedly, such as duration of 
surgery, postoperative mobility, infection and presence of 
malignant disease. Antiembolisin stockings are effective in 
the surgical patient, with a reduction in the incidence of 
postoperative DVT to approximately II per cent. Low- 
dose heparin administered via subcutaneous injection is 
slightly more effective, reducing the DVT rate to around 
3 9 per cent . 
In combination, subcutaneous heparin and 
antiembolism stockings are the most practical and effec- 
tive prophylaxis in surgery 3,9 . 
The efficacy, safety and 
acceptability of these two methods have led to their pop- 
ularity in surgical practice. It was proposed that LMVVH 
should be given to all patients having surgery under general 
anaesthesia, except those with medical contraindications. 
This policy was accepted throughout the surgical spe- 
cialties, although orthopaedic and neurosurgeons insisted 
on delayed heparin administration for their patients. The 
question arose as to which type of stocking was best in 
combination with LMVVH- 
Until this trial, only limited evidence was available to 
distinguish between the benefits of knee- and thigh-length 
antiembolism stockings. A number of studies have inves- 
tigated different stockings for effects on venous velocity, 
patient acceptability and compliance, but only three have 
compared knee-length with thigh-length stockings for the 
prevention of postoperative DVT'O- 12. All three studies 
were randomized7 but the number of patients in each was 
small and none demonstrated a significant difference. A 
recent review on antiembolic stockings highlighted some 
of the benefits of knee-length over thigh-length stockings, 
but offered no evidence on their efficacy in the reduc- 
tion of postoperative DVT 13. The international consensus 
statement 3 refers to the efficacy of knee-length compared 
with thigh-length stockings in the prevention of DVT as 
one of the 'key questions to be answered'. The present study 
showed that thigh-length antiembolism stockings were 
better at preventing postoperative DVF than knee-length 
stockings with the same graduated compression profile. 
The standard dose of 20 mg enoxaparin was given 
to all trial patients because it was simple and previous 
www. bis. co. uk British Jounial of Surge7 2 004; 
91: 842 - 847 
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studies had shown that increasing the dose of LMWH 
added no prophylactic benefit but increased postoperative 
bleeding 14 - 
In this study, orthopaedic and neurosurgeons at least 
had the reassurance that the major bleeding problems they 
feared did not occur. For them to allow LMVVH to be 
given 12 h before surgery could have increased the rate of 
bleeding whilst lowering the DVT rate. Patients undergo- 
ing 'bone cutting' or abdominal surgery are at high risk 
of thromboembolic complications and therefore require 
optimal prophylaxis. In the present study, neurosurgical 
and orthopaedic patients who received only postopera- 
tive LMV%7H had the highest rate of postoperative DVT, 
approximately twice that of the other specialties where 
LMVVH was given before the operation. The surgical pro- 
cedure initiates the thromboembolic process and therefore 
starting the heparin prophylaxis before surgery is probably 
optimal, although further research in this area is required. 
LMV, /H commenced the evening before operation also 
permits the use of epidural or spinal anaesthesia at the time 
ofsurgery. 
The combination of a good-quality thigh-length 
stocking and LMVVH for patients undergoing surgery 
produced a postoperative DVT rate of 2 per cent in high- 
risk patients and zero in patients at moderate or low 
risk. This simple and safe protocol for DVT prophylaxis 
of LMVVH and antiembolism stockings can be given to 
all surgical inpatients. To have a single hospital protocol 
means that prophylaxis against DVT is less likely to be 
forgotten. If a specialty insists on a delay in administration 
or an increased dosage for certain patients, this can be 
accommodated. Patients with medical contraindications 
to LMWH or stockings could receive only appropriate 
prophylaxis. 
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Amendments required: 
1. Why the evidence for DVT prophylaxis remains controversial. 
2. Discuss the conclusions from the audit and how many patients would be needed 
to prove safety. 
3. Limitations of the study design with reference to: 
i. Power calculations 
ii. Three pronged randomisation 
iii. Stratification of patients 
iv. Diagnostic modalities for calf vein DVT 
v. Study conclusions 
Why the evidence for DVT prophylaxis remains controversial 
In recent years, the majority of evidence for the prophylaxis of venous thromboembolisni 
has been summated and reported in numerous consensus guidelines and review articles. 
These articles stress the importance of risk factors for venous thromboembolism (VTE) 
and their incorporation into risk stratification systems, upon which the guidelines are 
reliant, and thereby recommend the appropriate types and intensities of prophylaxis 
required for patients undergoing a particular treatment. The risk factors reported by the 
International Consensus guidelines (applied in this thesis) included, presence of varicose 
veins, general immobility, thrombophilia, trauma, cancer, prior VTE, obesity, infectious 
disease, increasing age, oral contraceptives, pregnancy and hormone replacement therapy 
(Nicolaides et al 200 1). However, a number of these risk factors have dubious evidence 
supporting their inclusion, with the obvious knock on effect of affecting the theoretical 
thromboprohylactic risk and the subsequent prophylaxis given to the patients. 
Various studies report different risk factors. For example, a recent meta-analysis that 
assessed the evidence for post-operative thromboembolic risk factors (Edmonds et al 
2004) found that age, obesity, previous VTE, varicose veins, oral contraceptive pill, 
malignancy, factor V Leiden, general anaesthesia and orthopedic surgery were all 
significant risk factors. And interestingly, hormone replacement therapy, ethnicity, 
gender, chemotherapy, other thrombophilias, cardiovascular factors, smoking and blood 
type were not significant. However, another study in the Lancet (Sue-Ling et al 1986) 
reported very different 'significant' risk factors: age, euglobulin lysis time, previous 
abdominal surgery, varicose veins, antithrombin III, smoking and platelet count, these 
2 
were all predictive of post-operative DVT. To add to the confusion, a large observational 
study (Di Minno et al 2005) reported another set of risk factors and separated these into 
4 strong' (history of superficial venous thrombosis, DVT or PE, heart failure and 
malignancy), 'moderate and weak' factors (smoking, history of miscarriage, oestrogen 
therapy, obesity and varicose veins). Intriguingly, this study reports no difference 
between sexes for DVT, however the females had consistently more risk factors. The 
question arises, actually how significant are these risk factors? 
The inclusion of varicose veins as a risk factor by the International Consensus Statement 
(the main guideline used in this study) is controversial. A questionnaire survey (Caiiipbell 
and Ridler 1995) sent to 363 vascular surgeons revealed that only twenty-nine percent 
regarded varicose veins as an important risk factor for DVT. Oger et al (1997) reported 
varicose veins as a risk factor with an odds ratio of 2.56, however like many other 
studies, the presence of other risk factors are often numerous and potentially 
confounding. The argument over risk factors and their individual importance will 
continue to be complex and difficult to prove. Smoking, obesity, immobility are often 
quoted, but rarely quantified and new risk factors are continually being added, such as 
intravenous drug abuse in patients under forty years (Syed and Beeching 2005). 
Other areas of controversy within the literature surrounding VTE risk factor assessment 
are the 'Low risk' category of patients, the varied age brackets and operation times used 
for the classification into different risk categories. As previously stated in this thesis the 
low risk category does not have sufficient evidence to make recommendations 
in this 
group, they are a 'no treatment group by exclusion'. The risk of 
DVT increases ýN'Ith age 
and operative time, but the cut-off ages and operation times 
for separating patients into 
different risk groups are arbitrary and vary for different guidelines. 
Discuss the conclusions from the audit 
and how many patients would be needed to prove safety 
The audit of venous thromboprophyl axis perfonned in chapter four of this thesis involved 
one hundred and seventy-eight patients, all of which were surgical patients at Charing 
Cross Hospital; already occupying a ward bed or admitted to a hospital bed over a period 
of forty-eight hours. One hundred and six had all undergone one or more surgical 
procedures during the current hospital admission, which pen-nitted the use of the 
International Consensus statement guidelines to be used to assess the risk of post- 
operative VTE and the appropriateness of prophylaxis application (Nicolaides et al 200 1). 
The audit results were analysed as an overall 'post-operative' population (n= 106) and 
also in groups according to their surgical speciality. These subgroups produced groups 
with a very low number of patients, for example in ENT where n=4. The audit of the 
'Single Protocol' produced a significant improvement in overall application of 
appropriate VTE prophylaxis (figure 4g). However, with only a total of 106 patients there 
was a possibility that the very audit process and the awareness of the health professionals 
to the current audit may have improved the compliance of the prophylaxis rather than the 
change in protocol. Hence, the audit would need greater numbers overall to account for 
this and repeated on more than one occasion. The numbers required can be calculated 
from power calculations, an improvement of 20% would require n= 102 in each round of 
the audit, 30% required n= 34,40% required n= 21 in each group. Therefore the overall 
audit results had a statistical power of 76% because n= 34 
in the second round of the 
audit, this was because only certain specialities (breast, gastrointestinal surgery, vascular 
-1 
and urology) pennitted the use of the new protocol. And for 'surgical speciality' 
subgroup analysis each speci group would require n> 102 patients (DSS Research) 
to achieve sufficient power. 
Figure 4g - Improvements in DVT Prophylaxis after 
Education and Introduction of Single Protocol 
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In the current health service environment the junior doctors and nurses change posts 
approximately every 3,4 or 6 months. Repeated audit at 6 monthly intervals would allow 
5 
Phase One'Before P has e Two 'After 
Education' Education' 
staffing changes to occur between audits and then the 'real' effects of the single protocol 
can be evaluated with less bias introduced by audit awareness. In addition, the single 
protocol was only assessing on certain specialities (breast, gastrointestinal surgery, 
vascular and urology) that permitted the use of the new protocol, not orthopaedics or 
neurosurgery that were awaiting the results of the forthcoming trial. This ma,,,, also have 
introduced bias into the audit results by not including the very specialities that ,, N,, ere most 
resistant to using the single protocol. 
The evidence for the safety of using the single protocol was taken largely from the 
literature reporting bleeding and stocking complications with DVT prophylaxis. A 
summary of this literature is provided in the main text of this thesis (chapters 2 and 3). 
However, during the randomised clinical trial in this study the complications of both 
LMWH and GCS were recorded and the complication rate was low (chapter 6). If this 
study contained a control group without any prophylaxis but a placebo then the required 
numbers would be 473 patients in each group for a complication rate difference of 5% at 
90% power and p<0.05 (DSS Research). This control group was not ethically pen-nitted, 
and therefore the 'observed' complication rate was recorded and compared to traditional 
controls from the literature. The numbers required for an observation study are much 
larger, in the region of thousands of patients rather than hundreds like in this study. 
Limitations Of the study design 
with reference to: power calculations, three pronged randomisation, stratification 
of 
patients, and diagnostic modalities for calf vein 
DVT 
and study conclusions 
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i. Power calculations 
The power calculations in the study were based on detecting a possible difference in 
postoperative DVT rates of 20% in the knee-length stocking group and 5% in each of the 
thigh-length stocking groups. These calculations - based on 90% power at the 5% 
significance level - required 114 patients per group and 342 patients in total (Stata 6, TX, 
USA). The results of the trial demonstrated a 9% difference in DVT rate between the 
Medi thigh and Medi knee-length stockings and a 3% difference between the Medi thigh 
and the Kendall thigh stockings, this produced a statistical power of 83% and 3 1% 
respectively (DSS Research). The numbers required for 90% power at 5% significance, to 
show a 9% and 3% difference would approximate to 127 and 641 patients in each group 
respectively. 
ii. Three pronged randomisation 
In this study we chose the stockings from the UK market leaders Kendall and Medi UK. 
The study compared Medi thigh and knee-length and we chose to have Kendall thigh 
length as a 'traditional control' because the majority of the randomised trials in literature 
used this stocking type. In order to improve the power of the study and keep the 
recruitment numbers to a minimum, this study could have had a more efficient structure if 
just two groups were employed, one with thigh and one with knee-length 
GCS, with 127 
patients required for each group. In addition, a better control arm would 
have been a 
group without stockings and just LMWH, which may 
have been ethically pen-nitted. 
iii. Stratification of patients 
7 
In this study, computer randomisation was performed and this was stratified for surgical 
speciality and thromboembolic risk, in line with the International Consensus Statement 
for the Prevention of Venous Thromboembolism (Nicolaides et a] 2001). Patients were 
recruited from a variety of surgical specialities that included: breast and oncology (n=73), 
ENT (n=13), gastrointestinal (n=122), neurosurgery (n=34), orthopaedic (n=62), urology 
(n=58) and vascular surgical patients (n=14) (table 6b). Thromboembolic risk assessment 
in accordance with the International consensus (Nicolaides et al 2001) revealed 291 
patients were high risk, fifty-nine patients were moderate risk and twenty-six patients fell 
into the low risk category. Stratified randomisation allocated patients into three stocking 
groups (see table 6c) consisting of patients wearing Medi Thrombexin thigh-length 
stockings (n=121), Medi Thrombexin knee-length stockings (n=128) and Kendall T. E. D. 
thigh-length stockings (n=: 127) (figure 6d). This form of randomisation produced three 
groups of patients that were statistically similar with regard to demographics and surgical 
speciality. There was no significant difference in terms of age (P=0.850), gender 
(P=0.998) (table 6c), thromboembolic risk (P=0.230) (figure 6e) and surgical speciality 
(figure 6f). In addition, there was no significant difference between groups for 
compliance with the trial protocol (P=0.277). Figure 6f demonstrates graphically the 
group similarities for speciality. 
However, these similarities do not account for the disparity between groups for the actual 
types of operation performed. There were potentially many confounding variables 
produced, for example, by the wide variety of operations, surgeons, surgical techniques, 
operative times and peri-operative managements. Therefore the actual 
differences 
between stocking groups would have been better evaluated 
by stratifying the 
randomisation for surgical procedures for each group and standardising 
the operations 
and the peri-operative managements perfon-ned. 
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Figure 6f - Similarity of stocking groups for surgical 
speciality 
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iv. Diagnostic modalities for calf vein DVT 
The diagnostic capabilities of duplex for calf vein DVT have been debated regularly over 
the last decade. Those in favour of duplex proffer the latest developments in power 
Doppler and zoom technologies. More recently the improved software processing the B 
mode image, such as high definition zoom, together with Doppler and now power 
Doppler, has enabled good visualisation of small calf veins and low flow scenarios can 
9 
Kendall Thigh Medi Thigh Medi Knee 
reliably be assessed. The accuracy has been reported to reach between 94 and 97.9% for 
detecting acute isolated calf DVT and 97% accuracy (confidence interval 96-98%) for the 
diagnosis of proximal DVT (Baumgartner et al 1998 & Keearon et al 1998). The 
sensitivity has been reported to reach one hundred percent, specificity 71%, positive 
predictive value 71%, achieved with 100% of scans completed successfully (Forbes & 
Stevenson 1998). Colour duplex scanning for DVT is non-invasive, time efficlem, 
acceptable to patients, harmless and repeatable. On the other hand, contrast venography, 
is expensive, uncomfortable to the patient, occasionally painful, technically difficult to 
perfonn and exposes the patient to radiation. It is inadequate, impossible to perform or 
difficult to interpret in up to ten percent of patients. Isotopic fibrinogen scanning suffers 
similar set backs to venography as it is invasive, uncomfortable for the patients, 
technically difficult to interpret, involves radiation exposure and it has limited ability to 
image proximal DVT in patients with knee and hip replacements due to artefact. Burn et 
al (1997) reported how duplex ultrasonography has become increasing prevalent as a first 
line diagnostic instrument for the diagnosis of lower limb DVT in UK hospitals and that 
venography is used in only a minority of departments as the principal diagnostic 
technique. 
None of the three available methods are 100% accurate for detecting calf vein DVT, 
however for the results of this study to be more accurate we should have employed a 
second diagnostic modality to use in conjunction with 
duplex ultrasound. The 
introduction of an invasive investigation in this study may 
however have reduced patient 
recruitment and increased complications. 
To avoid this the use of the second modality to 
assess 6quality control' of duplex may 
have been more feasible, 
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V. Study conclusions 
The results from this study suggested that there was a significant difference between post- 
operative DVT rates for thigh versus knee-length GCS, there was an improved patient 
satisfaction with knee-length GCS and that the 'single protocol' improved prophylactic 
compliance. However, due to the borderline power (83%) and limitations in terms of 
stratified randomisation and calf vein diagnostic techniques, the differences between 
stocking groups may or may not be real. Further studies would need to undertaken to test 
the study hypothesis, 
c provided LMWH is given to allpatients, 
thigh length anti-embolic stockings are equal to knee-length of the same design in the 
prevention ofpost-operative deep vein thrombosis ý 
Or to test the hypothesis generated by this study that thigh-length GCS may be better at 
preventing post-operative DVT than knee length GCS of the same compression profile. 
As far as the assessment of patient satisfaction; there was a significant difference for knee 
length GCS, but further validation of the questionnaire and again further studies would be 
required to evaluate my findings more thoroughly. 
The Single protocol was found to improve the compliance of thromboprophyl axis in 
surgical patients, however this was only audited (before the randomised trial) in breast, 
gastrointestinal surgery, vascular and urology 
because of the reluctance of neurosurgery 
and orthopaedic specialists to use this protocol at 
the time of this study. The closing of 
the audit cycle was, in this case perforined 
by re-auditing only 34 patients (figure 4g). 
Therefore a further evaluation of the single protocol is required and was not performed 
immediately after the trial completion 
due to time constraints. The Single protocol 
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became the trust guideline and was later re-audited two years after performing and 
C writing-up' of this study. This has now been completed in 2006 and once again the DVT 
prophylaxis across the trust has become disparate and inadequate with an overall surgical 
compliance rate of 33% for adequate VTE prophylaxis in line with the international 
guidelines (Nicolaides et al 2001). The compliance rate in medical patients was worse at 
8%, giving an overall compliance rate for patients staying in Charing Cross Hospital was 
19%. We have therefore, in conjunction with the Picker Institute (Oxford, UK) begun to 
set up a second study investigating the effect of patient education on VTE prophylactic 
compliance in hospital. 
The current methods of staff education, repeated audit and clinical governance 
enforcement of the hospital single protocol have continued. Recent rewriting of the 
Single protocol for the Hammersmith Hospitals NHS Trust has taken place in conjunction 
with the department of Clinical Governance. A consensus from medical, anaesthetic, 
haernatological and surgical consultants across the trust has been sort and once again 
achieved, with the necessary adjustments made to the protocol published on the trust 
intranet. The department of Clinical Governance will audit the VTE prophylaxis at six 
monthly intervals with the aim of maintaining prophylaxis compliance. 
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